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ABSTRACT 
 
 Cleft palate is one of the most common birth abnormalities. Figures published 
in 2006 by the American Centres for Disease Control and Prevention, report the 
incidence of those born in the United States with a cleft palate without the presence of 
a cleft lip (CPI) to be 6.39 for every 10000 in the three years between 1999 to 2001 
and for cleft lip in association with a cleft palate (CLP) to be even greater - 10.48 per 
10000 live births.  In 2001, Braybrook and colleagues reported that mutations in the 
TBX22 gene cause X-linked cleft palate (CPX), a disease characterised by a cleft of 
the secondary palate and is often seen in association with ankyloglossia (tongue-tie) 
(Braybrook et al. 2001). 
 A cleft of the secondary palate arises as a consequence of disturbance to 
correct development during palatogenesis: an anomaly in palatal shelf growth; 
delayed or failed shelf elevation; defective shelf fusion or a failure of medial edge 
epithelium cell death. This thesis reveals that the expression of TBX22 during these 
key developmental events in human embryos is consistent with the phenotype seen in 
CPX.  
 To enable an investigation for TBX22 target genes, a DNA binding sequence 
is determined for the TBX22 protein. This sequence is used to generate a generic 
TBX22 DNA binding site, the presence of which is screened for in promoter regions, 
defined as 2kb upstream of transcription start sites. 132 genes were selected as 
candidate TBX22 targets on the basis that they underlie human disorders that include 
a cleft palate. The screen shows that 28 of these genes have at least one perfect or near 
perfect match to the generic TBX22 DNA binding site.  Of these, only two both 
contained a perfect TBX22 generic DNA binding site and mouse mutants also had 
cleft palates: SUMO1 and MSX1. Interaction between SUMO1 and TBX22 has 
already been shown (Andreou et al. 2007). This study investigated MSX1 as a 
downstream target of TBX22 using a luciferase reporter gene construct in vitro. The 
results showed that in the presence of TBX22, the luciferase signal was reduced and 
support MSX1 being a downstream target gene of TBX22. 
 These findings further the understanding of the molecular networks regulating 
craniofacial development. Unravelling these complex interactions is crucial to 
identifying the mechanisms of oro-facial clefting, important steps towards improved 
methods of counselling, treatment and prevention of these common birth disorders. 
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CHAPTER 1  
 
 
INTRODUCTION 
 
 
The thesis centres upon TBX22 - the underlying genetic cause of X-linked cleft palate 
(Braybrook et al. 2001). More specifically, this thesis will consider the mRNA 
expression pattern of TBX22; the DNA binding specificity of the TBX22 protein and 
the investigation of a possible downstream target gene of the TBX22 protein. 
 
An orofacial cleft is a frequent birth defect. Recent figures for the population of the 
USA estimate that the average prevalence of cleft lip with or without a cleft palate to 
be 10.48 per 10000 live births and those born with a cleft palate without the presence 
of a  cleft lip to be 6.39 for every 10000 (C.D.C. 2006). Several genes have been 
uncovered where a cleft palate is present together with multiple congenital 
malformations as part of a syndrome. Whilst studies are uncovering genes associated 
with non-syndromic oral clefts all the time (Moreno et al. 2009; Carter et al. 2010; 
Ingersoll et al. 2010), TBX22 remains one of only a handful of genes that have been 
shown to underlie non-syndromic cleft (Carinci et al. 2007). Although some patients 
with mutations in the TBX22 gene display ankyloglossia (tongue-tie) as well as a cleft 
of the secondary palate, TBX22 mutations account for a significant proportion of non-
syndromic cleft palate cases (Marcano et al. 2004; Suphapeetiporn et al. 2007).  
 
This thesis attempts to further the understanding of the biological role of TBX22 
through its interaction with other genes. This is a necessary step in order that TBX22 
can be placed in relation to other transcription factors and signalling molecules within 
the complex mechanisms underpinning palate formation. 
 
The following introduction aims to provide a background to the study and to highlight 
the context of the work from the start of the project 2001 to our current understanding. 
Topics introduced here will be expanded upon in specific chapters as indicated in 1.4. 
This introduction will begin with a brief overview of the TBX22 gene and the T-box 
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gene family, followed by a review of the development of the head and face with 
particular emphasis on the formation of the palate; relating how defects in the correct 
formation of these structures may give rise to a cleft, giving an overview of known 
cleft palate genes; as well as giving more detail about the X-linked cleft palate 
phenotype.  
 
1.1  BRACHYURY, TBX22 AND THE T-BOX GENE FAMILY 
 
In 1927, a mouse mutant was described as having a short tail phenotype and the 
mutation responsible named T, for tail, or more elaborately, Brachyury, the Greek for 
short tail (Dobrovolskïa-Zavadskaa 1927). The T gene was identified when the 
Brachyury mutation was isolated more than sixty years later  (Herrmann et al. 1990). 
Soon after, the Drosophila gene, optomotor-blind (omb), was shown to be related to 
the T gene (Pflugfelder et al. 1992), when an homology domain was identified 
between the central region of the omb protein and the amino-terminal region of T. 
Despite clearly not being orthologues, these two gene products certainly belonged to 
the same protein family. The homologous region was named the T-box, and since the 
discovery of sequence similarity between omb and T, a host of other genes have been 
identified in many diverse animal species that share this same homology, known 
collectively as T-box genes. T-box genes are part of the larger protein clan, P53-like, 
which share similarity in their immunoglobulin-like, beta-sandwich DNA-binding 
domains (Berardi et al. 1999); pfam [http://pfam.sanger.ac.uk/]). 
 
The T-box domain is a conserved region encompassing ~200 amino acids, and has 
been shown to display binding activity to specific DNA sequences (Kispert and 
Herrmann 1993). All T-box genes show ability to bind variations of a similar DNA 
sequence (Tada and Smith 2001); known as the T-box binding element. It is this 
DNA-binding capability that enables T-box genes to function as transcriptional 
regulators. The importance of these transcription factors during development is 
highlighted by the effect of mutations in T-box genes in different organisms and the 
resultant phenotypes observed (Chapman and Papaioannou 1998; Bruneau et al. 2001; 
Jerome and Papaioannou 2001; Szabo et al. 2002; Davenport et al. 2003; Naiche and 
Papaioannou 2003; Bussen et al. 2004; Harrelson et al. 2004; Singh et al. 2005a; 
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Singh et al. 2005b). The developmental functions of T-box genes are varied: having a 
role in very early embryogenesis – specifying the primary germ layers as in the case 
of Brachyury and VegT (reviewed in Showell et al. 2004); as well as later in 
development, for example in conveying identity and patterning the limbs (reviewed in 
Simon 1999).  
 4 
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FIGURE 1: Phylogenetic tree of human T-box genes. The evolution of 
the human T-box genes is shown in relation to the common ancestral 
genes from which they arose during gene duplication events (adapted 
from Ruvinsky et al. 2000; Larroux et al. 2008).
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 By comparative analysis of the genomes of lower organisms, particularly that 
of the cephalochordate amphioxus which is believed to be the closest living 
invertebrate relative to vertebrates (Holland et al. 2004), to those of higher organisms 
the evolution of the T-box genes from a single ancestral gene has been determined 
(see Fig. 1). The amphioxus genome only contains a basic set of chordate genes 
involved in development and many of these have retained their identity through 
evolution through to higher organisms. However, whereas the amphioxus genome 
only has one of these genes, as a consequence of whole genome duplication, 
vertebrates will often have two, three, or four paralogues of the same genes (Holland 
et al. 2008).  
 
The duplication of pre-existing genes, whether through whole genome, or whole or 
partial chromosome duplication, had a major role in evolution and has lead to the 
emergence of the various human T-box genes. Following a gene duplication event, 
one copy may inherit a null mutation, and that copy is likely to be subsequently lost, 
providing the function is maintained by the other copy. However, if one or both 
copies of the gene gain mutations such that a new function is acquired, then this gene 
will be retained through evolution through positive selection. A third possibility is 
that mutations result in both gene copies having reduced expression and/or functional 
alterations such that both copies of the gene must be retained in order for the function 
of the ancestral gene to be preserved (Minguillon and Logan 2003; Innan and 
Kondrashov 2010).  
 
The phylogenetic study of the T-box genes has enabled all of the human T-box genes 
to be grouped together into one of five subfamilies: Brachyury (T), T-Brain, TBX1, 
TBX2 and TBX6 (see Fig. 1) based upon the ancestral gene from which they arose. 
TBX22 is a member of the Tbx1 subfamily and is most closely related to TBX15 and 
TBX18 (Ruvinsky et al. 2000; Larroux et al. 2008). Genes of the same subfamily 
often display over-lapping expression patterns. Several members of the Tbx1 
subfamily - Tbx1, Tbx10, Tbx15, Tbx18 and Tbx22 have been shown to be expressed 
during craniofacial development (Chapman et al. 1996; Agulnik et al. 1998; Kraus et 
al. 2001a; Bush et al. 2002; Bush et al. 2003; Herr et al. 2003), however this is not 
apparent for Tbx20 (Kraus et al. 2001b).  
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The possibility of over-lapping but distinct functions is also highlighted by the human 
disorders that mutations within related T-box genes cause. Mutations in TBX5 have 
been shown to cause Holt-Oram syndrome (Basson et al. 1997; Li et al. 1997). 
Characteristically this syndrome involves atrial septal defects and anomalies of the 
thumbs  (MIM #142900)  (Holt and Oram 1960). Mutations in TBX3, similarly to 
TBX5 a member of the Tbx2 subfamily, lead to Ulnar-Mammary syndrome (MIM 
#181450) (Bamshad et al. 1997). The phenotype of this disorder is usually 
characterised by complete absence or malformation of the fingers, rather than the 
thumbs as seen in Holt-Oram syndrome, often accompanied with delayed growth and 
onset of puberty, obesity, hypogenitalism and hypoplasia of nipples (Schinzel et al. 
1987). 
 
The importance of T-box genes during normal development is clear given the disease 
phenotypes described above and further human diseases caused by mutations in other 
T-box genes have been described. Mutations in TBX1 have been found in patients 
with conotruncal anomaly face syndrome (MIM #217095) (Yagi et al. 2003) and 
(Paylor et al. 2006; Zweier et al. 2007) and have also been linked to DiGeorge 
syndrome (MIM # 188400) (Yagi et al. 2003; Stoller and Epstein 2005). Mutations in 
TBX4 were shown to cause small patella syndrome (MIM #147891) (Bongers et al. 
2004); mutations in TBX15 give rise to Cousin syndrome (MIM #260660) (Lausch et 
al. 2008); mutations to TBX19 cause adrenocorticotropic hormone deficiency (MIM 
#201400) (Lamolet et al. 2001) and disruption to the regulatory region surrounding 
EOMES co-segregated with microcephaly with polymicrogyria and corpus callosum 
agenesis in one family (Baala et al. 2007). A single nucleotide polymorphism in the 
promoter region of TBX21 has been shown to lead to an increased risk to aspirin-
induced asthma (Akahoshi et al. 2005) and carrying an allelic variant of the T locus, 
TIVS7-2 , has been associated with increased risk of neural tube defects and spina 
bifida (Morrison et al. 1996; Jensen et al. 2004)  
 
 
1.1.1  TBX22 Chromosomal location and Gene Structure 
 
Whilst trying to identify candidate genes involved in X-linked metal retardation, 
through searching the human genome databases and using gene prediction tools, 
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Laugier-Anfossi and Villard isolated a new T-box gene, namely, TBX22 (Laugier-
Anfossi and Villard 2000). This gene was originally thought to have a truncated T-
box domain, which was missing the first 20 amino acids and in a zoo blot was found 
only in the porcine genome and absent in all others, including the mouse, leading the 
authors to suggest that TBX22 may have appeared relatively recently in the evolution 
of higher mammals. Additional upstream exons in TBX22 were later identified, 
increasing the TBX22 protein by 120 amino acids, showing that TBX22 did indeed 
contain a full length T-box domain (Braybrook et al. 2001) and far from being a gene 
found exclusively in higher mammals, phylogenetic analysis has shown that since its 
diversion from TBX15/18, TBX22 is in fact conserved throughout metazoan evolution 
(Papaioannou 2001).   
 
The TBX22 gene consists of eight coding exons and one non-coding exon and is 
located between the genes ITMA and FAM46D on the chromosome Xq21.1. Three 
mRNA transcripts exist; the first contains exons 1-7, whilst a second contains the 
additional exon 0 spliced to the 5΄ end. However, both transcripts encode the same 
protein, using the same translation start site located in exon 1 (Andreou et al. 2007). A 
third smaller transcript includes the 5΄ exon 0, but is translated from an AUG site 
further downstream resulting in a shorter isoform (Andreou et al. 2007). The T-box 
domain is located between exons 2 and 6 (Fig. 2). 
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Figure 2: The genomic structure of TBX22.  A schematic diagram of the genomic structure of 
TBX22, based on Braybrook et al. 2001; Andreou et al. 2007. TBX22 is comprised of eight coding 
exons (1-8) and one non-coding exon (0). The numbers below the red bar indicate the numbers of 
bases of intronic sequence and the numbers above the blue bars indicate the size of each intron, 
the light blue region indicates the T-box domain.  The start and stop codons are also shown. 
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1.2  EARLY MORPHOGENESIS OF THE HUMAN FACE  
 
A disturbance to any of the mechanisms involved in the correct fusion of the palatal 
shelves, from the very foundations of head formation right through to the final fusion 
of the palatal shelves themselves may result in a cleft of the palate (Satokata and 
Maas 1994). As mutations in TBX22 result in a cleft palate, then it is highly likely that 
TBX22 will be involved with one or more of these mechanisms during development. 
It is for this reason that the following background on the formation of the human face 
and palate is given; Table 1 provides a summary of the main events and timings and 
Fig. 3 summarises the precursors of the future face. The source and staging systems 
used for embryos and foetuses are given in section 2.2.1.  
 
 
Carnegie Stage Embryo or OPT Image Summary of events 
CS12 
 
 
 
Between ~CS9 and CS12, 
neural crest from specific 
neuromeres migrate to a pre-
determined position; either a 
specific pharyngeal arch 
(arches 1, 2 and 3 indicated in 
image), or the mesoderm 
surrounding the 
prosencephalon (p). 
 
 
 
CS13 
 
 
Nasal placodes (npl) form in 
the frontonasal process 
Paired swellings (mandibular 
processes) form from the first 
pharyngeal arch (mp). 
 
continued overleaf … 
P 1 2 
 3 
 
mp 
npl 
 11 
 
vCS14 
 
 
The mandibular processes have 
fused in the midline (mp). 
Appearance of the facial processes 
- medial (m) and lateral (l) nasal 
processes and the maxillary 
process (max) can be seen. 
CS16 
 
 
By CS15-CS16 fusion of the nasal 
and maxillary processes – forms 
the premaxilla. Fusion of the 
medial and lateral nasal processes, 
combined with deepening of the 
nasal pit (np) forms the anterior 
nares. 
CS17 
 
 
From CS16 to CS17, the palatine 
processes (pp) emerge from the 
maxillary processes. 
CS20  
 
Between CS19 and CS21, there is 
further proliferation of the palatine 
processes forming palatal shelves 
(ps) which extend vertically either 
side of the tongue. 
continued overleaf … 
max 
m 
l 
np 
mp 
m 
l 
max 
 pp 
  ps 
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CS22 
 
 
From around CS20 to CS22, 
the palatal shelves (ps) move 
to take a horizontal position 
above the tongue and continue 
to grow towards each other. 
9 wpc 
 
 
The palatal shelves contact 
and fuse with each other. The 
remains of the medial edge 
epithelia (mee) can be seen in 
the midline of the secondary 
palate. 
 
. 
 
Table 1: A summary of the key events during the formation of the human 
palate. Images representing CS12, CS13, CS14, CS16 and CS22 are optical 
projection tomography reconstructions (Sharpe et al. 2002) generated from 
intact embryos. Volume renders of the OPT reconstructions are shown at CS12 
and CS22 while surface renders of the reconstructions are shown at CS13, CS14 
and CS16. The CS17, CS20 and the 9 week post conception (wpc) foetus images 
are of the head with the mandible removed to aid viewing using a Zeiss stereo 
microscope. All specimens are from the Newcastle HDBR collection (see 2.2.1). 
  ps 
  mee 
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Figure 3: The development of the human face.  A schematic 
representation showing the structures formed during the development of 
the human face 
 
 
 
1.2.1  The Pharyngeal Arches 
 
The first external evidence of the pharyngeal arches, are the paired swellings of the 
mandibular (arch 1) and hyoid (arch 2) in the CS10 embryo. The arches form in 
cranio-caudal sequence and the five pharyngeal arches that develop in human 
correspond to numbers 1, 2, 3, 4 and 6 of the primitive complement in the 
evolutionary line leading to land vertebrates. Arch 5 never develops in humans, or 
else forms as a short lived rudiment and regresses (Larsen 1997). 
  
Initially, the arches resemble gills, except that, the gill slits never become perforated. 
Instead, the internal pharyngeal pouches (p, in Fig. 4) are separated from the external 
pharyngeal clefts (c, in Fig. 4) by three cell layers - an outer covering of ectoderm, an 
inner layer of endoderm and a central core of mesenchymal tissue derived from both 
neural crest and mesoderm.  
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Each of these different cell populations will eventually become distinct tissues: the 
ectoderm giving rise to the epidermis and sensory neurons associated with that arch 
(Couly and Le Douarin 1990); the endoderm will become the oral epithelia lining 
(Haworth et al. 2004); the mesenchyme derived from the neural crest and mesoderm 
will form primarily the smooth and skeletal muscles of the face and connective and 
skeletal tissues of the skull and jaw (Bhattacherjee et al. 2007). 
 
 It is important that the arches are patterned correctly, as distinct structures develop 
from different pharyngeal arches. The eventual structures that arise from each arch are 
summarised in Table 2. 
 
Table 2: A simplified summary of the structures that will form from 
each of the pharyngeal arches. The actual structures that are derived 
from each arch are more extensive than is represented here (Drake et al. 
2009).
Pharyngeal arch Structures 
1st (mandibular) Mandible and muscles of the lower jaw 
2nd (hyoid) Hyoid, stapes bone of the ear, the throat and neck 
3rd Elevator muscles of pharynx and tongue 
4th Constrictor muscles of the pharynx and vocal chords 
6th Muscles of the larynx 
Figure 4: The mammalian pharyngeal 
arches.  A frontal diagram representing the 
mammalian pharyngeal arches (adapted from 
Graham and Smith 2001). The components of 
the arches indicated by colour: Neural crest 
derived mesenchyme, yellow; ectoderm, green; 
mesoderm, blue; endoderm, red.  The external 
pharyngeal clefts (c) and the internal pharyngeal 
pouches (p) are highlighted. 
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 The embryonic neural tube (in the brain) is segmented anterior-posterior into 
prosencephalon, mesencephalon, and rhombencephalon. These are then further 
subdivided into discrete segments; known as neuromeres. Each neuromere has a 
specific identity in relation to its position along the neuroaxis (Fig. 5). The 
prosencephalon is divided into six prosomeres (p1-p6) (Rubenstein et al. 1994; 
Puelles and Rubenstein 2003), and the mesencephalon into two mesomeres (m1 and 
m2) which are separated from the rhombomeres by the isthmic neuromere (Muller 
and O'Rahilly 1997) . Rhombomeres 1-7 (rh1-rh7) can usually be distinguished while 
rh8 incorporates rhombomeres 8-11 (see Fig. 5).  This early segmentation of the 
embryo provides the blueprint for patterning the developing head and neck, largely 
dependent upon neural crest cells (NCC) that migrate from neuromeres and 
intermingle with other cell types in specific pharyngeal arches. NCC arising from the 
neural folds of the developing embryo are multipotent and migrate to form many 
varied structures (Bronner-Fraser 1995). As a general rule: neural crest migrating to 
cell populations of mesoderm generally induce membranous bone; in the absence of 
mesoderm, neural crest in contact with an epithelial derivative will induce only 
cartilage (Carstens 2002).  
  
The majority of experimental work investigating the role of neural crest in pharyngeal 
arch patterning has been performed in the chick due to the relative ease of 
transplantation of embryonic tissue. It is inferred from these experiments that the 
processes will be similar in human, although it must be remembered that in the 
following discussion the data comes from the chick, and must only be used as a model 
for development in human. 
 
The tissues that will arise from the each pharyngeal arch into which the neural crest 
cells migrate, is somewhat predetermined by the NCC themselves, prior to their 
migration from their neuromeres. This was demonstrated in chick and quail embryos 
by first exercising the NCC from pharyngeal arches 2 and 3 and replacing with 
transplanted NCC that would normaly migrate to the first pharyngeal arch, and then 
following the subsequent migration of these cells into the pharyngeal arches (Noden 
1983). This resulted in the animals developing tissues normally associated with the 
first pharyngeal arch, including a beak-like structure, being superimposed onto 
structures that would normally develop from pharyngeal arches 2 and 3.   
 16 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Each of the neuromeres can be defined by the gene expression that they exhibit (for 
review see (Trainor and Krumlauf 2001; Creuzet et al. 2005; Iimura and Pourquie 
2007; Wellik 2007) and references therein), and each neuromere shares a common 
gene expression pattern with the structures to which the neural crest from that 
neuromere migrates. For example, the nasal and orbital mesoderm shares a common 
gene coding with prosomeres p6 and p5 respectively, as this is where the neural crest 
in these structures originated from. It is because the same NCC populations are 
present in both of these structures that clinical conditions affecting naso-orbital 
structures are often accompanied by structural abnormalities of the prosencephalon 
(Carstens 2002).  
Figure 5: The neural crest from each rhombomere migrates to a 
specific position along the neuroaxis.  The neural crest cells (NCC) 
migrate from a specific neuromere (prosomere (P), mesomere (M1 and 
M2) or rhombomere (rh1-8)). A shows the position of the neuromeres 
along the neuroaxis and B indicates where the NCC from each 
neuromere migrates to. p1-p4 represent pharyngeal arches 1-4 (adapted 
from Creuzet et al. 2005). 
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Using quail-chick chimeras to study the long-term fate of neural crest subpopulations 
of individual neuromeres (Kontges and Lumsden 1996) showed that each pharyngeal 
arch mesenchyme is derived from a particular neuromere of the cranial neural crest 
(see Fig. 5). The most distal regions of the first arch, including those regions that will 
form the maxilla and palatine bones, are exclusively derived from the midbrain neural 
crest. The rhombomere 1 and 2 neural crest forms the more proximal regions of the 1st 
arch, with rhombomere 2 derivatives surrounding the middle ear cavity. The second 
arch was shown to be derived mainly from rhombomere 4 NCC, with a few cells from 
rhombomeres 3 and 5 that formed small cell islands. The NCC from rhombomeres 6 
and 7 were shown to mix freely with each other in the third and fourth pharyngeal 
arches.  This separation of neural crest into discrete migratory streams (i.e. neural 
crest from rhombomere 4 migrating to arch 2, and neural crest from rhombomeres 6 
and 7 to arches 3 and 4) is aided by the majority of neural crest cells from 
rhombomeres 3 and 5 undergoing apoptosis (Lumsden et al. 1991). The apoptosis 
seen in rhombomeres 3 and 5 is directed by the up regulation of Msx1 and Msx2 
(Graham et al. 1993). 
 
The majority of the pharyngeal arch mesenchyme is derived from neural crest 
originating in the rhombencephalon (Noden 1983). The HOX gene family show 
discrete expression domains within the rhombomeres, displaying a definite boundary 
of expression between the rhombomeres (Nieto et al. 1992). This expression is 
replicated in the pharyngeal arch that the NCC from these rhombomeres migrate to, 
such that each arch has a specific combination of HOX gene expression (Trainor and 
Krumlauf 2001; Wellik 2007). This shows that the mesenchyme within the arches is 
derived from neural crest from specific neuromeres, and implies that specific sets of 
HOX genes impart the molecular specification to allow correct positioning and 
identity to the arches, often referred to as the Hox Code (Hunt et al. 1991). It has been 
shown that mutations in these HOX genes result in phenotypes with disrupted arch 
formation (Condie and Capecchi 1993; Gendron-Maguire et al. 1993; Rijli et al. 
1993).  
  
The experiments of Noden and colleagues, described above, suggested that neural 
crest would be pre-programmed and that the NCC would themselves confer the 
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identity of the arch to the surrounding cells. However, by transposing neural crest 
from one rhombomere to a pharyngeal arch that it was not intended to migrate to, and 
by the subsequent expression of the correct HOX for that arch - despite the presence 
of the foreign neural crest - it was demonstrated that NCC display a certain amount of 
plasticity (Trainor and Krumlauf 2000; Schilling et al. 2001). It was suggested 
therefore, that patterning of the pharyngeal arches was determined by signalling 
between the neural crest and other cells in the surrounding environment. Indeed, it has 
been shown that pharyngeal arches are capable of forming in the absence of neural 
crest (Veitch et al. 1999), whilst maintaining regionalised identity. However, in order 
that the complex structures that arise from the pharyngeal arches that lower animals 
do not posses are formed, it is likely that interactions are necessary between signalling 
molecules arising from both the neural crest of the neuromeres, and the ectoderm, 
endoderm and mesoderm of the pharyngeal arches to which they migrate (Graham 
and Smith 2001; Trainor and Krumlauf 2001). 
 
 
 
1.2.2  Formation of the Facial Processes 
  
The tissue in front of prosomeres 5 and 6 is invaded by migrating NCC to establish a 
new layer of mesenchymal-ectomesenchymal tissue known as the frontonasal process 
(fnp in Fig. 6). The oronasal cavity (or stomodeum) is bound rostrally by the 
frontonasal process and caudally by the developing gut and cardiac plate (Fig. 6). The 
stomodeum is sealed from the outside amniotic cavity by the buccopharyngeal (or 
oropharyngeal) membrane, which will later breakdown around CS11 (Yoon et al. 
2000) which allows amniotic fluid to come into contact with the internal structures of 
the developing embryo (McLachlan 1994).  Two regions of thickened surface 
ectoderm appear in the frontonasal process of the CS13 embryo, the nasal discs, or 
placodes (O'Rahilly and Muller 1987). This is accompanied by the formation of a 
groove in the mandibular pharyngeal arch which gives rise to a pair of maxillary and 
mandibular processes (Yoon et al. 2000). 
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 These facial processes (or prominences): maxillary, mandibular and the frontonasal 
processes; were first described by the 19th Century Swiss anatomist Wilhelm His and 
will form the basic morphology of the human face. Carstens (2002) noted that each 
process is not a singular anatomical unit in itself, but is composed of many cell 
populations and therefore proposed the field theory of facial midline development. 
Field theory defines structures by the neuromeres from which they are coded: all 
structures derived from prechordal mesoderm are known as A fields and are coded by 
prosomeres p5 and p6; structures that are associated with paraxial mesoderm receive 
their coding from the rhombomeres and are known as the B fields. Therefore one 
must be mindful when describing fusion of the facial processes, that each process is 
not in itself a singular structure, rather it is composed of several cell types all 
interacting with each other and their surroundings, and that the facial processes that 
we see are the result of these inter-cellular interactions. 
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Figure 6: The Pharyngeal arches and frontonasal process. A 
stereomicroscopy image of the head region of a CS12 embryo 
from the Newcastle HDBR collection (see 2.2.1) indicating the 
frontonasal process (fnp), the recessed nasal placodes (np) and 
stomodeum (s). The first (1), second (2) and third (3) pharyngeal 
arches are also evident. The first pharyngeal arch is also called the 
mandibular arch. 
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The first of the facial prominences to fuse are the mandibular processes (Fig. 7). 
Extending from the lateral swellings on the mandibular pharyngeal arch, the two 
mandibular processes expand in a horizontal direction eventually merging with each 
other in the midline of the embryo. This process is almost complete in the CS14 
embryo “such that only a shallow depression remains central to a continuous structure 
on the rostral surface of the stomodeum” (Yoon et al. 2000). It is from this fused 
structure that the lower mandible, lip and other features associated with the lower jaw 
will develop. Proliferation in the mesenchyme of the frontonasal processes 
surrounding the nasal placodes (np in Fig. 6) produces a pair of swellings forming a 
horseshoe ridge around the placodes. These swellings are known as the medial nasal  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
process and lateral nasal process (mnp and lnp in Fig. 8a). The maxillary process is 
separated from the lateral nasal process by the nasolacrimal groove. The emergence of 
these nasal processes allows the nasal placodes to deepen forming a nasal pit. 
Figure 7: The 
mandibular processes 
are the first of the 
facial prominences to 
fuse. A transverse 
section through the 
pharagnyeal arches of a 
CS13 embryo, just prior 
to the fusion of the 
swellings of the 
mandibular processes. 
Taken from Gasser 
1975. 
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The formation of the upper lip and maxilla are formed by the continued growth and 
fusion of the nasal and maxillary processes. The medial and lateral nasal processes 
continue to swell which cause the nasal pits to deepen further and to fuse, forming a 
single ectodermal nasal sac. A nasal fin is formed by proliferation of ectoderm in the 
floor and posterior wall of the nasal sac (Moore and Persaud 2003). Vacuoles develop 
within the nasal fin, which forms the oronasal membrane. The oronasal membrane is 
then ruptured, thus forming a continuous chamber between the primary nasal cavity 
and primitive oral cavity (Kitamura 1989). 
 
As the nasal processes are enlarging, so too are the maxillary processes, which grow 
towards each other in a horizontal direction (mp in Fig. 8a), forcing the medial nasal 
processes towards each other and into the medial plane of the face.  
  
a       b     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The formation of the nasal processes.  (a) A schematic 
of a frontal view of the CS15 embryo (adapted from Kitamura 1989). 
fnp,frontonasal process; np, nasal pit; mp, maxillary process; man p, 
mandible process; mnp, medial nasal process; lnp, lateral nasal 
process. (b) A CS17 embryo from the Newcastle HDBR collection 
showing the nasal processes fused with each other and the maxillary 
process. The lateral palatal process can also be seen to be emerging 
from the maxillary process. 
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Following further enlargement and fusion of the facial processes, the morphology of 
the face begins to take shape (Fig. 9b). The medial and lateral nasal processes merge - 
closing the opening to the nasal sac, now known as the anterior nares. The medial 
nasal processes merge with each other and with the maxillary processes, making the 
groove between them indistinct in the CS19 embryo (Yoon et al. 2000). These 
combined fusions form a continuous structure above the mandible; namely the pre-
maxilla, which separates the anterior nares from the stomodeum. The pre-maxilla will 
give rise to the primary palate and the incisors. The region in which the medial nasal 
processes and maxillary processes fuse is known as the intermaxillary segment and 
from this the indent in the middle of the upper lip, the philtrum, is formed.  The 
maxillary processes also fuse with the lateral nasal processes along the nasolacrimal 
groove forming a continuation between the lateral side of the face and the nose (Fig. 
8a). During the fusion of the facial processes, the epithelial cell covering of the 
adjoining processes must disintegrate to allow a structure composed of continuous 
mesenchyme cells to be formed (see 1.2.5).  
 
1.2.3  Formation of the Secondary Palate 
  
At around 40 days of development from each of the maxillary processes emerge a 
further pair of swellings, the lateral palatal processes (Fig. 9a). These swellings 
proliferate, forming palatal shelves and grow vertically extending down into the oral 
cavity (Fig. 9c). The shelves then elevate above the tongue to a horizontal position 
and continue to extend until they come to abut each other and fuse (Luke 1976). The 
process of shelf elevation occurs within a few hours and there are several theories on 
the mechanism behind it, as reviewed by (Ferguson 1981; Shuler 1995), which can be 
categorised into two broad groups. 
 
In the first, the palatal shelves are thought to elevate through an involuntary process 
mediated by some extrinsic factor. This extrinsic factor is thought to act through 
forces exerted on the shelves as a consequence of pressure differences caused by the 
growth of the lower jaw, movement of the tongue and the head rising from the chest, 
all of which are seen in the developing embryo (Diewert 1983). The second group 
postulates that the shelves have some kind of intrinsic action, which enables them to 
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elevate.  This intrinsic force is likely to be chiefly generated by the progressive 
accumulation and hydration of glycosaminoglycans, mainly hyaluronic acid (or 
hyaluronate). Hyaluronic acid is a highly electrostatically charged molecule capable 
of binding up to ten times its own weight in water. It has been shown that hyaluronic 
acid (HA) makes up around 60% of the  extra cellular matrix of the palatal shelves in 
vitro and in vivo (Pratt et al. 1973). The accumulation of hyaluronic acid is 
regionalised to the anterior region of the palate, where it causes a swelling of 
extracellular matrix and a decrease in mesenchyme cell density brought about by 
changes in osmotic pressure (Brinkley and Bookstein 1986). This regionalised 
swelling, due to the induced osmotic force, is constrained and directed by the 
epithelial covering of the palatal shelves (Brinkley 1984; Brinkley et al. 1992), and 
partly by the anchoring of fibronectin and collagen III molecules throughout the 
extracellular matrix of the vertical palatal shelf (Ferguson 1988). This has the 
consequential effect of causing a swinging flip-up mechanism in the anterior third of 
the shelves (Brinkley and Morris-Wiman 1987). 
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Figure 9: The formation of the secondary palate and pre-maxilla. (a) 
Transverse sections through a CS17 embryo at the level of the eye (e) and 
(b) through the nasal pit (np); sections through the developing secondary 
palate in a CS21 (c); CS23 (d) and 9 week foetus (e). The fusion of the 
lateral nasal process (filled arrow), medial nasal process (arrow outline) 
and maxillary process (arrow head) form the pre-maxilla (b). The 
secondary palate is formed by the elongation of the lateral palatal 
processes (lpp), (b), which form vertical palatal shelves (ps), (c), either 
side of the tongue (t) which then grow horizontally toward each other (d) 
and eventually fuse with each other and the nasal septum (e). 3, 3rd 
ventricle; sc, spinal cord. 
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Transforming Growth Factor Beta, TGFβ, (D'Angelo and Greene 1991); 
Transforming Growth Factor Alpha, TGFα and Epidermal Growth Factor, EGF, 
(Turley et al. 1985) have been shown to stimulate the synthesis of HA in the palatal 
shelves. (Yoshikawa et al. 1987) showed that a Vitamin A derivative; retinoic acid 
(RA), was capable of reducing the production of glycosaminoglycans in cultured fetal 
mouse palatal shelf cells. Later, (Degitz et al. 1998) showed in whole palatal shelf 
cultures a significant delay of the presence of HA in palatal shelves grown in the 
presence of RA compared to that of the controls. These RA treated palatal shelf 
cultures showed delayed palatal shelf elevation – although the mesenchyme appeared 
to have undergone hydration. The expansion of the mesenchyme within the shelves 
altered the curvature of the palate pushing downward towards the oral cavity. These 
shelves were substantially smaller than the controls and never fused. The authors 
postulated that: precise timing of palate elevation is required for correct fusion. 
Interestingly, RA has been shown to be crucial to the proper formation of the facial 
prominences (Song et al. 2004). By blocking RA synthesis in the nasal placodes, Fgf8 
failed to be correctly regulated in this region, resulting in a significant increase in 
programmed cell death in the lateral nasal processes. 
  
After elevation of the palatal shelves, growth continues in a horizontal direction, until 
contact is established between the two palatal shelves and with the nasal septum: a 
structure which has arisen as a vertical protrusion into the oral cavity by growth of the 
merged medial nasal processes (Fig. 9e). The initial point of contact of the palatal 
shelves is the middle third region of the palate, with fusion spreading in both 
directions from here (Ferguson 1988). Fusion is completed along the entire length of 
the palate and with the primary palate in the anterior region of the mouth. 
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1.2.4  Extension of the palate  
 
Restricted expression of some genes to either the anterior – Msx1, Bmp2, Bmp4, 
Fgf10, Shox2 (Zhang et al. 2002; Alappat et al. 2005) or posterior – Meox2, Baxx1 
(Peters et al. 1998; Jin and Ding 2006) palate leads to the possibility of an 
anterior/posterior axis within the palatal shelves, distinguishing the anterior hard 
palate from the posterior soft palate (Hilliard et al. 2005). The anterior/posterior gene 
expression boundary was later shown to be linked to the formation of palatal rugae 
(Hilliard et al. 2005). Palatal rugae are regions of epithelia thickening which form 
transversal ridges on the hard palate in mammals (Peterkova et al. 1987; Pantalacci et 
al. 2008). The number of rugae varies according to species and also within species – 3 
or 4 in human, 7-10 in mouse depending on the strain and 18 in the horse (Pantalacci 
et al. 2008; Welsh and O'Brien 2009) and function to aid in mastication (Peterkova et 
al. 1987). The rugae of mouse and hamster have been shown to develop in a 
sequential manner within the anterior region of the palatal shelves. The first formed of 
which (R1)  is positioned at the junction of the future hard and soft palate (Welsh and 
O'Brien 2009). Additional rugae are then formed in the region anterior to first formed 
rugae, with the next ruga being positioned between the first and the most recently 
formed rugae. The addition of the forming rugae is accompanied with expansion of 
the region between R1 and the most recently formed ruga, such that all the previously 
developed and the most recently formed rugae are extended anteriorly away from the 
anterior/posterior junction thus extending the future hard palate (Welsh and O'Brien 
2009).  A proposed molecular mechanism for the sequential addition of rugue within 
the oral epithelia are formed and how this relates to the accompanied extension of the 
anterior palate has been proposed (Welsh and O'Brien 2009) and is outlined in Fig. 
10. 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
Figure 10: Models of the molecular and morphogenetic activity 
associated with the rugae growth zone (RGZ) (taken from Welsh and 
O'Brien 2009).   
(A) A suggested model of molecular interactions integrating FGF10 and 
BMP4 signalling during rugae formation within the RGZ has been 
proposed (Welsh and O'Brien 2009). Both Fgf10 and Bmp4 are required 
for epithelial expression of Shh. Fgf10 is expressed in a gradient 
extending from R1 to the site of nascent rugae formation. It is proposed 
that FGF10 signalling, mediated through ∆Np63α and its targets Jag2 and 
Fgfr2b, maintains proliferation of epithelial progenitors at the posterior 
end of the RGZ. Epithelial expression of the Bmp4 antagonist Sostdc1 in 
the anterior palate also requires Fgf10. Sostdc1 acts to restrict induction 
of Shh in the RGZ. Induction of Shh and p21 expression at the site of the 
next forming rugae results in epithelial differentiation while continued 
proliferation of inter-rugae epithelium moves the R1+n rugae away from 
the RGZ. Signals from the R1+n rugae (bar and arrow) are also proposed 
to influence the fate of RGZ epithelium.  
 
(B) The anterior growth of the anterior palate (ant) proceeds from the first 
formed rugae (red arrow) and is coincident with the establishment of 
segmental signalling domains (rugae). Fusion of the bilateral shelves 
requires medially directed growth (red arrowheads) and patterning of the 
medial edge epithelium (MEE, pink). The lateral boundary of the MEE 
coincides with the medial edge of the rugae, suggesting that signals from 
the rugae also participate in the intrinsic program that patterns the MEE. 
Thus, rugae and the RGZ provide a reference frame for visualizing the 
organization of signalling domains with respect to the anterior–posterior 
and medial–lateral patterning and growth of the palatal shelves. 
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1.2.5  Removal of the midline epithelia cells  
 
The epithelia covering the palatal shelves are divided into oral, nasal and medial edge 
epithelia (MEE), depending on their regional position, and each cell type has a 
different fate: the nasal epithelia differentiate into pseudo-stratified epithelia; the oral 
epithelia into squamous epithelia; the epithelial cells covering the shelves in the 
region of fusion – namely, the medial edge epithelia – are removed (Chai and Maxson 
2006).  
 
Upon fusion, the opposing palatal shelves adhere to each other through a coat of 
glycoprotein molecules secreted by the MEE (Greene and Kochhar 1974) and by the 
formation of desmosomes (DeAngelis and Nalbandian 1968; Mogass et al. 2000), 
thus forming a midline epithelial seam (MES). It has been shown that the cell 
adherence properties of the MEE is specific and will not fuse with other epithelia 
under normal conditions (Ferguson et al. 1984). 
  
The palatal shelves, similar to every other soft tissue in the oronasal region, are 
covered by two layers of epithelial cells: an inner layer of basal cells on the basement 
membrane; and an outer layer, consisting of periderm cells (Dudas et al. 2007). The 
periderm cells either peel out from the epithelial surface layer prior to contact of the 
palatal shelves, or else they become trapped by the two opposing shelves after fusion 
and undergo apoptosis (Fitchett and Hay 1989). The basal epithelia form the MES 
following fusion.  
  
For complete unison of the shelves to occur and a continuous secondary palate of 
confluent mesenchyme cells to be formed, the MES must be removed. The process 
through which the MES is removed is still the subject of some debate and even the 
same technique has revealed contradictory results. The evidence for and against the 
principle mechanisms proposed for MEE removal is shown in Table 3.   
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Method Used Observations and Interpretations Suggestion or Evidence  References 
No midline-crossing migration of green cells into the wild type tissue, 
suggesting that the MES cells die and/or migrate away from midline. 
No epithelia-mesenchyme 
transformation. (Cuervo and Covarrubias 2004) CCFSE – intravital permanent epithelial 
staining (whole palates and living palatal 
slices. 
After fusion, labelled cells identified as fibroblasts in the mesenchyme Epithelia-mesenchyme transformation. 
(Griffith and Hay 1992; Sun et al. 1998; Kang 
and Svoboda 2002) 
Tracing with adenovirus expressing lacZ. No midline-crossing migration of labelled cells into the mesenchyme No Epithelia-mesenchyme transformation. (Cuervo and Covarrubias 2004) 
Tracing with retrovis expressing lacZr. Clusters of labelled cells into the mesenchyme Epithelia-mesenchyme transformation. (Martinez-Alvarez et al. 2000) 
Lineage tracing with transgenic reporters. No epithelial cells migrate into the mesenchyme. No labelled cells of the 
epithelial origin are present in the palatal midline after fusion. 
No Epithelia-mesenchyme 
transformation. (Vaziri Sani et al. 2005; Dudas et al. 2006) 
GFP transgenic shelves fused with wild-
type shelves. 
No midline-crossing migration of green cells into the wild type tissue, 
suggesting that the MES cells die and/or migrate away from midline. 
Intraepithelial interactions (mixing) of green and wild type cells in the MES 
at the time of peak occurrence of apoptosis. Limited to shelf-to-shelf 
migration of oral and nasal epithelial cells recorded. 
No epithelia-mesenchyme 
transformation, Epithelial 
motility. 
(Cuervo and Covarrubias 2004) 
MEE cells migrate vertically from the midline towards the oral and nasal 
surfaces, but not into the mesenchyme or across the midline. 
No epithelia-mesenchyme 
transformation migration. 
(Carette and Ferguson 1992; Tudela et al. 
2002; Cuervo and Covarrubias 2004) 
Cell tracing after labelling with lipophilic 
fluorescent dyes DiO and/or Dil. 
MEE cells migrate vertically from the midline towards the oral and nasal 
surfaces, but not into the mesenchyme or across the midline. 
Epithelia-mesenchyme 
transformation. (Shuler et al. 1991; Shuler et al. 1992) 
Blocking cell migration by cytochalasin D. Oral and nasal epithelial triangles not found, and cell death did not occur in 
any of MES cells Periderm migration. (Cuervo and Covarrubias 2004) 
continued overleaf … 
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Multiple apoptotic cells detected by TUNEL. Cell death. 
(Mori et al. 1994; Taniguchi et al. 1995; 
Martinez-Alvarez et al. 2000; Cuervo et al. 
2002; Holtgrave and Stoltenburg-Didinger 
2002; Martinez-Alvarez et al. 2004) 
Molecular detection of apoptosis, 
No apoptotic cells detected by TUNEL. Epithelia-mesenchyme transformation. (Nawshad et al. 2004) 
MES persists, no fusion occurs, the basal lamina stays intact, and no 
migration of labelled cells detected in the mesenchyme. This suggests either 
that the occurrence of EMT is low and insufficient to allow for palatal 
fusion, or that EMT does not occur prior to the death of the MES cells at all. 
Also suggests that basement membrane degradation is secondary to cell 
death (“cataptosis”) and not vice versa (“anoikis”). 
Cell death. (Cuervo et al. 2002; Cuervo and Covarrubias 2004) 
Complete fusion occurred No cell death (Honarpour et al. 2000; Takahara et al. 2004) 
 
 
 
 
 
 
 
 
 
 
 
Blocking of cell death (± combined with 
epithelial cell labelling), 
Palatal fusion failed (after Apaf1 gene inactivation in mice) Cell death (Cecconi et al. 1998) 
continued overleaf … 
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Table 3: A summary of the evidence for and against the principle mechanisms involved with MES disappearance. (Taken 
from Dudas et al. 2007). 
All cells disappear from the midline. Cell death, no anoikis. (Cuervo and Covarrubias 2004) 
Apoptosis occurs naturally, but the mesenchyme of apposed shelves remain 
separated by intact basement membranes without cells, suggesting basement 
membrane degradation is secondary to cell death (“cataptosis”) and not vice 
versa (“anoikis”). 
Cell death, no anoikis. (Cuervo and Covarrubias 2004) 
Blocking of degradation of the basement 
membrane (BM) by MMP inhibitor, 
Cells did not disappear from the midline. Cell death, anoikis. (Blavier et al. 2001) 
Removal of the periderm by tripsin, No triangles formed, and resulting palate is thinner. Periderm migration. (Cuervo and Covarrubias 2004) 
No cell death or EMT seen, only epithelium migrating orally and nasally. Migration. (Carette and Ferguson 1992; Bittencourt and Bolognese 2000) 
No cell death seen, only epithelium changing to mesenchyme. Epithelia-mesenchyme transformation. (Fitchett and Hay 1989; Nawshad et al. 2004) 
Signs of cell death seen: dense bodies, autophagic vacuoles, lysomes. Cell death. 
(Pourtois 1966; DeAngelis and Nalbandian 
1968; Farbman 1968; Hayward 1969; Smiley 
1970; Holtgrave and Stoltenburg-Didinger 
2002) 
Bulging cells observed, protruding from the MEE towards the opposite 
shelf. 
Epithelial cell 
motility.(Martinez-Alvarez 
et al. 2000; Martinez-
Alvarez et al. 2000) 
(Martinez-Alvarez et al. 2000; Martinez-
Alvarez et al. 2000) 
Electron and/or light microscopy 
observations, 
All three: EMT, death, and migration occur (statements based purely on 
static images). MEE cells can disappear from shelves before contact when 
amniotic fluid is not present in culture. 
Epithelia-mesenchyme 
transformation, apoptosis, 
migration. 
(Tsai and Verrusio 1977; Schupbach and 
Schroeder 1983; Takigawa and Shiota 2004) 
Examination of cell differentiation markers. MEE cells express cytokeratin and vimentin, and profusion midline 
mesenchyme just vimentin 
Epithelia-mesenchyme 
transformation. 
(Fitchett and Hay 1989; Shuler et al. 1991; 
Shuler et al. 1992) 
 
Assessing metabolic health of midline cells. Midline cells are alive and healthy. No cell death (Gartner et al. 1978; Gartner et al. 1978) 
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1.2.6  Palate formation in other vertebrates  
 
Much of the understanding of human palate development has been derived from work 
using animal models in which a wide range of experimental and genetic tools are 
available (e.g. Jheon and Schneider 2009) and experimental manipulation is possible 
that for obvious ethical reasons would not be possible in human subjects. Although 
the information obtained from experiments using animal models is often very 
revealing (reviewed in Gritli-Linde 2008), it should be noted that the formation of the 
secondary palate varies in birds, amphibians and reptiles to that of mammals, 
reviewed in Ferguson (1988).  
 
The palatal shelves of birds arise from the maxillary processes, but instead of 
extending vertically they develop in a horizontal direction. The palatal shelves contact 
each other but the MEE never adhere. The MEE cells also do not produce 
glycoproteins or desmosomes, instead, these cells keratinise - leaving birds with a 
naturally occurring cleft palate (Koch and Smiley 1981).  
  
In amphibians and some reptiles, the roof of the mouth consists largely of an extended 
primary palate; although other reptiles have a secondary palate similar to that found in 
birds, and the palate of the crocodilians is fused, similar to the mammalian secondary 
palate. The formation of a secondary palate seems to be an evolutionary feature 
exclusive to higher vertebrates and is absent in species lower on the evolutionary tree, 
including fish.  
   
Although the development of the palate proceeds in mostly the same fashion in all 
mammals, there are differences between species. The floor of the nasal chamber in 
human, for example, recedes following the disruption of the oronasal membrane (see 
1.2.2), to form a singular oro-nasal cavity; in non-primate mammals, including mouse, 
the floor of the nasal region consists of a “continuous cartilaginous flange” (Carstens 
2002). 
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1.3 CLEFT PALATE 
 
Stedman’s medical dictionary describes a cleft palate as “a congenital fissure in the 
median line of the palate, often associated with cleft lip” (Stedman 2005). Any 
orofacial cleft, either of the palate or lip, is formed as a consequence of two 
embryonic structures that would normally fuse during development, not being able to 
properly do so.  Improper fusion of any of the lateral nasal, medial nasal or maxillary 
processes (Fig. 8) may result in a child being born with a cleft lip or with a cleft of the 
primary palate, or in some instances both. As there are two pairs of these processes at 
either side of the developing face, such clefts may be present as either unilateral or 
bilateral.  A cleft of the secondary palate is formed when there has been incomplete 
fusion of the palatal shelves.  
 
 
1.3.1.  Syndromic and Non-syndromic CL/P  and CPI 
  
A cleft lip, with or without a cleft palate, is conventionally notated as CL/P and 
isolated cleft palate CPI. A cleft of either the palate or the lip is referred to as “non-
syndromic” in incidences where no other anomalies are present; or conversely, if an 
orofacial cleft is present together with other clinical features then the cleft is classed 
as “syndromic”.  
 
Several hundred syndromes are known to have a cleft lip or palate along with other 
abnormalities (OMIM; http://www.ncbi.nlm.nih.gov/omim/) and in many of these 
cases, a specific gene has been identified, for example: IRF6 - Van der Woude and 
popliteal pterygium syndromes (Kondo et al. 2002); MID1 – Opitz syndrome 
(Quaderi et al. 1997); ESCO2 - Roberts syndrome (Vega et al. 2005) and many more 
have been shown to be caused by chromosomal abnormalities, such as DiGeorge 
syndrome which is caused by a deletion in chromosome 22 (Kelley et al. 1982). It is 
now thought that some of the genes responsible for syndromic clefts may also 
underlie non-syndromic clefts, either through incomplete penetrance or through the 
action of additional genetic or environmental factors (Stanier and Moore 2004). In 
addition to the syndromes mentioned above, IRF6 has also been attributed to non-
syndromic CL/P (Zucchero et al. 2004; Blanton et al. 2005; Scapoli et al. 2005). Van 
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der Woude is the most common form of syndromic CL/P and is often seen together 
with a pit of the lower lip. Although people affected by Van der Woude syndrome 
may also have brain abnormalities, they are often undetectable without an MRI scan 
and in cases where lower lip pits are absent, Van der Woude is impossible to 
differentiate from non-syndromic CL/P. 
 
 
1.3.2  The Aetiology of Cleft palate  
 
A cleft palate may arise as a consequence of incorrect development at any stage of 
palatogenesis: an anomaly in palatal shelf growth; delayed or failed shelf elevation; 
defective shelf fusion or a failure of medial edge epithelium cell death (reviewed in 
(Kerrigan et al. 2000; Murray and Schutte 2004; Rice 2005; Meng et al. 2009). These 
events are orchestrated by restricted gene expression and protein signalling, requiring 
precisely timed cell interactions and modifications. Disruptions to these processes 
lead to the failure of the correct fusion of one or more of the facial prominences, 
ultimately leading to facial anomalies, which in many cases display as a facial cleft.  
 
A cleft of the secondary palate at birth can be caused by an anomaly at any time 
during the patterning of the pharyngeal arches, as well as incorrect growth or fusion 
of the palatal shelves, or incomplete disintegration of the MEE. Abnormal timing of 
head movements and tongue position in the mouth during embryogenesis have also 
been proposed as potentially being involved in forming a cleft palate (Ferguson 
1981). The mammalian tongue occupies the space of the oral cavity to such an extent 
that the vertical palatal shelves cannot extend horizontally until the tongue has 
physically moved to enable sufficient space for the shelves to extend horizontally. It 
has therefore been suggested that incorrect movement of the tongue during 
development may in turn lead to insufficient space in the oral cavity for the horizontal 
extension of the palatal shelves, thus resulting in a cleft. 
 
The actual aetiology of why normal development of the head and palate are distrupted 
and a cleft is formed appears to have both genetic and environmental contributing 
factors.  The mutilfactorial threshold model of inheritance (Roberts 1961; Roberts 
1964) used to model the inheritance of pyloric stenosis, has since been applied to the 
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inheritance of a cleft palate (Fraser 1976; Fraser 1996; Fraser 1998; Lin et al. 1999).  
The multifactorial threshold model of inheritance (MFT) postulates that the various 
genetic and environmental factors are interacting to provide a “continuous distribution 
of liability”. This liability is separated by a threshold value. In the case of cleft palate, 
Fraser explains that the liability can be thought of as the embryonic stages over which 
the palatal shelves are fusing. The threshold is the time point at which the shelves can 
no longer fuse with each other. Any factor that contributes to delaying the movement 
or fusion of the palatal shelves will increase the frequency of liability. The closer that 
an embryo is to the threshold, the more likely any delay in palate formation will result 
in the threshold stage being missed and therefore the susceptibility to a cleft will be 
increased. Although this model has been challenged recently by a Norwegian study 
(Sivertsen et al. 2008), the data produced from a much larger study (Grosen et al. 
2009), concluded that their data supported a mutlifactorial threshold model of 
inheritance. 
 
 
1.3.3  Cleft Palate Risk Factors 
 
A.  ENVIRONMENTAL FACTORS  
 
There have been many studies into the various environmental factors that contribute 
to the liability of a cleft palate. That is to say; non-genetic causes influencing the 
disruption, or delaying, the correct formation of the head, face and palate. Such 
environmental factors have been shown to include: parental age and maternal weight 
(Bille et al. 2005; Cedergren and Kallen 2005); geographic location (Poletta et al. 
2007), which the authors ascribe to variance in altitude and socioeconomic status; 
seasonal variance (Krost and Schubert 2006), attributed to differences in exposure to 
ultra-violet light, fluctuations in diet and infectious disease cycles; exposure to 
various teratogens, including cigarette smoke, alcohol, mutil-vitamins and anti-
epilepsy drugs (Wyszynski and Beaty 1996; Shaw and Lammer 1999; Heilbronner 
2005).   
 
Various genetic risk factors have also been discovered (1.3.3.B), but it must be 
remembered that inheritance of cleft palate is multifactorial and as such, the effect of 
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environmental factors and genetic susceptibility to a cleft palate must be considered 
together. Despite this, gene-environment studies remain relatively few and difficult to 
interpret given the nature of these studies where so many unknown variables can 
influence findings. Indeed, whilst one study has shown the incidence of cleft palate to 
be higher in children born with a mutation in the cleft palate candidate gene TGFα if 
they had a maternal parent who smoked (Shaw et al. 1996), other studies have shown 
no such association between these two factors (Beaty et al. 1997; Christensen et al. 
1999; Zeiger et al. 2005).  
 
B.  GENETIC FACTORS 
 
It was postulated relatively early that CL/P may have an hereditary component (Fogh-
Anderson 1942).  Reports have shown that gender is a determining factor; with cleft 
lip and palate being more common in males than females and cleft palate only, being 
more likely to be seen in females than males (Fraser 1970). In the most recent, and 
largest study to date, studied data from a Danish cohort of over 54000 relatives of 
individuals with an oral cleft (Grosen et al. 2009), the risk of oral cleft recurrence 
between first, second and third degree relatives was established. This study found that 
recurrence of a non-syndromic isolated cleft lip or palate between first degree 
relatives was 2.7%, with a relative risk – the ratio of the probability of a first degree 
relative of an individual with non-syndromic cleft lip being born with the same 
condition to that of the probability an individual being born with the condition in the 
background population – of 13. This effectively means that a first degree relative of 
an individual with isolated cleft palate would be 13 times more likely to be born with 
the same malformation. Relative risk for first degree relatives were established for 
non-syndromic cleft lip and palate (risk – 3.5%; relative risk 17) and non-syndromic 
isolated cleft palate (risk 3.1%, relative risk 15) (Grosen et al. 2009). Relative risks 
were also calculated for second and third degree relatives.  Such information is 
invaluable in the counselling of families with these conditions (Gagnon et al. 2009), 
however with more complete understanding of the genetics involved in the 
inheritance of an oro-facial cleft, more accurate calculations of the risk of recurrence 
can be made e.g. depending on the specific genetic risk factor involved. 
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 To date, there have been 12 distinct loci identified for non-syndromic CL/P 
designated orofacial cleft (OFC) 1-12 (Table 4) and in some of these cases a specific 
gene has been identified (Stanier and Moore 2004; Carinci et al. 2007). Of the six 
genes that have been confirmed as being causative agents in CL/P, four of those are 
also involved in syndromic CL/P diseases.  
 
Non-syndromic loci 
MIM number 
Gene 
Chromosomal 
Location 
OFC1 119530  6p23-p24 
OFC2 602966 TGFα ? 2p13 
OFC3 600757 
BLC3 ? 
/PVR?/PVRL2 
19q13 
OFC4 608371 SCD5 ? 4q21-q31 
OFC5 608874 MSX1 # 4p16.1 
OFC6 608864 IRF6 # 1q32-q41 
OFC7 225060 * PVRL1 # 11q23.3 
OFC8 129400  * TP63 # 3q27 
OFC9 610361  13q33.1-q34 
OFC10 601912 SUMO1 2q33 
OFC11 600625 BMP4 14q22-q23 
OFC12 612858  8q24.31 
 
Table 4: A list of known loci for CL/P (Adapted from Carinci et al. 
2007 and OMIM (http://www.ncbi.nlm.nih.gov/omim/ [28 Feb 2010]). A 
? denotes that linkage studies have suggested a link between CL/P and 
that gene in the region, but has not been confirmed to date. # denotes that 
this gene has also been implicated in a syndromic CL/P condition, * 
denotes that the MIM number actually refers to a syndrome in which an 
orofacial cleft is a feature of the phenotype, but the entry also includes 
reference to the highlighted non-syndromic OFC loci. 
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 Of particular interest is the OFC10 locus, small ubiquitin-like modifier 1 - 
SUMO1.  The SUMO1 protein is known to target specific proteins through a process 
known as sumoylation. This is a reversible action, capable of modifying the protein in 
question altering protein stability, facilitating transcriptional regulation and nuclear 
transport and apoptosis(Su and Li 2002; Meulmeester and Melchior 2008). There are 
4 known SUMO genes in human, SUMO1, SUMO2, SUMO3 (Su and Li 2002) and 
SUMO4 (Bohren et al. 2004). A balanced translocation in the SUMO1 gene was 
identified in individual with non-syndromic cleft lip and palate (Alkuraya et al. 2006). 
Further evidence of the importance of SUMO1 in palatogenesis has been provided by 
gene expression studies in mice, which demonstrated that SUMO1 is expressed within 
the primary and secondary palate and in the developing lip (Alkuraya et al. 2006). 
Moreover, a number of the heterozygous Sumo1Gt/+  mice displayed a cleft palate or 
oblique facial cleft and in Sumo1Gt/+; Eyal +/- compound heterozygotes the occurrence 
of cleft palate (36%) was significantly increased (Alkuraya et al. 2006). However,  a 
separate Sumo1 gene trap mutant generated phenotypically normal mice, suggesting 
that SUMO proteins may compensate for one another (Evdokimov et al. 2008).  
SUMO1 has been shown to interact with other proteins implicated in palate 
formation, including SATB2, SMAD, MSX1, SOX9, EYA1,  p53, p63 and TBX22 
(Rodriguez et al. 1999; Dobreva et al. 2003; FitzPatrick et al. 2003; Lin et al. 2003; 
Huang et al. 2004; Taylor and Labonne 2005; Alkuraya et al. 2006; Gupta and Bei 
2006; Andreou et al. 2007) and reviewed in (Pauws and Stanier 2007; Gritli-Linde 
2008). This extensive number of proteins points towards a common genetic pathway 
regulating palatogenesis.  Interestingly, sumoylation has been shown to be affected by 
various environmental factors including: heat shock, oxidative and osmotic stress and 
viral infection (Meulmeester and Melchior 2008), thus providing a link between the 
known genetic and environmental influences involved in the CL/P. 
 
Although the known causative loci for non-syndromic genes is still relatively limited 
(Table 4), there are other genes that have been implicated in human non-syndromic 
oro-facial clefts on the basis of human gene linkage association studies, gene 
expression and phenotypic analysis gained from animal models and mutants 
(reviewed in Gritli-Linde 2008; Jugessur et al. 2009) and shown in Table 5.
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Gene References 
CHD7 (Felix et al. 2006) 
CRISPLD2 (Chiquet et al. 2007) 
ESR1 (Osoegawa et al. 2008) 
ESCO2 (Vega et al. 2005) 
FGF3 (Riley et al. 2007a) 
FGF8 (Riley et al. 2007a) 
FGF10 (Riley et al. 2007a) 
FGF18 (Riley et al. 2007a) 
FGFR1 (Riley et al. 2007a) 
FGFR2 
(Riley et al. 2007a; Riley et al. 
2007b; Osoegawa et al. 2008) 
FGFR3 (Riley et al. 2007a) 
FOXE1 (Vieira et al. 2005) 
GABRB3 
(Scapoli et al. 2002; Inoue et al. 
2008) 
GAD1 (Kanno et al. 2004) 
GLI2 (Vieira et al. 2005) 
IRF6 (Kondo et al. 2002) 
JAG2 (Vieira et al. 2005) 
LHX8 (Vieira et al. 2005) 
MSX1 (van den Boogaard et al. 2000) 
MSX2 (Vieira et al. 2005) 
MYH9 (Martinelli et al. 2007) 
PTCH 
(Mansilla et al. 2006; Carter et al. 
2010) 
PAX9 (Ichikawa et al. 2006) 
PVR (Warrington et al. 2006) 
Gene References 
PDGFC (Ding et al. 2004) 
PVRL1 (Suzuki et al. 2000) 
PVRL2 (Warrington et al. 2006) 
RARA (Chenevix-Trench et al. 1993) 
RUNX2 (Sull et al. 2008a) 
RYK Watanabe et al., 2006 
SATB2 
(Brewer et al. 1999; FitzPatrick et 
al. 2003; Vieira et al. 2005) 
SKI (Vieira et al. 2005) 
SPRY2 (Vieira et al. 2005) 
TBX1 
(Yagi et al. 2003; Paylor et al. 2006; 
Zweier et al. 2007) 
TBX10 (Vieira et al. 2005) 
TBX22 
(Braybrook et al. 2002; Marcano et 
al. 2004) 
TCOF1 (Sull et al. 2008b) 
TFAP2A (Milunsky et al. 2008) 
TGFA (Carter et al. 2010) 
TGFB1 
(Nawshad et al. 2004; Stoll et al. 
2004) 
TGFB3 (Lidral et al. 1998) 
TP63 (p63) 
(Celli et al. 1999; McGrath et al. 
2001) 
WNT3A (Chiquet et al. 2008) 
WNT5A (Chiquet et al. 2008) 
WNT11 (Chiquet et al. 2008) 
WNT9B (Juriloff et al. 2006) 
Table 5: Genes implicated in human syndromic orofacial clefting based on evidence from human genetic studies, 
mouse models, and expression data in orofacial primordial (from Gritli-Linde 2008; Jugessur et al. 2009). 
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Although there are fewer loci genes identified for CPI, the first reported study 
suggesting that the genetic heredity of cleft palate may follow an X-linked pattern was 
described in 1966 (Weinstein and Cohen 1966); although cleft palate was not the only 
clinical feature present in this family. An X-linked inheritance for CPI was described 
in an British Colombia Indian family (Lowry 1970) and then a single causative gene 
for non-syndromic cleft palate was eventually mapped to a locus on the X 
chromosome in an Icelandic population (Moore et al. 1987; Bjornsson et al. 1989). In 
affected individuals in the Icelandic pedigrees presenting with problems of the 
secondary palate, the severity varied from a complete cleft of the secondary palate, 
through a fused but sumbmucous cleft with an associated bifid uvula, to a high 
vaulted palate. In some cases there was no obvious palate cleft at all, but patients 
showed signs of ankyloglossia. Indeed, ankyloglossia was often seen in many cases in 
conjunction with the observed secondary palate malformations and it was therefore 
speculated that the cleft palate may in fact be a secondary consequence caused by 
inappropriate cell death in the tongue during palatogenesis (Gorski et al. 1992; Stanier 
et al. 1993).  As the inheritance of this trait followed an X-linked pattern, the disease 
was given the notation CPX – X-linked cleft palate (MIM# 303400).  Linkage 
analysis mapped the CPX locus to marker DXYS1X (Moore et al. 1991) on the long 
arm of the X chromosome in the region Xq21.1. This CPX locus was then further 
refined (Gorski et al. 1992; Stanier et al. 1993; Gorski et al. 1994) and finally TBX22 
was identified as the causative gene (Braybrook et al. 2001).  Usually affected males 
are seen with cleft palate and ankyloglossia (CPA), although they do present CPI 
17%, and rarely with ankyloglossia alone 4%. Female carriers vary from being fully 
affected, to displaying an entirely normal phenotype - CPA 11%, CPI 6%, 
ankyloglossia alone 43% and unaffected 40% (figures from Stanier and Moore 2004). 
Loss-of-function mutations have been found in coding regions of TBX22 in CPX 
patients (Braybrook et al. 2002; Marcano et al. 2004; Suphapeetiporn et al. 2007). A 
haplotype containing risk single nucleotide polymorphisms within the promoter 
region of the TBX22 gene and consequently reducing transcription of TBX22, has also 
been associated with cleft palate and ankyloglossia (Pauws et al. 2009b). The severity 
of the palate cleft seen in these CPX patients varies greatly, with the most severe 
cases presenting with a complete cleft of both the hard and soft palate, whilst others 
display a submucous cleft palate (SMCP), a condition where a layer of mucosa covers 
the roof of the mouth, but the underlying muscles do not join correctly leading to 
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velopharngeal insufficiency. SMCP may also present with uvula bifida – a splitting of 
the uvula, or a v-shaped notch in the hard palate, a translucent line in the midline of 
the soft palate and a short palate (Wales et al. 2009). Cases where a SMCP has not 
given rise to velopharyngeal insufficiency are referred to as occult SMCP (Pauws et 
al. 2009a). CPX patients may also present with ankyloglossia together with any of 
these features, or indeed it may be the only clinical feature present.  
 
There is also statistical evidence for a second CPI locus at 2q32 (Brewer et al. 1999). 
Two genes in this region have been suggested as possible candidates - TGFα and 
SATB2. Several studies have tried to link TGFα and SATB2 to CPI with varying 
degrees of success (FitzPatrick et al. 2003; Vieira 2006; Leoyklang et al. 2007).  It is 
likely that sampling biases lack of statistical power, and genuine population diversity 
have all contributed to the various studies leading to differing conclusions as to 
whether or not these genes are implicated in CPI. 
 
As previously mentioned all of the syndromic cases of CL/P must be considered as 
potential candidates for non-syndromic CL/P too (Stanier and Moore 2004). Due to 
the mutilfactorial nature of CL/P, different genetic or environmental modifiers could 
affect the clinical presentation of a mutation in such a gene. As well as the known 
syndromic and non-syndromic CL/P causing genes, targeted gene disruption in animal 
models provide us with yet more possible CL/P candidate genes, as do gene 
expression profiles that reveal genes which are expressed in the facial prominences 
during development.  
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1.3.4  Detection, Treatment and Outcomes  
 
In countries where routine antenatal ultrasound checks are common place, an oral 
cleft is often detected prior to birth. Even where antenatal ultrasound checks are not 
routine, a cleft lip being an external feature will be recognised immediately after birth. 
However a cleft palate, particularly a sumbmucous cleft palate, in isolation is 
sometimes harder to detect and is sometimes not diagnosed until some weeks after 
birth. However, with the arrival of 3-dimensional ultrasound techniques, antenatal 
diagnosis is improving (Maarse et al. 2010). Suckling problems and faltering weight 
gain in children born with a CL/P are common (Beaumont 2008) and advice is often 
given by a specialised health practitioner on techniques to help mothers breastfeed 
and specialist aids can be offered to assist with this (Cole et al. 2009). In some cases, 
particularly with children born with a cleft of the secondary palate, children are 
unable to produce sufficient negative pressure in the oral cavity and therefore cannot 
move the bolus backward to the pharynx; rendering suckling impossible. In such 
cases the child will be fitted with a palatal lift obturator to aid nutritional intake prior 
to surgery (Karayazgan et al. 2009). In extreme cases feeding via a nasogastric tube is 
necessary (Oliver and Jones 1997). 
 
After a period of around three to six months surgical repair of the cleft  can be 
undertaken (De Mey et al. 2009). Follow up surgery is also sometimes required and a 
bone graft may be required in later childhood. A significantly higher proportion of 
children born with a facial cleft present with otitis media with effusion, or glue ear, 
than children who do not have a facial cleft (Flynn et al. 2009). This often leads to 
long term hearing difficulties, even following successful palate repair (Sharma and 
Nanda 2009)and may require separate surgical intervention and/or require the use of a 
hearing aid (Zambonato et al. 2009). 
 
Whilst children born with a cleft lip usually develop speech normally, those born with 
a cleft palate are more likely to experience difficulties with speech development. Such 
speech development problems have also shown to affect their intelligibility, social 
competence and emotional development (Rullo et al. 2009), although the intervention 
of a speech therapist can reduce these effects. 
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Many cleft palate diseases are also associated with tooth abnormalities (van den 
Boogaard et al. 2000)and children often have to undergo orthodontic treatment to 
correct for teeth malformations. A higher proportion of tooth decay has also been 
observed in children born with a cleft lip or palate than those without (Al-Dajani 
2009). 
 
The emotional and physiological impairment to a child born with an oro-facial cleft is 
not to be underestimated. Their physical appearance and social embarrassment from 
not being understood contribute to reducing, to varying degrees, their quality of life 
into adulthood even following a complete treatment plan including surgery, speech 
therapy and audiology management (Mani et al. 2010). The reality exists that whilst 
children born in the Western World receive intervention from multidisciplinary teams 
offering both primary and secondary care (Austin et al. 2010), many of those children 
born with a cleft in underdeveloped countries will be denied access to any of this 
treatment due to the prohibitive costs of treatment in these countries. Left untreated 
these unfortunate children are often destined for a life of rejection due to social 
ignorance of their deformity and many never go to school. Without education and 
lacking social skills these children grow up never being unable to find employment 
(Mendoza 2009). 
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1.4 AIMS AND STRUCTURE OF THE THESIS 
 
The overarching goal of the thesis is to increase our understanding of the role that 
TBX22 plays during normal development and in CPX. 
 
 There are four specific aims of this thesis: 
 
1. To investigate the spatial and temporal expression of TBX22 during 
early human development, with a particular focus on the developing 
face and palate (Chapter 2).  Potential functions of TBX22 can be 
postulated from the timing of and tissue type where TBX22 is 
expressed.  
 
2. To synthesise a TBX22 protein, in its native conformation, so that it 
can be used in functional studies to determine a preferential DNA 
binding site for TBX22 (Chapter 3). Finding genes that contain this 
sequence is one approach to identifying potential downstream 
targets of TBX22. 
 
3. To define potential TBX22 downstream targets and screen their 
promoters in silico for the presence of possible TBX22 binding sites 
(Chapter 4). Identifying potential downstream targets will suggest 
pathways in which TBX22 may be involved and hence possible 
mechanisms for its action(s).  
 
4. To investigate the possibility that one of the genes identified by the 
in silico search is a TBX22 downstream target in vivo (Chapter5). 
Characterising the interaction of TBX22 and one of the potential 
downstream targets will validate the results gained in silico and 
provide stronger evidence for one possible role for TBX22.  
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CHAPTER 2 
 
EXPRESSION OF TBX22 DURING EARLY HUMAN 
DEVELOPMENT 
 
 
 
2.1  INTRODUCTION 
 
Since mutations in the TBX22 gene had been shown to cause CPX ((Braybrook et al. 
2001); reviewed in Chapter1) it was likely that TBX22 played a significant role in the 
normal development of the palate. Elucidating its expression pattern would be an 
important first step towards understanding exactly when and where TBX22 could be 
exerting its effect(s). It might distinguish, for example, between the possibilities that 
the cleft palate seen in CPX arose as a secondary consequence of the incorrect 
separation of the tongue from the floor of the mouth during palatogenesis (leading to a 
decrease in the amount of space available in the oral cavity to allow correct fusion of 
the shelves) or alternatively, if the cleft might be due to a failure of the growth or 
fusion of the palatal shelves themselves (see 1.3.2). 
 
TBX22 expression was examined at the RNA level by tissue in situ hybridisation. 
Studying the RNA, rather than the protein, has the advantage that primers or probes 
can be easily synthesised to be specific for a particular region of the mRNA. Although 
when working with RNA, the additional technical issues of eliminating RNase 
contamination become important. There are various methods to study the RNA 
expression profile of a gene of interest. RT-PCR amplifies cDNA which has been 
generated from RNA within the sample tissue using the reverse transcriptase enzyme 
with specific primers ensuring detection of the gene of interest.  However, this 
approach only gives a “yes or no” answer as to whether an mRNA is present in the 
experimental sample or not. Any indication of the tissue specificity of expression is 
dependent on the degree to which the tissue sample can be sub-divided by dissection 
but there is no indication of cellular distribution of the RNA within the dissected 
tissue. As detection is performed by amplifications of the RNA within tissues, some 
low level transcripts or even cross-contamination from nearby tissues can produce 
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unexpected results. Early RT-PCR studies of the full length TBX22 transcript 
indicated that TBX22 was expressed in all of the fetal tissues examined (Braybrook et 
al. 2001), perhaps indicating that TBX22 did not have a tissue specific expression. 
Real time quantitative PCR (Chiang et al. 1996; Gibson et al. 1996; Heid et al. 1996), 
whilst still being limited to the same sample size restraints as traditional RT-PCR has, 
as the name suggests, the additional benefit of measuring the abundance of an RNA 
transcript within a particular sample allowing the level of expression in one tissue to 
be compared to that of another.  
 
Insights into whether there are different RNA transcripts within a tissue may be 
gained by Northern blot (Alwine et al. 1977). This entails blotting a labelled probe to 
a membrane blot of an RNA gel of a tissue sample. Information about the spatial 
distribution is again limited by the range of tissues tested and the specificity of the 
tissue sample dissections. This was highlighted when the TBX22 gene was first 
cloned. As tissue from the palate was not included in the test tissues, no mRNA 
transcript was detected in any of the human adult or fetal tissues tested in a northern 
blot hybridisation (Laugier-Anfossi and Villard 2000). However, this technique does 
give insights into the size and number of RNA transcripts (Law et al. 1998). 
 
Originally using RNA or DNA probes to detect specific DNA molecules within a 
tissue sample, tissue in situ hybridisation, first described in 1969 (Gall and Pardue 
1969; Pardue and Gall 1969) enabled detection directly within a histological sample. 
There have been many refinements to the technique since 1969, including the use of 
RNA probes to detect RNA molecules within tissue sections and as whole-mount 
preparations (Hargrave et al. 2006). By directly hybridising probes to tissue 
preparations of various ages, the temporal and spatial expression patterns can be 
visualised in the host tissue. Hence, this technique was chosen to characterise the 
temporospatial expression pattern of TBX22 during facial development.  
 
It was important that this study be undertaken directly in human. It has been shown 
that although a gene’s coding sequence may be highly conserved during evolution, 
this does not necessarily indicate that its expression pattern will also be conserved 
(Fougerousse et al. 2000). It has also been noted that there are differences between 
gene expression patterns in human and other vertebrates. For example, Tbx5 
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expression has been shown to be heart chamber specific in chick and mouse (Bruneau 
et al. 1999) although this specificity has not been reported in humans (Li et al. 1997). 
Despite potential differences in expression patterns between, for example, mouse and 
human, the expression profiles of many genes have been studied using other species 
as a model for human development, partly due to the relative ease with which such 
tissue is available to researchers and to the variety and extent of experimental studies 
that can be performed. To facilitate cross-species comparisons, studies have defined 
equivalent developmental stages in different species (summarised in Table 6 and see 
http://embryology.med.unsw.edu.au/) although these are estimates based on the 
development of a number of organ systems and specific organs and tissues may 
develop at differential rates across species (Clancy et al. 2001; Clancy et al. 2007) 
including the formation of the face and secondary palate (see 1.2).  
 
Much valuable information has been obtained by studying mouse gene expression 
patterns (Bush et al. 2002; Herr et al. 2003; Kim et al. 2009b; Pauws et al. 2009a). 
However, in some aspects mouse is not an ideal model of human oral development. 
For example, although displaying a fused palate, tooth development differs and they 
only have one set of teeth. The formation of rugae, which have been proposed as a 
signalling centre determining anterior and posterior palate (Pantalacci et al. 2008; 
Welsh and O'Brien 2009), occurs during palatal shelf growth in mice but are only 
reported in humans after fusion has occurred (Patil et al. 2008).  
 
Animal models, especially mouse, have provided many useful tools for the 
understanding of human disease, for example by knocking out, reducing or altering 
the expression of specific genes. However, the resultant phenotypes do not always 
match the human disorder they were designed to mimic. Indeed, the Tbx22 mouse null 
mutant displayed differences to the human CPX phenotype it models (Pauws et al. 
2009a). A major phenotypic feature of this mutant was choanal atresia, which has not 
been described in the CPX phenotype. Also, ankyloglossia was found in all of the 
Tbx22 mutants examined. Ankyloglossia is variably penetrant and often not seen at all 
in CPX. Therefore comparing the expression pattern of human to that of mouse will 
help to assess how much reliance can be placed upon a mouse model of CPX. 
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TBX22 expression was investigated during the time when the face is forming, from 
~33 days – 9 weeks (see 1.2). Particular attention was paid to the formation of the 
palatal shelves; as developmental delays in the formation of the shelves are thought to 
determine whether a cleft of the secondary palate, as seen in CPX patients, will occur 
(see 1.2.3).  
Human Mouse Chick 
Carnegie 
Stage 
Age 
(dpo) 
Theiler 
Stage 
Age 
(dpc) 
Hamburger-Hamilton 
(HH) Stages 
Age 
(dpc) 
9 20 12 8 7-8 1 
10 22 13 8.5 9-10 1.5 
11 24 14 9 11-13 2 
12 28 15 9.5 14-17 2.25 
13 30 16 10 18-21 2.5 
14 33 17 10.5 21-22 3 
15 36 18 11 23-24 3.25 
16 40 19 11.5 24-25 3.75 
17 42 20 12 26 4.75 
18 44 21 13 27-28 5.5 
19 48 22 14 29 6.25 
20 52 23 15 30 7.25 
21 54 24 16 31-32 7.75 
22 55 25 17 33-38 8.5 
23 58 26 18 39-44 10 
Table 6: A cross-species comparison of developmental timings (Butler and 
Juurlink 1987; O'Rahilly and Muller 1987; Hamburger and Hamilton 1992) 
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2.2  MATERIALS AND METHODS 
 
Tissue in situ hybridisation (TISH) using 35S-UTP labelled riboprobes was employed 
to determine the temporal and spatial mRNA expression pattern of TBX22 directly in 
human embryonic tissue. These expression studies were undertaken using material 
made available from the MRC-Wellcome Trust Human Developmental Biology 
Resource (www.HDBR.org). 
 
 
2.2.1  Embryo collection and Processing 
 
Human embryonic and fetal tissues were collected by the MRC-Wellcome Trust 
Human Developmental Biology Resource (HDBR) in Newcastle (Lindsay and Copp 
2005), with ethical approval by the Newcastle and North Tyneside Local Research 
Ethics Committee and appropriate maternal consent. Following either surgical or 
medically induced termination of pregnancy (Bullen et al. 1998), embryos were 
staged using the Carnegie stage classification; using the definitions in Table 7, which 
is taken from the staging guidelines in (Bullen and Wilson 1997). These staging 
guidelines are a revision of the original definitions of (O'Rahilly and Muller 1987) 
and are based on external characteristics of single embryos, rather than a comparison 
of several embryos at the same Carnegie stage. This staging system describes 
specimens prior to fixation, a process that often leads to artificial changes in 
morphology and is especially useful as no dissection is necessary and minimal 
manipulation of the embryo is needed in order to stage it, which is obviously desirable 
given the delicate nature of the unfixed embryo. 
 
 The fetal human samples (those older than CS23) that were collected were staged 
using the guidelines set out in Table 8. The fetal staging guide uses foot and knee to 
heel lengths to estimate developmental age and is adapted from (Hern 1984). 
  
Where possible, all embryos are subjected to karyotype analysis using a small amount 
of placental tissue or, in cases where there is insufficient tissue, a skin sample from 
the embryo itself. Only embryos that have a normal chromosomal complement and 
arrangement are used in this study and two embryos are used at each stage to verify 
the findings.  
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The embryos were fixed in 4% PFA/PBS for 24 hours and then transferred to 70% 
ethanol. After successive changes through a graded series of 80%, 90% and 100% 
ethanol (AnalaR, BDH) the embryos were then embedded in paraffin wax (Fibrowax, 
BDH). Serial sections were taken using a standard microtome at 5µm intervals and 
mounted onto Marienfeld HistoBond slides. To aid with orientation through the 
embryo, every ninth section was stained with haematoxylin and eosin, following the 
standard procedures for paraffin sections (Wilson and Gamble 2002).  
 
Carnegie 
Stage 
External Characteristics – 
“diagnostic” 
Secondary 
features 
Crown – Rump 
length (mm) 
10 Mainly open neural groove; 
up to 12 somites  1.5 – 3 
11 Anterior neuropore closing, posterior open  2.5 – 4.5 
12 No limb buds, or minimal 
upper bud 
Posterior 
neuropore may be 
open 
3 – 5 
13 4 limb buds, tiny lowers  5 – 7 
14 Tapering upper limb, no hand plate Open lens pit 7 – 9 
15 Hand plate now Lens pit closed 11 - 14 
16 Foot plate and retinal pigment 
Pharyngeal arch 3 
receding. Auricular 
hillocks 
11 - 14 
17 Digital rays of hand; full 
round foot plate 
Full auricular 
hillocks now 11 - 14 
18 Notched hand +/- elbow Eyelid folds in later specimens 13 - 17 
19 Prominent toe rays 
Limbs all extended 
nearly directly 
forward 
17 - 20 
20 Stubby fingers; toe notches; 
vascular plexus of head  
Elbows bent. 
Hands still well 
apart 
21 - 23 
21 
Fingers longer, getting closer. 
Toes not just notches, may 
touch 
“Tactile pads” on 
ends of fingers 22 - 24 
22 Fingers touch/overlap. Vascular plexus ¾
 
up head 
Ear features more 
prominent 25 - 27 
23 
Vascular plexus almost at 
vertex. Limbs generally more 
mature. 
Eyelids may be 
starting to fuse at 
margins 
28 – 30 
 
 
Table 7: Embryo staging guide (from Bullen and Wilson, 1997) 
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Fetal Age 
(completed 
menstrual weeks) 
Developmental Age 
(weeks post 
fertilisation) 
Foot length 
(mm) 
Knee – heel 
length  
(mm) 
10 8 (CS23) 5 - 6 8 
11 9 (F1) 7 11 
12 10 (F2) 8 - 9  13 
13 11 (F3) 10 – 12 17 
14 12 (F4) 13 – 16 24 
15 13 (F5) 17 – 19 31 
16 14 F6) 20 – 22 36 
17 15 (F7) 23 – 24 40 
18 16 (F8) 25 – 27 43 
 
Table 8: Fetal staging guide (from Hern, 1984) 
 
 
 
2.2.2  Tissue in Situ Hybridisation 
  
TISH was performed using radio labelled RNA probes and visualised by coating the 
slides with a photo-sensitive emulsion. The method was devised by Moorman and his 
colleagues (Moorman et al. 1993) and is described below. For this procedure all 
glassware was pre baked at 180oC for 4 hours to denature any potential contaminating 
RNase enzymes. 
 
A. DNA TEMPLATE PREPARATION 
 
A 336-bp fragment (nucleotides 640-976 of Genbank accession no. NM_016954) - 
which includes regions of exon 6 and 7 outside of the T-box domain to increase 
specificity - was cloned into a pGEM-T vector between the T3 and T7 RNA 
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polymerase promoter sites. This plasmid was a kind gift from Dr. Laurent Villard and 
was used as a template to synthesise RNA probes. 1µg of plasmid DNA were digested 
to completion with either SalI restriction enzyme (Promega) to generate the sense 
probe, or ApaI (Promega) to generate the antisense probe. The sequences of both the 
sense and antisense probes were determined (3130XL, Applied Biosystems) and then 
verified using the BLAST alignment program (Altschul et al., 1990), housed at the 
National Centre for Biological Information (NCBI (http://www.ncbi.nlm.nih. gov/)) to 
ensure that they were specific to TBX22 mRNA and that there was minimal similarity 
to other sequences. As expected 100% similarity was seen between the probe template 
sequence and all three TBX22 mRNA transcripts, with 94% similarity between the 
probe and the TBX22 genomic sequence. The highest similarity of the probe to a 
sequence other than TBX22 was to a 61 nucleotide region of TBX1 (NM_ 005992 
797-857). As TBX22 shares the highest sequence homology to TBX15 and TBX18 
(see 1.1), the probe sequence was blasted directly against the mRNA sequences of 
these genes (NM_152380 and NM_001080508). This resulted in a 74% match 
covering 250 nucleotides for the TBX15 mRNA and 68% similarity over a 231 
nucleotide region for TBX18. These results meant that it was very unlikely that either 
sense or antisense probe would cross-hybridise to other RNA targets. 
 
The DNA was purified by 1:1 phenol/chloroform extraction, precipitated with 96% 
ethanol and 0.3M NaAc, washed with 70% ethanol and resuspended in 10µl TE buffer 
(10mM Tris, 1mM EDTA, pH 7.6). The linearised plasmid DNA was verified by 
visualisation on 1% agarose check gel, and the size of the linearised DNA was 
confirmed by comparison to a 1kb ladder (Promega). DNA concentration was 
estimated by comparing the intensity of the electrophoresed DNA band to a known 
amount of λ phage DNA pre-digested to completion with a HindIII restriction enzyme 
(Promega).  
 
B.  RNA TRANSCRIPTION AND INCORPORATION OF RADIOACTIVE 35S-UTP 
  
The linearised template DNA was used to synthesise sense and antisense RNA probes 
via transcription with either T3 or T7 RNA polymerase respectively. 500ng of 
linearised template DNA was added to a transcription reaction containing a final 
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concentration of 500µM ATP (Roche), 500µM CTP(Roche), 500µM GTP(Roche),  
500µM (50 µCi) 35S-UTP (Amersham Biosciences), 1X RNA transcription buffer 
(Roche), 1U/µl RNAsin (RNAase inhibitor, Sigma), 50µM DTT, 1U specific RNA 
polymerase (Roche) and double distilled DEPC treated H2O in a 10µl volume. The 
reaction was incubated at 37oC for 2 hours, and then the DNA template was digested 
by the addition of 1U DNAse (Roche) and incubated at 37oC for a further 15 minutes.  
Unincorporated NTPs and the template DNA fragments were removed by adjusting 
the volume to 100µl, adding the equivalent volume of 1:1 ratio phenol 
(Sigma)/chloroform (BDH), mixing and following centrifugation at 12000g for 5 
minutes in a microcentrifuge, applying the aqueous phase to a NICK column 
(Amersham). The probe was eluted from the column by the addition of TE buffer and 
further purified by ethanol precipitation (see 2.2.2.A) with the addition of 1µl Yeast 
tRNA (Sigma) as a carrier, and finally resuspended in 10µl TE/10mM DDT.   
 
C.  QUANTIFICATION 
 
The amount of RNA probe used in each experiment was adjusted to a standard 
working concentration, based on the incorporation of 35S-UTP. This was achieved by 
measuring 0.5µl aliquots of the probe in 1ml of scintillation fluid and counting the 
isotopic activity using a liquid scintillation counter (Camberra-Parkard, Tricarb 
2100TR) and adjusting the volume of TE buffer until the probe reached a 
concentration of 106 cpm/µl. 
 
D.  PROBE HYBRIDISATION 
 
DEPC treated Milli-Q water was added to the required amount of probe estimated to 
give 5x104 cpm/µl and the RNA probe denatured by heating for 5 minutes at 96oC.  
The denatured probe was added to a hybridisation mix of final concentration; 50% 
deionised formamide, 10% dextran sulphate, 2X SSC, 2X Denhardt’s solution 
(Sigma) , 0.1% Triton X-100 (Sigma), 10mM DTT (Sigma) and 2000ng/ml salmon 
sperm DNA (Sigma).  
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Paraffin was removed from the tissue sections by immersing the slides in 3 changes of 
xylene for 5 minutes and rinsing for 3 minutes in 1:1 xylene/ethanol and twice in 
absolute ethanol. The slides were dried for 1 hour before being soaked in 2N HCl for 
20 minutes, rinsed in water and washed in 2X SSC at 70oC for 10 minutes. The tissue 
was the subjected to proteolytic digestion in a 1% pepsin solution at 37oC for varying 
times dependent upon the age of the tissue: CS16, 3 minutes; CS17, 3.5 minutes; 
CS19, 4 minutes; CS20, 4.5 minutes; CS23, 6 minutes and 9 week fetal, 6.5 minutes. 
This was necessary to permeate the cells to increase the accessibility of the target 
mRNA. The pepsin was neutralised by rinsing in a 0.2% glycine/PBS solution.  The 
sections were then fixed in 4% PFA/PBS for 20 minutes, to maintain the localisation 
of the nucleic acids, before being air-dried. 6µl of the probe/hybridisation mix was 
placed onto each section and hybridised in a humidified chamber at 52oC overnight. 
 
E.  POST HYBRIDISATION WASHES 
 
Following hybridisation, the sections were rinsed with 5X SSC and washed twice 
with 50% formamide/1X SSC 10mM DTT and once with 1X SSC 10mM DTT for 15 
minutes at 52oC.  Slides were next washed in RNAse buffer at 37oC then transferred 
to fresh 1X RNAse buffer containing 1U RNAse for 30 minutes at 37oC.  Finally the 
slides were washed with 1X SSC, then 0.1X SSC for 15 minutes each at 52oC.  The 
slides were then dried in a filtered airstream for 1 hour.  
 
F.  VISUALISATION 
 
The dry slides were coated in Ilford K5 photographic emulsion under dark room 
conditions.  The coated slides were then exposed to the emulsion for ten days. The 
emulsion was developed using Kodak D-19 developer and fixed in 30% 
Na2S203.5H2O.  The sections were then counter stained with 0.1 % nuclear fast red 
kernechtrot (R. A. Lamb) with 5% aluminium sulphate, dehydrated in ethanol, cleared 
in xylene and mounted in mananol (Klinipath) and covered with a glass cover slip. 
 
G.  IMAGING 
  
58 
 The glass mounted slides were examined using a Zeiss Axioplan microscope 
using a dark field viewing stage and illumination (Leica). Whole embryos were 
viewed using a Zeiss stereo-microscope MC80. On both microscopes digital images 
were recorded using an Axicocam camera and Axiovision (version 3.2) software 
package (Imaging Associates). 
59 
2.3  RESULTS 
 
The sense probe did not show any signal in any of the in situ hybridisation 
experiments (Fig. 11f and Fig. 12e and f and data not shown). During the early 
formation of the jaw and palate, at CS14 and CS15, TBX22 was not detected, or was 
expressed at levels below those which could be detected by in situ hybridisation (Fig. 
11).  
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Figure 11: TBX22 is not detected at CS14 or CS15. A CS14 embryo, sagittal 
section (a and b) and transverse section (c); a CS15 embryo sectioned 
transversely (d – f). a and d are bright field images of haematoxylin and eosin 
stained sections, b, c and e are dark-field images of antisense TBX22 probe f is 
a dark-field images of sense probe. Arrow, mandibular process; arrow head, 
maxillary process; 1, first pharyngeal arch; s, somites; sc, spinal cord. Bar = 
100µm. 
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It was not until CS16 that the first definitive expression of TBX22 during the 
formation of the face was detected (Fig. 12). The expression in the CS16 embryo was 
detected most strongly in the maxillary process (the arrow in Fig. 12) and appeared 
stronger in lateral (Fig. 12c) than medial sections (Fig. 12d), although weaker 
expression was seen surrounding the nasal pit in both medial and lateral sections (Fig. 
12c and d).  
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Figure 12: TBX22 is expressed in the nasal and maxillary processes of a 
CS16 embryo. Transverse sections of a CS16 embryo, lateral (a, c and e) and 
midline sections (b, d and f).  a and b are bright field images of haematoxylin 
and eosin stained sections, c and d are dark-field images of antisense TBX22 
probe and e and f are dark-field images of sense probe. Bar = 100µm. np, nasal 
pit; arrow, maxillary process; arrow head, mandibular process; p2, second 
pharyngeal arch. 
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The site of this expression in the CS16 embryo corresponded to the maxillary process 
and also the area surrounding the nasal pit. There was no obvious expression detected 
in the mandibular process in any of the embryonic stages studied (figs. 11 – 16 and 
data not shown). 
At CS17, strong, restricted expression was observed in the mesenchyme of the medial 
and lateral nasal processes and the lateral palatal processes (Fig. 13). Signal was also 
detected in the frenulum of the tongue and the mesenchyme of the future skull 
beneath the forebrain and surrounding the eye. This expression was observed in the 
medial and lateral nasal processes at the front of the stomodeum in the CS19 embryo 
(Fig. 14e), as they swelled to form the nasal sacs and the primary palate. (see 1.2.2).  
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Figure 13: Expression of TBX22 in the CS17 embryo. TBX22 is 
expressed in the maxillary processes and medial and lateral nasal 
processes. Transverse sections of a CS16 (a) and (b) and CS17 (c) and 
(d) though the stomodeum. (a) and (c) are dark-field images of 
antisense TBX22 probe and (b) and (d) are bright field images of 
haematoxylin and eosin stained sections. Bar = 400µm. max, maxillary 
process; man, mandibular process; p2, second pharyngeal arch; lpp, 
lateral palatal process; m, medial nasal process; l, lateral nasal process; 
t, tongue. No expression was seen with sense probes (data not shown). 
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Further towards the back of the oronasal cavity, expression was detected in the 
swellings of the lateral palatal processes (Fig. 10c) although the expression reduced at 
the rear most region of the stomodeum (Fig. 11a). By CS 20 (Fig. 12a and b) and 
CS21 (Fig. 12c - f), intense expression was evident in the most posterior ends of the 
vertically extending palatal shelves and the floor of the tongue, which has by now 
mostly separated from the mandible.   
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Figure 14: TBX22 is expressed during the formation of the primary and 
secondary palate. Transverse sections of a CS19 embryo, at the back (a and 
b), middle (c and d) and front of the stomodeum (e and  f). (a), (c) and (e) are 
dark-field images of antisense TBX22 probe and (b), (d) and (f) are bright 
field images of haematoxylin and eosin stained sections. Bar = 400µm. lpp, 
lateral palatal process; m, medial nasal process; l, lateral nasal process; t, 
tongue. No expression was seen with sense probes (data not shown). 
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Very intense expression was detected in the swellings of the lateral palatal processes 
of the CS19 embryos (Fig. 14c). The regions of the maxillary processes where the 
palatine processes were not expanding showed reduced expression (figs. 14a and e); 
although localised expression was detected in the mesenchyme surrounding the nasal 
pit (Fig. 14e) and the region where the maxillary and mandibular processes will fuse 
along the nasolacrimal groove (Fig. 14a, see 1.2.2 for more detail). The signal in the 
base of the tongue, first seen at CS17 (Fig. 13c), continued to be detected at CS19 
(figs. 1c and e). 
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Figure 15: TBX22 expression in the extending palatal shelves and in the 
frenulum of the tongue. Transverse sections of a CS20 (a) and (b) and a 
CS21 (c) and (d) embryo. (a) and (c) are dark-field images of antisense TBX22 
probe and (b) and (d) are bright field images of haematoxylin and eosin 
stained sections. Bar = 1000µm. ns, nasal septum; ps, palatal shelf; t, tongue. 
No expression was seen with sense probes (data not shown). 
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By CS20 (figs. 15a and b) and CS21 (figs. 15c and d), intense expression was most 
evident in the regions closest to the oral cavity of the vertically extending palatal 
shelves and the floor of the tongue, which has by now mostly separated from the 
mandible.   
 
At CS23, TBX22 expression was down regulated in the palatal shelves (figs. 16a); 
although, there was a clear band of expression in the mesenchyme of the nasal septum 
adjacent to the epithelial cells where fusion with the palatal shelves will occur (Fig. 
16e). After 9 weeks of development the shelves have fused and TBX22 was 
completely undetected in the palatal shelves (Fig. 16c and e). At this time the 
restricted expression seen at the base of the tongue had become more widespread 
through the whole of the tongue and the expression in the nasal septum was now seen 
throughout the nasal cartilage. The forming odontogenic mesenchyme was now 
expressing TBX22 as well as the regions where cartilage will form in the septum and 
wings of the nose (om in Fig. 16d).
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Figure 16: TBX22 is down regulated as the palatal shelves fuse. 
Transverse sections of a CS23 embryo (a) and (b), and a 9 week foetus (c – 
f). (a), (c) and (e) are dark-field images of antisense TBX22 probe and (b), 
(d) and (f) are bright field images of haematoxylin and eosin stained sections. 
Bar = 1000µm. ns, nasal septum; ps, palatal shelf; t, tongue. No expression 
was seen with sense probes (data not shown). (c) and (d) are sections through 
the anterior region of the stomodeum in the region of the pre-maxilla and (e) 
and (f) are more posterior sections through the secondary plate. 
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2.4  DISCUSSION 
 
As TBX22 functions as a transcription factor (see 1.1), the ideal methodology to 
reveal the tissues where TBX22 was exerting its effect would be by investigating the 
protein expression pattern, using an antibody specific to the TBX22 protein. However, 
at the time of performing these studies no suitable commercial antibody was available 
to do this. Such antibodies are now available, although they have not been validated 
for use in immmunohistochemistry experiments. Therefore, there were two options 
available: either produce an antibody to use for this purpose, or use an alternative 
method. A major obstacle in the production of antibody is to verify its specificity, 
especially in relation to other related proteins, which in this case would be other T-
box family members. To allay doubts as to cross-hybridisation with other T-box 
proteins and to ensure that an accurate temporal and spatial expression pattern was 
determined, rather than investigate the TBX22 protein expression, the alternative 
approach of determining the TBX22 mRNA was undertaken. A probe was designed 
such that only 74% similarity existed between the nearest human T-box homologs  
TBX15/18 and then only over a 250 nucleotide region of a 336 nucleotide probe. 
Although radioactive tissue in situ hybridisation was undertaken to study the 
expression of TBX22, non-radioactive methods have now been developed (Darby et 
al. 2009) which retain the sensitivity of radioactive methods but have the added 
advantage of cellular resolution. This would now be the method of choice and was 
employed in later tissue in situ hybridisation experiments (Chapter 4). 
 
Unlike the results of the RT-PCR screen in which all tissues examined showed 
expression of TBX22 (Braybrook et al. 2001), tissue in situ hybridisation revealed a 
very specific expression profile in the developing human. Expression is observed 
from an early period in craniofacial development, prior to the formation of the palatal 
processes and then in the mesenchyme of the extending palatal shelves until fusion. 
Significantly, strong expression is also detected in the floor of the tongue. This 
expression pattern correlates well with the observed phenotype in the CPX disorder: a 
cleft of the secondary palate and ankyloglossia. However, there are also regions of 
TBX22 expression in tissues other than those associated with CPX and this will be 
discussed in section 2.4.3. 
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2.4.1  TBX22 Expression correlates with the CPX phenotype  
 
TBX22 expression was first detected at CS16, in the maxillary processes as they 
extend from the first pharyngeal arch (Fig. 12c). From this stage until fusion, TBX22 
is expressed in the mesenchyme of all developing oronasal processes: the medial and 
lateral nasal processes and the palatal shelves (figs. 12 – 16). This is most evident in 
the palatal shelves where the expression is seen at the tip of the expanding shelves as 
they extend into the oral cavity.  
 
Just prior to fusion of the shelves at CS23, the expression in the palatal shelves is 
down regulated and the expression is restricted to a thin band in the nasal septum 
where it will fuse with the shelves. Post fusion of the shelves, after approximately 9 
weeks of development, the expression in the palate shelves is completely undetectable 
as it is in the region where they have fused with the nasal septum.  Throughout the 
formation of the secondary palate, strong expression is detected at the base of the 
tongue in the region where cell apoptosis is occurring to enable the tongue to separate 
from the floor of the mouth. This is consistent with the ankyloglossia phenotype seen 
in CPX patients, whereby the frenulum linguae does not recede sufficiently and 
instead continues to extend the full length of the tongue (Bjornsson et al. 1989). 
 
 
2.4.2  A Mechanism for a Cleft Palate 
 
As expression is observed in both the palatal shelves and at the base of the tongue, it 
is likely that the cleft palate and the ankyloglossia features observed in CPX are 
independent of each other and that the cleft palate seen in CPX patients is not due to 
incorrect movement or position of the tongue during palatogenesis, but involves errors 
in the growth or fusion of the palatal shelves themselves. TBX22 within the palatal 
shelves is only present during the extension of the palatal shelves and after fusion an 
mRNA transcript is no longer detected. In the 9 week foetus after the shelves have 
fused and the medial edge epithelia (MEE) is transforming to mesenchyme (Fig. 16e 
and f), TBX22 expression is no longer evident in the shelves, suggesting that TBX22 
has no direct function in this process. The expression in the palatal shelves is at its 
most prominent in the mesenchymal tissue during the period when they are extending 
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(figs. 12-15) and the expression appears to be down regulated as this process nears 
completion (Fig. 16). Thus, from the expression profile of TBX22 in the palatal 
shelves during palatogenesis, it would appear that the cleft palate in the CPX is a 
consequence of insufficient growth of the palatal shelves and not as a result of 
incorrect fusion of the shelves. However, studies of the TBX22 mutant mouse (Pauws 
et al. 2009a) revealed that the major role played by TBX22 during palatogenesis is in 
orchestrating osteoblast formation, although studies in the chick do suggest that 
TBX22 does also have a role in regulating proliferation (Higashihori et al. 2010). 
 
 
A. A POSSIBLE FUNCTION OF TBX22 
 
As expression of TBX22 is not detected until the formation of the maxillary processes 
(Fig. 12, earlier stages not shown), it would appear unlikely that TBX22 has a role in 
directing neural crest cells to the first pharyngeal arch. It would seem that TBX22 
exerts its influence on palate formation at a later stage of development, perhaps in the 
mesenchyme cells in the region in which it is expressed. Due to the intense expression 
during the extension of the palatal shelves (figs. 12-15) and subsequent down 
regulation just prior to fusion of the shelves (Fig. 16), it does suggest, that TBX22 has 
an influence on a gene or genes which are involved in either establishing or 
maintaining cell proliferation during the initiation and/or extension of the palatal 
shelves until such time that the two shelves have extended far enough that fusion 
between them is possible. While it might be postulated that TBX22 is regulating a 
pathway of cell proliferation during the establishment and extension of the medial and 
lateral nasal processes and the palatal shelves, it would seem that the reverse might be 
true where expression is seen in the region of the floor of the tongue. At this stage of 
embryonic development, the cells in this region are undergoing apoptosis. This may 
suggest that: TBX22 is in fact a regulator of programmed cell death; however, if this 
was true in the palatal shelves, one would envisage that a mutation in TBX22 leading 
to a loss of protein function (Braybrook et al., 2001) would give rise to an over 
enlarged palate rather than the underdeveloped palate observed in the CPX phenotype. 
One explanation is that TBX22 has more than one target; it may act to regulate 
different pathways in different tissues. Indeed, it has been shown that T-box genes 
have several different downstream targets. The Xenopus Brachyury protein (Xbra), for 
example, has been shown to have at least 3 different direct target genes: Bix1 (Tada et 
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al. 1998); Bix4 (Casey et al. 1999) and eFGF (Casey et al. 1998). Another screen 
identified a possible 4 additional targets (Saka et al. 2000).  As the TBX22 protein is 
known to contain both repression and activation domains (Andreou et al. 2007), the 
regulation of more then one genetic pathway is a plausible theory. 
 
Another possibility is that TBX22 may function as a repressor or an activator 
depending on which co-factors are interacting with it. Another transcription factor - 
the Mga protein – which contains a T-box domain, has been shown to repress the 
expression of reporter genes containing a Brachyury DNA binding site and also act as 
a transcription activator when tested with reporter genes carrying a Brachyury and a 
Myc-like basic helix-loop-helix leucine zipper motif (Hurlin et al. 1999). Interaction 
of T-box proteins with different cofactors has been shown to change the specificity of  
binding to target genes and hence the same proteins are capable of regulating different 
pathways during cardiac formation (Boogerd et al. 2009). 
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2.4.3 Expression outside of the palate 
 
The typical phenotype of a CPX patient has neither a cleft of the primary palate (the 
most anterior region of the future hard palate, which includes the first four incisors 
and extends back to the incisive foramen (see section 1.2), nor a cleft lip. However, 
TBX22 is expressed during the expansion of the medial and lateral nasal process, 
which when fused with each other and the maxillary process forms the primary palate 
and the upper lip (see 1.2). A cleft of the primary palate or of the lip is caused by 
failure of mesodermal delivery and proliferation from the maxillary and nasal 
processes (Talmant 2006). As TBX22 is expressed in the maxillary and nasal 
processes (Fig. 13) one might expect that a disruption of the TBX22 protein would 
have an effect on these structures also. However, cleft lip is not evident in classical 
CPX and the mouse knockout also does not have a cleft lip (Pauws et al. 2009a). 
 
However, it has been reported that an individual with cleft lip and cleft palate was 
found in a family which displayed CPX and carried the same mutation in the TBX22 
gene as other family members who only had a cleft palate (Braybrook et al. 2001). 
Also, it has been shown that susceptibility to non-syndromic cleft lip may be linked to 
the X chromosome. There is also evidence that when TBX22 is virally over-expressed 
in the frontonasal process in chick, a cleft lip often results (Higashihori et al.). It has 
been suggested that genetic or environmental disruption in the upstream regulation of 
TBX22, such that a gain of function of TBX22 was brought about, may cause a cleft 
lip phenotype in human (Higashihori et al. 2010). 
 
Alterations in TBX22 in the maxillary process of CPX patients may not be critical to 
the correct formation of the lip as other T-box proteins may be able to functionally 
compensate for TBX22 during the development of the upper lip. RNA in situ 
hybridisation experiments in mouse have shown that T-box genes other than Tbx22 
are expressed in the maxillary process: Tbx1, Tbx2, Tbx18 and Tbx19 (Kraus et al. 
2001a; Bush et al. 2003; Gray et al. 2004) and perhaps this may explain why, 
although TBX22 is expressed in the maxillary process, a cleft lip is not an observed 
clinical feature of CPX. It has been shown in vitro at least that the binding sites of all 
T-box proteins share a similar recognition sequence ((Tada and Smith 2001) and 
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references therein) and the possibility of trans-activation of the same downstream 
target genes cannot be disregarded. 
 
There are other sites of expression, as well as those discussed above, primarily in the 
region surrounding the eye and at the base of the brain from CS17 – 19 (figs. 13 and 
14). Following fusion of the palatal shelves the major sites of expression are the nasal 
cartilage and the forming orthodontic mesenchyme. However, none of the individuals 
with CPX have been reported with malformations of the eye, skull or tooth 
development (Lowry 1970; Moore et al. 1987; Bjornsson et al. 1989) and 
compensation by other T-box genes may be the reason defects of these structures have 
not been reported in CPX patients.  
 
As has already been stated, tongue-tie (ankyloglossia) is not always observed in CPX 
patients (see 1.3.3.B). Again a compensation effect by another T-box gene could 
explain this observation. It has been suggested, in chick at least, that the cells 
expressing Tbx3 in the tongue (Huang et al. 1999) are the same cells that express 
Tbx22 (Haenig et al. 2002). If the expression patterns are similar in human, then one 
could envisage that TBX3 was able to functionally compensate for the lack of TBX22 
in those CPX patients where tongue tie was not evident. 
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2.4.4 Comparison with Mouse and Chick Tbx22 expression 
 
 
Expression studies have shown that the expression profile of mouse (Braybrook et al. 
2002; Bush et al. 2002; Herr et al. 2003) and chick (Haenig et al. 2002) Tbx22 closely 
resembles that of human TBX22 and in all species the expression is always restricted 
to mesenchymal tissue. However, there are subtle differences in the expression of 
Tbx22 in each of the three species. Table 9 shows a comparison amongst these three 
species and the sites of Tbx22 expression during development, reference to Table 6 
may be needed to compare equivalent human, mouse and chick stages.  
 
In both chick and mouse Tbx22 expression was detected much earlier in development 
with expression seen in the emerging somites in mouse at E9.25 before being then 
down-regulated in newly formed somites and then upregulated once more in more 
mature somites at E10.5. The expression in the somites was also detected in the 
studies in chick from HH stage 7 through to later stages becoming restricted to the 
myotome around E3. The Tbx22 expression seen in the mature somites in the E10.5 
mouse and E3 chick was not evident in the equivalent human stage, the CS14 embryo 
(Fig. 11b). 
 
Even earlier expression of Tbx22 has been reported during chick development, with 
signal detected in the mesoderm surrounding the primitive streak as early as HH stage 
4 (c.f. mouse ~ 7 dpc, Thieller stage10; and human ~ 18 dpo, Carnegie stage 8), 
however comparative stage mouse studies are not reported. Due to the constraints 
working with human material, very early tissue is incredibly hard to obtain and 
whether TBX22 is expressed in these structures at this time is so far unknown.  
 
Another notable difference in the expression pattern between chick and human is in 
the developing limbs. Tbx22 expression in both the hind and forelimbs is seen in the 
E4 chick, which is certainly absent in the hindlimb at an equivalent human stage (Fig. 
12) although expression in the forelimb was not examined. 
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Tissue Human Mouse Chick 
Mesoderm surrounding 
the primitive streak 
? ? From HH stage 4 
Nascent somites ? Evident at E9.25 
Evident at HH 
stage 7 
Newly formed somites ? 
 
X 
No signal in E10.5 
newly formed 
somites 
Evident at HH 
stage 13 
Mature somites 
X 
No signal in CS14 
embryo (Fig. 11) 
Evident at E10.5 
Restricted to 
myotome E3 
Mandibular Process 
At the tongue 
boundary only 
At the tongue 
boundary only 
Evident at E5 
Maxillary 
Process/Palatal Shelves 
Evident from CS16 
(Fig. 12) Evident from E10.5 
Evident from HH 
stage 18 
Medial and Lateral 
nasal Processes 
Evident from CS17 
(Fig. 13) 
Evident from E10.5 
Evident from HH 
stage 18 
Mesenchyme 
surrounding the eye 
Evident from CS17 
(Fig. 13) 
Evident from E13.5 
Evident from HH 
stage 18 
Hindlimb 
X 
No signal in CS15 or 
CS16 embryo (figs. 
11 and 12) 
? Evident from E4 
Forelimb ? ? Evident from E4 
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Table 9: Sites of Tbx22 expression during development of the human, 
mouse and chick. Mouse data from Bush et al. 2002 and chick data from 
Haenig et al. 2002. ? signifies that expression in that tissue hasn’t been 
reported in that species and an X indicates expression is not detected in 
that tissue in that species.
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 In all three species during the formation of the palate, a remarkably similar 
TBX22 expression pattern is observed. This gives credence to the possibility that the 
role of TBX22 in the formation of the secondary palate has been conserved through 
evolution. This conservation, in turn, suggests that TBX22 is critical for correct palate 
development and that TBX22 has a function that cannot be compensated for by other 
proteins. This may also form part of the explanation as to why the observed clinical 
feature of CPX is solely a cleft of the secondary palate, despite expression seen in 
other tissues.  
 
It appears that the evolutionary pressure to conserve the presence of the protein in 
regions outside the palate (where TBX22 expression differs across species) has not 
been as great - suggesting that it may not be as critical in the formation other tissues. 
The absence of TBX22 expression in the limbs and somites which is seen in chick and 
mouse may be due to other T-box proteins replacing the function of TBX22 in these 
tissues in human. 
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CHAPTER 3  
 
 
THE TBX22 DNA BINDING SEQUENCE 
 
 
 
3.1 INTRODUCTION 
 
Understanding the interaction between the various genetic factors involved in the 
formation of the palate is fundamental to establishing how normal palatogenesis 
occurs, which in itself is a necessary prerequisite if we are to fully appreciate how 
disruptions to these processes may result in a cleft. Elucidating the roles of 
transcription factors and the genes that they are regulating within these genetic 
pathways is one of the steps necessary to achieve this goal. Following the discovery 
that TBX22 is expressed throughout the facial processes during palate formation 
(Braybrook et al. 2002) and that mutations in the TBX22 gene lead to CPX 
(Braybrook et al. 2001; Chaabouni et al. 2005; Andreou et al. 2007), establishing 
which genes TBX22 may regulate during palatogenesis would not only provide 
insights into the genetic factors involved in normal palatogenesis, but also further our 
understanding of the aetiology of CPX. Furthermore, it may suggest other candidate 
genes for cleft palate disorders. Although TBX22 has been shown to be directly 
regulated by MN1(Liu et al. 2008), to date the only gene that TBX22 has been shown 
specifically to trans regulate is TBX22 itself (Andreou et al. 2007), although there is 
evidence suggesting that it may regulate MSX2 and DLX5 (Higashihori et al 2009).  
 
 
3.1.1 T-box domains 
 
In a similar manner to other T-box family members, TBX22 is likely to bind to the 
DNA sequences of the genes it is regulating via the T-box domain. The specific DNA 
sequence or T-box element (TBE) that TBX22 binds will determine which genes it 
will regulate. Finding the genes that TBX22 regulates would be greatly aided by 
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knowing the TBE to which it binds, as it would be expected that this TBE, or similar 
sequence to it, would be found within the regulatory regions of such genes.  
 
Preferential DNA binding sequences have been revealed for several T-box proteins 
(Table 10) and all have been shown to bind to a core DNA sequence similar to that 
found for the original Brachyury protein (Kispert et al. 1995). However, slight 
variations in the preferred DNA binding sequences, especially in the flanking 
nucleotides, have been observed for several T-box proteins and it is postulated that 
these slight variations in DNA binding sequence is one mechanism by which 
functional specificity of different T-box proteins is conferred (Conlon et al. 2001).  
 
The original Brachyury protein was shown to preferentially bind to the 20 nucleotide 
DNA sequence TTTCACACCTAGGTGTGAAA (Kispert et al. 1995). This is a 
palindromic sequence comprised of two 10 bp half-sites which are the reverse 
complement of each other. Since the identification of this DNA binding site several 
other T-box proteins have been shown to bind to DNA sequences similar to either this 
full length 20 bp sequence (T-site) or one half of it (T1/2-site). Table 10 summarises 
the experimentally determined variety of T-box DNA binding sites. In some cases the 
standard IUPAC notation (IUPAC-IUB 1971) has been used to represent ambiguous 
nucleotides and these definitions are shown in Table 11. 
 
Whilst the T-box domain is a highly conserved region throughout all of the T-box 
protein family, the way in which these different proteins bind to DNA has been shown 
to be varied and T-box proteins have been reported as binding to DNA as either a 
monomer or a dimer (see 3.4). If the protein binds to the DNA as a dimer, then a full 
length T-site recognition sequence is needed; each monomer binding to one half of the 
sequence as is the case with Brachyury (Papapetrou et al. 1997). However, if the 
protein binds as a monomer, then only a half site sequence (T1/2-site) is required for 
the protein to bind to DNA, as has been revealed for TBX2 and Tbx3 proteins (Sinha 
et al. 2000; Carlson et al. 2001).  
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Table 10: A summary of different experimentally determined T-box 
protein DNA binding sites.  The DNA binding sequences of the 
different T-box proteins shown in this table include both the preferred in 
vitro DNA binding sites and known in vivo target sequences. Standard 
IUPAC abbreviations have been used to represent ambiguous bases (see 
Table 11). 
 
 
 
 
 
Table 11: The recommended IUPAC abbreviations for nucleic acids 
(IUPAC-IUB 1971).  
 
Species Protein DNA Binding Sequence Reference 
Human Brachyury 
 T T T C A C A C C T A G G T G T G A A A  (Papapetrou et al. 1997) 
Human TBX1 
 T T T C A C A C C T A G G T G T G A A A  (Sinha et al. 2000) 
Human TBX2 
           A G G T G T G A A A  (Sinha et al. 2000; Lingbeek et al. 2002) 
Human TBX3 
 T C A C A C A C C T T G G T G C C A A A  (Lingbeek et al. 2002) 
Human TBX5 
           R G G T G T B R N N  (Ghosh et al. 2001) 
Mouse Brachyury 
 T T T C A C A C C T A G G T G T G A A A  (Kispert et al. 1995) 
Mouse Tbx6 
           A G G T G T B R N N  (White and Chapman 2005) 
Xenopus VegT 
 C T T G A C A C C T            (Casey et al. 1999) 
Xenopus VegT 
           A G G T G T G A A G  (Hyde and Old 2000) 
Xenopus Xbra 
 T T T C A C A C C T            (Casey et al. 1998) 
Xenopus Xbra 
 C T T G A C A C C T            (Casey et al. 1999) 
Ciona Ci-Bra 
 G G C A C C T C C T            (Di Gregorio and Levine 1999) 
UPAC 
nucleotide 
code 
A C G T R Y S W K M B D H V N 
Base Adenine Cytosine Guanine Thymine 
A 
or 
G 
C 
or 
T 
G 
or 
C 
A 
or 
T 
G 
or 
T 
A 
or 
C 
C 
or 
G 
or 
T 
A 
or 
G 
or 
T 
A 
or 
C 
or 
T 
A 
or 
C 
or 
G 
Any 
Base 
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3.1.2 Generating the TBX22 protein 
 
In order to study the DNA binding properties of TBX22, a suitable TBX22 protein 
must be synthesised. However, not only must TBX22 protein be generated, it must be 
prepared in a suitable manner such that it can be used in protein function studies; that 
is, a biologically functional TBX22 protein must be produced. This essentially means 
that protein conformation must be similar to that seen in vitro. To achieve this aim, 
the protein must be recovered under native buffer conditions which do not alter the 
structure of the protein or else the protein must be recovered and then correctly re-
folded back to its native state. 
 
Two methodologies were investigated to produce a native TBX22 protein: a bacterial 
cell approach, whereby the TBX22 protein is expressed by the bacteriophage T7, 
which can be induced in the BL21 star (DE3) host E.coli strain (Invitrogen) in the 
presence of IPTG; and a coupled cell-free transcription/translation approach whereby 
plasmid DNA is first transcribed by the addition of a bacteriophage RNA polymerase, 
and the resultant RNA is then translated into protein using the translation machinery 
from a Rabbit Reticulate Lysate System (TNT T7 Coupled Reticulocyte Lysate 
System; Promega). The bacterial cell system can deliver a considerably greater yield, 
but the recombinant protein is often difficult to recover from the cell lysate in a native 
form, whereas the Rabbit Reticulate Lysate method overcomes this problem as cells 
are pre-lysed, but the amount of protein generated in this way is usually much less 
(Hurst et al. 1996). 
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3.2  MATERIALS AND METHODS 
 
 
3.2.1 Producing TBX22 Protein with an N-terminal 6xHis tag in E. coli 
 
TBX22 with an N-terminal 6 amino acid Histidine tag (6xHis) was expressed in 
Escherichia coli by cloning the TBX22 coding sequence (see 3.2.1.B below) into a 
pET100/D-TOPO vector (Invitrogen). The pET100/D-TOPO vector contains the 
DNA coding sequence for a 6xHis tag which is placed in frame, upstream of the 
cloned insert. Thus when translated an RNA transcript containing the coding sequence 
for a 6xHis tagged TBX22 protein is generated. 
 
The 6xHis tag was necessary to aid subsequent recovery and purification of the 
plasmid by Ni-NTA. Another reason to generate a 6xHis tagged protein was that 
although commercial antibodies to TBX22 are available, the majority have only been 
tested for use in Western blot applications. As antibodies to a 6xHis tag have been 
used successfully in several applications, including use in gel-shift assays of T-box 
genes (Ghosh et al. 2001) verification of the presence of a His tagged protein using an 
anti-6xHis tag antibody should be possible.  
 
The protein was synthesised in bacteria because it was possible to generate a large 
yield of recombinant protein. The pET100/D-TOPO vector utilises a T7 bacteriophage 
promoter site to drive the expression of the cloned DNA insert in the presence of a T7 
RNA polymerase. BL21 Star (DE3) cells (Invitrogen) were used to express the 
recombinant 6xHis tagged TBX22 protein. BL21 Star (DE3) cells contain the DE3 
bacteriophage lambda (λDE3) lysogen. The λDE3 lysogen contains a T7 RNA 
polymerase gene under the control of the lacUV5 promoter. Addition of isopropyl β-
D-thiogalactoside (IPTG) can induce expression of the RNA polymerase by the 
lacUV5 promoter, and therefore drive the expression of the 6xHis-TBX22 protein 
from the T7 promoter.  
 
As the 6xHis-TBX22 protein is foreign to the host cell, it is potentially toxic and 
could reduce growth of the bacterial culture in which it is expressed. It is preferable to 
only express the 6xHis-TBX22 protein following significant growth of the bacterial 
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culture, thereby limiting these potential effects. However, there will always be some 
basal level expression of the RNA polymerase from the lacUV5 promoter. To help 
prevent the expression of 6xHis-TBX22 protein from this basal expression of T7 
RNA polymerase, the pET100/D-TOPO has a lac operator sequence placed 
immediately down stream of the T7 RNA polymerase promoter site, prior to the 
6xHis-TBX22 coding sequence. The lac operator sequence is a binding site for the lac 
repressor which when bound to the DNA is capable of preventing the T7 RNA 
polymerase from binding to DNA and transcribing the 6xHis-TBX22 sequence 
downstream. Within the λDE3 lysogen is the lac I gene which encodes for the lac 
repressor. The lac repressor is removed from the lac operator sequence in the presence 
of IPTG, allowing the T7 RNA polymerase to bind to the DNA and transcribe the 
6xHis-TBX22 sequence. 
 
 
 
A.  PRIMER DESIGN AND SYNTHESIS 
  
Primer pairs were designed using the software program “Web primer” 
(http://seq.yeastgenome.org/cgi-bin/web-primer) and were commercially synthesised 
by MWG Biotech. The oligonucleotides were received desiccated and were 
reconstituted using Milli-Q water to stock concentration of 100pmol/µl, based on the 
concentration supplied by the manufacture. The melting temperature for each 
oligonucleotide was also specified by the supplier. Appendix 1 summarises all the 
primer pairs used in these studies.  
 
 
B.  POLYMERASE CHAIN REACTION 
 
The polymerase chain reaction (Mullis et al. 1986) was used to amplify the TBX22 
coding sequence from a plasmid containing the TBX22 cDNA (clone BC014194; 
I.M.A.G.E. Consortium) using a Dyad MJ Reasearch Thermo Cycle instrument. A 
reaction mix contained a final concentration of 100ng plasmid DNA, 10mM dNTPs 
(Fermentas), 1X PFU polymerase buffer (20mM Tris-HCl (pH 8.8 at 25°C), 10mM 
KCl, 10mM (NH4)2SO4, 2mM MgSO4, 0.1% Triton X-100, 0.1mg/ml nuclease-free 
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BSA; Promega), 1.25U Pfu DNA polymerase (Promega) and 0.5µM forward and 
reverse primers made to a final volume of 50µl using Milli-Q water.  
  
The Thermo cycler was programmed to perform an initial denaturation step of 5 
minutes at 95oC, followed by 25 cycles of 95oC denaturation for 1 minute, l minute at 
the specific annealing temperature, followed by an extension time of 3 minutes.  The 
annealing temperature was determined specifically for each primer pair (Appendix 1 
gives details of the primer pairs). To begin with an initial annealing temperature 5°C 
lower than the lowest melting temperature of primer set was used for the reaction. If 
non-specific PCR products were produced, the annealing temperature was increased 
stepwise by 1-2°C. If however, the desired product was not obtained, then the 
annealing temperature was reduced stepwise by 1-2°C until a single, discrete product 
could be visualised by UV illumination following electrophoresis on a 1% agarose 
gel. 
 
An amplicon consisting of the TBX22 coding sequence  - Genbank Accession number 
NM_016954, nucleotides 28-1560 (http://www.ncbi.nlm.nih.gov) was synthesised 
using a forward primer 5 -CACCATGGCTCTGAGCTCTCGGG- 	3 and reverse 
primer 5 -CTAAAGGTAATGGTTAATTGCTGG- 	3 using I.M.A.G.E. clone 
BC014194 (Geneservice) as a DNA template. 
 
 
C.  CLONING THE PCR PRODUCT  
   
 The TBX22 coding sequence was cloned in frame into a pET100/D-TOPO 
(Invitrogen) plasmid expression vector. The initial CACC at the 5  end of the forward 
primer immediately prior to the ATG initiation codon of the TBX22 coding sequence 
enables the resultant PCR product to anneal to the GTGG overhang of the cloning 
vector increasing the likelihood of correct orientation of the insert into the vector. The 
pET100/D-TOPO vector utilises the DNA binding capabilities of Topoisomerase I 
from the Vaccinia virus, enabling the insert to be cloned into the vector without the 
need of a ligation reaction. Following PCR, the insert was cloned into the pET100/D-
TOPO according to the manufacturer’s protocol, using a 2:1 molar ration of PCR 
product: TOPO cloning vector, calculated using the formula:- 
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Xng PCR product = (Y bp PCR product) (Z ng vector)  
    (Z bp vector)   
Where X is the amount of PCR product needed for a 1:1 insert:vector molar ratio. For 
a molar ration of 2:1, X is multiplied by a factor of 2. 
 
D.  TRANSFORMATION OF THE PLASMID DNA  
 
The expression plasmid construct was transformed into TOP10 E. coli chemically 
competent cells (Invitrogen). A vial of TOP10 cells was thawed on ice. 3µl of the 
TOPO cloning reaction was added to the vial and was incubated on ice for 30 
minutes. The cells were heat shocked for 30 seconds at 42oC and were then placed in 
ice water. 250µl of sterilised S.O.C media (2% Tryptone, 0.5% Yeast Extract, 0.05% 
NaCl, 20mM glucose, 2.5mM KCl, 10mM MgCl, pH 7.5) was added to the vial and 
incubated horizontally at 37 oC in a shaking incubator with a rotation speed of 200 
rpm for 1 hour. 100µl and 200µl volumes of the transformation were plated on to 
Petri dishes containing Luria-Bertani (LB) media (1% tryptone; 1% NaCl; 0.5% Yeast 
Extract pH 7.0) with 1.5% agar and with 50µg/ml kanamycin (Sigma) as a selective 
antibiotic and incubated overnight at 37oC. 
 
 
E.  DNA PLASMID PREPARATION 
 
Single bacterial colonies were picked from the selective plates and inoculated in a 5ml 
culture containing LB and 50µg/ml kanamycin (Sigma) and incubated at 37oC for 16 
hours in a shacking incubator at 200 rpm. The bacterial cells were harvested by 
centrifugation in a Beckman Gene Genius gel doc system from Syngene at 6000g for 
10 minutes at 4 oC. Following centrifugation, the plasmid DNA from bacterial pellet 
was recovered using a Miniprep Kit (Qiagen) in a microcentrifuge, in accordance with 
the manufacturer’s instructions. 
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F.  DNA SEQUENCING 
  
DNA from each of the clones was sequenced by the Institute of Human Genetics 
sequencing service, performed using a MegaBACE 1000 (Amersham/GE Healthcare) 
machine using T7 promoter and T7 Reverse primers and TBX22 sequencing primers 
(see Appendix 1). The resulting sequence file was converted to FASTA format using 
the software programme Chromas (http://www.technelysium.com.au/chromas.html) 
from Technelysium Pty Ltd and aligned against the expected sequence using BLAST 
(Altschul et al. 1990). Clones containing the correct plasmid sequence were used for 
subsequent protein expression. 
 
 
G.  INDUCING EXPRESSION OF RECOMBINANT PROTEIN IN E. COLI 
 
5µg of the purified plasmid DNA was used to transform one vial of BL21 Star (DE3) 
cells, following the transformation protocol in 3.2.1.C, except that the transformation 
reaction was not plated onto a Petri dish. Instead, the entire reaction volume was used 
to inoculate 10ml of LB containing 50µg/ml ampicillin and was incubated in a 
shaking incubator, at 37oC, 250 rpm, overnight until the OD600 was in the range of 1-
2. 
 
For initial pilot studies, 10ml LB containing 50µg/ml ampicillin was inoculated with 
500µl of this overnight culture. In purification experiments the volume was increased 
to 50ml of LB. The bacterial culture was then incubated at 37oC with shaking at 250 
rpm until the cells were in mid-log phase (OD600 = 0.6). At this point the pilot study 
cultures were split into two 5ml volumes, one of which was induced with IPTG, the 
other was uninduced to serve as a negative control. Following addition of 1mM IPTG 
to induce expression of the 6xHis-TBX22 plasmid; the cultures were replaced into the 
shaking incubator under the same conditions as previously. The cultures were grown 
for the optimum time determined using the time course pilot study (see 3.2.1.H). At 
this point the cells were harvested by centrifugation at 4000g for 15 minutes at 4oC 
and stored at -20oC. 
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H.  TIME COURSE PROTEIN EXPRESSION PILOT STUDY 
  
In order to establish the optimum growth time for the bacteria following induction, 
500µl samples were taken from the induced and uninduced growing cultures 
immediately after the addition of IPTG and then after 2, 4 and 6 hours. The cells were 
harvested by centrifugation at 13000g in a microcentrifuge and stored at  
-20oC. 
 
The cells were then thawed on ice and resuspended in Lysis buffer 1 (50mM 
potassium phosphate, 400mM NaCl, 100mM KCl, 10% glycerol, 0.5% Triton X-100, 
10mM imidazole, 8M urea). The cells were then frozen on dry ice and thawed at 42oC 
and then re-frozen and thawed again before being centrifuged at 13000g in a 
microcentrifuge at 4 oC for 1 minute. The supernatant was collected and the resultant 
pellet was resuspended in 500µl of 1X SDS. 6.5µl of the supernatant was added to 
sample running buffer and 10µl of the resuspended pellet (without the addition of 
sample running buffer) was separated on a polyacrylamide gel (see 3.2.3.A). 
  
 
I.   NI-NTA PURIFICATION 
 
A Nickel-Nitrolotriacetic acid (Ni-NTA) affinity column (Qiagen) was chosen for the 
recovery of the 6xHis tagged protein. This purification system is centred upon the 
high affinity for histidine residues to nickel ions which are bound to a NTA resin. 
However, to be employed successfully, a run of histidine residues must be 
incorporated into the protein. This histidine tag is commonly placed at either the N- or 
C-terminal of the recombinant protein. The decision was taken to place a 6x histidine 
tag at the N-terminal of the TBX22 protein using the pET100/D-TOPO from 
Invtrogen as it is possible to cleave the N-terminal His tag from the expressed protein. 
It is possible that the addition of a His tag to a protein may affect the natural 
biological function of the protein, so the possibility to remove it was an attractive 
feature. 
 
Several cell lysate, wash and elution buffers were employed in order to purify the 
6xHis tagged TBX22 protein under native conditions; initially however, the cells 
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harvested from a 10ml culture were lysed under denaturing conditions. The cell lysate 
was resuspended in 1ml urea buffer (8M urea, 0.1M NAH2PO4, 0.01M Tris-Cl, pH 
8.0) loaded onto the Ni-NTA spin column; washed in urea buffer, pH 6.3; and eluted 
in urea buffer, pH 4.5; following the manufacturer’s directions. By reducing the pH of 
the sample buffer, the affinity of the polyhistidine tag to the Ni-NTA column is 
reduced, making purification of the 6xHis tag protein possible. 
  
Samples of the original un-purified cell lysate and the flow-through following each 
wash and elution step were collected and analysed on a Coomassie stained PAGE gel 
(see 3.2.3.A). The resultant single band in the final elution step was excised from the 
PAGE gel and used for verification by MALDI-TOF analysis (3.2.3.C).  
 
The samples were also used in a second PAGE analysis which was subsequently used 
for a Western transfer (see 3.2.3.B) to a PVDF membrane and the N-Terminal 6xHis 
tag was detected using an Anti-HisG-HRP Antibody (Invitrogen). 
  
In order to purify the 6xHis tagged TBX22 protein under native conditions, various 
different cell lysis buffers were evaluated for their ability to lyse the bacterial cells 
and solubilise the 6xHis tagged TBX22 protein. Following lysis, a sample of the cell 
lysate was analysed for the presence of the 6xHis tagged fusion protein. 
  
The cell culture volume for these experiments was increased to 50ml and following 
centrifugation to harvest the bacterial cells, 1ml of the various lysis buffers was used 
to resuspend the cells. To aid cell lysis under these milder conditions, 1mg/ml 
lysozyme (Sigma) was added to the lysis buffer and the cells were sonicated on ice 
using a Sonics Vibra Cell machine for six sets of 10 seconds, with 5 second pauses in 
between each sonication. The various lysis buffers used in this study are detailed in 
Table 12. 
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Table 12: Cell lysis buffers used to solubilise the 6xHis tagged protein 
under native conditions. The conditions used for lysing the cells under 
native conditions. * These lysis buffers were used separately with the 
addition of 5mM β-mercaptoethanol (Merck) and 0.5% Tween (Sigma). 
 
 
J.  ON COLUMN RE-FOLDING 
 
The bacterial cells were lysed in cell lysis buffer (6M urea, 0.1M NAH2PO4, 0.01M 
Tris-Cl, 5mM β-mercaptoethanol) and the cell lysate applied to a Ni-NTA spin 
column. The bound 6xHis tag protein was then washed in the lysis buffer with a 
gradual lowering of the urea concentration in the wash buffer, in a 0.5M step-wise 
gradient until the urea was completely removed from the wash solution. This was 
performed at 4oC using a previously published protocol (Oganesyan et al. 2005). 
 
 
3.2.2 Rabbit Reticulocyte Transcription translation 
 
The TNT Coupled Reticulocyte Lysate System from Promega enables the 
transcription and translation of plasmid DNA. The plasmid must contain a prokaryotic 
phage RNA polymerase promoter upstream of a protein coding sequence, this RNA 
polymerase is utilised by an RNA polymerase which is added to a rabbit reticulocyte 
lysate, to transcribe the DNA template. The rabbit reticulocyte lysate contains all of 
the necessary components for the translation of this RNA to protein.  
 
Lysis Buffer 
 
Composition Reference 
Sodium dihydrogen 
Phosphate * 
 
50 mM Na2HPO4, 300 mM 
NaCl (pH 8.0) 
 
Ni-NTA Spin Handbook 
(Qiagen) 
Tris-Cl * 
 
50 mM Tris-Cl (pH 7.6) (Silva et al. 2003) 
PBS * 
140 mM NaCl, 2.7 mM 
KCl, 10 mM  Na2HPO4, 
1.8 mM KH2PO4 
HisPur Ni-NTA Resin 
Instructions (Thermo 
Scientific) 
IP-50 Lysis buffer 
 
Cell Lysis buffer from 
Immuno Precipitation Kit 
 
IP Kit Handbook (Sigma-
Aldrich) 
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1µg of purified 6xHis tagged TBX22 pET100/D-TOPO vector DNA was used in a 
transcription translation reaction mix containing: 25µl TNT Rabbit reticulocyte lysate; 
2µl TNT Reaction buffer; 1µl T7 RNA polymerase; 0.5µl 1mM amino acid mix 
(minus leucine); 0.5µl 1mM amino acid mix (minus methionine); brought to a final 
volume of 50µl with nuclease free water and incubated at 30oC for 90 minutes.  
 
 For use in the EMSA binding studies (see 3.2.5) the TBX22 coding sequence 
was cloned into pTNT vector (Promega). This was achieved by amplifying the cDNA 
sequence, including the 6xHis tag from the pET100/D-TOPO TBX22 expression 
vector (3.2.1) using primers incorporating SalI and XhoI restriction enzyme sites 
respectively (see Appendix 1). Following separate double digestion reactions 
according to the manufactures’ instructions using SalI and XhoI restriction enzymes  
(Promega) of the PCR fragment and pTNT vector, the plasmid was ligated (see 
3.2.1.C). The plasmid sequence was verified using T7 forward and reverse primers 
and the TBX22 sequencing primers outlined in Appendix 1. The pTNT vector, like 
the that of the pET100/D-TOPO vector contains a T7 RNA polymerase binding site 
ahead of the multiple coding region, but with the addition of the 5 untranslated region 
from the  5´ β-globin gene positioned upstream of the cloned insert and synthetic 
poly(A)30 tail downstream of it. These two elements have both been shown to increase 
the translation activity (Annweiler et al. 1991; Wakiyama et al. 1997). The 
transcription/translation reaction using this plasmid was performed in exactly the 
same way as outlined above.
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3.2.3  Protein Verification 
 
A.  POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
An XCell Surelock electrophoresis mini-gel tank (Invitrogen) was used for the 
electrophoresis and Western transfer of protein samples. All of the gels used 
conatined 12% bis-acrylamide and were precast in a 10X 1mm well format (NuPAGE 
Mini-Gel; Invitrogen) and were performed under denaturing conditions. An 
appropriate concentration of protein sample to a maximum of 6.5µl was mixed with 
sample running buffer (2.5µl 4X NuPAGE LDS Sample buffer (Invitrogen) and 1µl 
10X NuPAGE Reducing Agent (Invitrogen) and brought to 10µl with Milli-Q water. 
The samples were then heated for 10 minutes at 70oC and loaded onto a 12% bis-tris 
10X 1mm well NuPAGE Mini-Gel (Invitrogen) together with 6µl of Page Ruler 
Unstained Protein Ladder 10-200 KDa (Fermentas) which had been heated to 40 oC 
for 5 minutes. The gels ran with 200ml 1X NuPAGE MES buffer (Invitrogen) 
containing 500µl NuPAGE Antioxidant (Invitrogen) in the upper chamber and 200ml 
1X NuPAGE MES Buffer (Invitrogen) in the lower chamber for 35 minutes at a 
constant 200 Volts. 
 
To visualise the gel, the gel was removed from its apparatus and covered with 
Coomassie stain (0.5 % Coomassie Blue R-250 in 40% methanol, 10% acetic acid in 
Milli-Q water) for 30 minutes with gentle shaking. The gel was then destained in 
several changes of 40% methanol, 10% acetic acid with gentle agitation until the 
background was reduced to an acceptable level. The gel was then transferred to 5% 
acetic acid and imaged using Gene Genius gel doc system from Syngene with a UV 
filter.  
  
 
B.  WESTERN TRANSFER AND IMMUNO-BLOTTING 
  
The PAGE gel was transferred to a blotting membrane using the XCell II Blot Module 
(Invitrogen). Following the electrophoresis, the PAGE gel was removed from its 
housing cassette and placed adjacent to a polyvinylidene difluoride (PVDF, 
Invitrogen) membrane which had been pre-soaked for 30 seconds in methanol, rinsed 
in deionised H2O and then soaked in NuPAGE transfer buffer (Invitrogen) for 10 
minutes. Filter paper was rinsed in NuPAGE transfer buffer and placed either side of 
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the gel and PVDF membrane. Two foam blotting pads were placed in 1X NuPAGE 
transfer buffer and squeezed whilst submerged to remove all of the trapped air. The 
blotting pads were then placed on both sides of the filter paper to securely fix the gel 
and PDVF membrane during protein transfer. The whole assembly was then inserted 
into the XCell II Bot Module such that the gel was positioned nearest the cathode and 
the PDVF membrane closest to the anode. The assembled blot module was then 
placed into the XCell SureLock mini-cell and secured with the fixing wedge. The blot 
module was filled with transfer buffer (1X NuPAGE transfer buffer with 10% 
methanol and 1% NuPAGE antioxidant) and the outer tank chamber was filled with 
H2O, to act as a coolant during transfer. The protein was then transferred to the 
membrane by applying a constant 30V across the blot assembly for 1 hour. 
   
Following transfer, the assembly was dismantled and the PVDF membrane was 
transferred to a small tray and covered with 10ml PBST (PBS containing 0.05% 
Tween-20 (Sigma-Aldrich)) and 0.5% Bovine Serum Albumin (BSA, Sigma-Aldrich) 
as a blocking solution. The membrane was washed in this solution for 1 hour with 
gentle agitation, then the solution was removed and the membrane was washed in two 
20ml washes of PBST for 5 minutes, again using gentle agitation. The Anti-6xHis 
antibody (Invitrogen) was diluted 1:5000 in PBST with 0.5% Bovine Serum Albumin 
(Sigma-Aldrich) and 10ml of the diluted antibody was added to the to the tray 
containing the membrane. The antibody was incubated for 1.5 hours at room 
temperature with gentle agitation on a rocker. The antibody solution was removed 
from the tray and the membrane was again washed in two 20ml washes of PBST for 5 
minutes with gentle agitation.  The membrane was then transferred to a new tray 
containing a DAB tablet (Amersham) diluted in 10ml of H2O with 10% H2O2. The 
membrane was incubated in this solution for 10 minutes and was washed in three 
rinses of H2O for 5 minutes each. The membrane was then air-dried and imaged using 
a Polaroid digital camera. 
 
C.  MADLI-TOF 
 
Following the identification of a single band on a PAGE gel after Coomassie staining 
(see 3.2.3.A), the band was excised from the gel and used for protein verification in a 
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Matrix-assisted laser desorption/ionization-Time of flight (MALDI-TOF) 
measurement.  The measurement, which was performed by the PINNACLE 
proteomics service at Newcastle University using a Voyager DE-STR mass 
spectrometer (Applied Biosystems), enabled a statistically significant match to the 
human TBX22 protein to be made. 
 
98 
3.2.4 In Vitro Oligonucleotide Selection Assay 
 
An in vitro oligonucleotide selection assay was employed (Pollock and Treisman 
1990) to identify the preferential TBX22 DNA binding site, as this method had 
previously been successful in identifying the DNA biding consensus sites for other T-
box family members (Kispert and Herrmann 1993; Ghosh et al. 2001).  The assay 
involves the selection of a particular DNA sequence from a pool of random 
oligonucleotides, based upon the binding of a T-box protein to that DNA sequence. 
 
 
A.  SYNTHESIS OF DOUBLE STRANDED RANDOM OLIGONUCLEOTIDES 
 
A forward primer (Forward_Rand) GCTGCAGTTGCACTGAATTCGCCT and 
reverse primer (Reverse_Rand) CAGGTCAGTTCAGCGGATCCTGTCG were 
synthesised by MWG- Biotech and used in a PCR reaction (see 3.2.1.B) to amplify a 
oligonucleotide, also synthesised by MWG-Biotech consisting of 5 -
GCTGCAGTTGCACTGAATTCGCCTC(NNNNNNNNNNNNNNNNNNNNNNNN
NN)GACAGGATCCGCTGAACTGACCTG-3  . At each of the 26 “N” bases all four 
possible nucleotides were represented, thus a 26-mer random oligonucleotide was 
synthesised with known 5  and 3  end sequences. 
 
10ng of the random oligonucleotide was used as a template in a 50µl PCR reaction 
using 0.2µM of the Forward_Rand and Reverse_Rand primers.  Following PCR the 
DNA was phenol/chloroform extracted and ethanol precipitated (see 2.2.2.A) to 
remove the protein and salt from the solution. The DNA was then incubated with 10U 
S1 Nuclease (Promega) in 1X reaction buffer (0.5M sodium acetate pH 4.5, 2.8M 
NaCl, 45mM ZnSO) at 37oC for 30 minutes to degrade the single-stranded DNA 
molecules. The nicked, single-stranded DNA was then removed from the solution by 
applying the DNA solution to a QIAquick Nucleotide Removal Kit (Qiagen) 
following the manufacturer’s instructions. 
 
 
B.  PROTEIN/OLIGONUCLEOTIDE BINDING REACTIONS 
 
A protein/DNA binding reaction containing 10µl of the transcription/translation 
reaction (see 3.2.2) was incubated with 200pg of the random oligonucleotide in the 
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presence of 1X Binding buffer (5X Binding buffer, Promega: 20% glycerol, 5mM 
MgCl2, 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 50mM Tris-Cl (pH 7.5), 
0.25mg/ml poly(dI-dC).poly(dI-dC) in a 20µl reaction volume and incubated at 25oC 
for 30 minutes. 
 
  
C.  CO-IMMUNOPRECIPITATION 
  
A Protein G Immuno-Precipitation kit (Sigma) was used to recover the bound 
TBX22/DNA complexes. The entire protein/oligonucleotide binding reaction was 
incubated in an IP spin column (Sigma), preprepared as per the manufacturer’s 
instructions, with the addition of 1µg Anti-6xHisG antibody (Invitrogen) and 10µl 
protease inhibitor cocktail (Sigma). This was made up to a final volume of 600µl with 
1X IP buffer (Sigma). The spin column was incubated overnight at 4oC with 
inversion.  
 
The following day the spin-column was washed in 700µl of 1X IP buffer and spun in 
a bench microcentrifuge at 12,000g for 30 seconds at 4oC. This wash and 
centrifugation step was repeated through 5 further rounds, with a final wash of 0.1% 
IP buffer and centrifugation at 12,000g for 30 seconds at 4oC. The bound 
protein/DNA was eluted from the spin columns by the addition of 40µl of 1X 
modified Laemelli sample buffer (2% SDS, 15% β-mercaptoethanol, 10% glycerol, 
60mM Tris-Cl pH 7.0) and heating the column to 95oC for 5 minutes, before 
centrifugation at 12,000g for 30 seconds. 
 
 
D.  DNA BINDING SITE ISOLATION 
 
The DNA was recovered from the solution by phenol/chloroform extraction, with the 
addition of 10µg glycogen (VWR) as a carrier, and subsequent ethanol precipitation 
(see 2.2.2.A) then resuspended in 10µl H2O. The DNA was then re-amplified by PCR 
using 150ng of the forward and reverse primers for 13 cycles (see 3.2.1 B) using 1U 
Taq polymerase (Promega). This amplified DNA was then used as the substrate for 
further rounds of protein/DNA binding selection assays. Following PCR amplification 
from the fifth round of the binding selection assay, the DNA was cloned into a pCRII-
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TOPO vector from Invitrogen (see 3.2.1.C) and transformed into Invitrogen’s TOP 10 
E. coli  competent cells (see 3.2.1.D).  The entire transformation reaction was plated 
onto LB plates containing 50µg/ml ampicillin which had been previously spread with 
40µl of 40mg/ml X-gal (Fermentas) in dimethylformamide. Transformants were 
picked and cultured, the DNA midi prepped and sequenced by the IHG sequencing 
service using the M13 forward and reverse primers (see 3.2.1.E and F). 
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3.2.5 Electrophoretic Mobility Shift Assay (EMSA) 
 
A.  5  END LABELLING 
 
Oligonucleotides were synthesised by MWG-Biotech and reconstituted in Milli-Q H20 
according to the suppliers’ directions. Four double-stranded oligonucleotides were 
generated: W=T_oligo – which represented the TBX22 DNA binding consensus 
sequence and contains a thymine base at the 8th position of the TBX22 consensus 
sequence (the “W” at this position within the TBX22 consensus sequence implies that 
this position can be represented equally by either a thymine or an adenine base). The 
515-20_oligo –  which was clone 515-20 from the in vitro binding assay (see Table 
14), is identical to the TBX22 consensus binding sequence at 8 of the 10 positions: the 
exceptions are a guanine base at the 7th position (instead of a cytosine) and a cytosine 
residue at the 10th position (in place of an adenine). The 8th position is an adenine base 
(this position can be either an adenine or thymine in the TBX22 DNA binding 
consensus sequence). The Mut_oligo corresponds to the TBX22 DNA binding 
consensus sequence, except that the guanine residues at the 2nd and 3rd position in the 
consensus sequence were replaced by adenine residues and contains an adenine base 
at the “W” position of the TBX22 consensus sequence. Finally, Cont_oligo is a 
positive control oligo which had previously been shown to bind TBX22 (Andreou et 
al. 2007). The oligos used are shown in Table 13. 
 
 
 
  
ds Oligo  Oligo 1 Oligo 2 
Cont_oligo CTAGCAAGGTGTGAAATTGTCACCTCAA GTTCCACACTTTAACAGTGGAGTTTCGA 
W=T_oligo CGAGAGGTGTCTTACGAG CTCGTAAGACACCTCTCG 
515-20_oligo CGAGAGGTGTGATCCGAG CTCGGATCACACCTCTCG 
Mut_oligo CGAGAAATGTCATACGAG CTCGTATGACATTTCTCG 
TBX22 DNA 
binding consensus 
sequence 
AGGTGTCWTA  
Table 13: The oligonucleotides used to generate the double-stranded oligos used in 
the electrophoretic mobility shift assay of TBX22 protein. The position of the TBX22 
DNA binding sequence within Oligo 1 of the W=T_oligo, 515-20_oligo and Mut_oligo 
is shown in bold and variations from this sequence are highlighted in red.  
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To generate the double-stranded oligos W=T, 515-20, Mut and Cont, the paired oligos 
(oligos 1 and 2 from Table 13) were heated to 10 oC  above their melting temperature 
for 30 minutes  and allowed to anneal by cooling slowly to room temperature. They 
were then treated with 1U of S1 Nuclease (Promega) for 30 minutes at 37oC and 
purified through a QIAquick nucleotide removal kit (Qiagen) following the 
manufacturer’s instructions. 
 
2pmol of the double-stranded oligonucleotides were 5 end-labelled using 10U of T4 
polynucleotide kinase (PNK; Promega) in a 10µl reaction containing 1X PNK buffer: 
50mM Tris-Cl pH 7.5, 10mM MgCl2, 5mM DTT, 0.1mM spermidine (Promega) and 
1µl of [γ_32P]ATP, 3000Ci/mmol at 1omCi/ml (Amersham Biosciences). The reaction 
was incubated at 37oC for 10 minutes after which time the reaction was stopped with 
the addition of 1µl 5mM EDTA and the PNK enzyme heat-inactivated by incubation 
at 70oC for 10 minutes. The volume was adjusted to 100µl with the addition of TE 
buffer. 
 
B.  ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
 
TBX22 protein/DNA binding site reactions were setup by combining the TBX22 
pTNT rabbit reticulocyte lysate with 5 end-labelled oligonucleotide (3.2.5.A). A 
binding reaction was setup by adding 2µl of the rabbit reticulate lysate with 2µl of 5X 
binding buffer. In initial experiments the binding buffer was that supplied from the 
Promega Gel Shift Kit, however in later experiments this was substituted for a binding 
buffer as described in (Andreou et al. 2007). For the positive competitor reaction, 
2pmol of unlabeled consensus TBX22 oligonucleotide (W=T_oligo) was also added 
to this reaction. To serve as negative controls, a further reaction containing 2µl lysate 
that contained the pTNT vector which lacked the TBX22 coding sequence insert and 
another in which the lysate was absent were also set up. For use in competition 
experiments 2pmol of the W=T_oligo was also included in the binding reaction. In all 
cases, the reaction volume was adjusted to 9µl with nuclease free water and incubated 
in a water bath at 25oC for 20 mins.  
 
An anti-TBX22 antibody (sc-17862X; Santa-Cruz) was used for super shift 
experiments. This antibody was specifically chosen as the manufactrer’s advise using 
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this antibody for gel super shift experiments. Here, 1µl of the TBX22 antibody was 
added to the EMSA binding reaction containing 2µl of the TBX22 pTNT rabbit 
reticulocyte lysate from the transcription/ translation and 2µl of the 5X binding buffer. 
This volume was adjusted to 9µl with H20 and incubated at 25oC for 20 mins. 
Following this, 1µl of the labelled oligonucleotide was added and the reaction was 
incubated for an additional 30 minutes at 25oC.  
 
 
 
C.  VISUALISING THE EMSA 
  
5µl of the reaction from 3.2.5.B was added to 3µl Milli-Q H20 and 3µl of Novex Hi-
Density TBE sample buffer (Invitrogen) and then loaded on a pre-cast 6% Novex 
DNA retardation gel (Invitrogen). The samples were electrophoresed at 300V in 0.5X 
TBE buffer (5X TBE = 5.4% Tris base, 2.75% boric acid, 0.29% EDTA – free acid, 
pH 8.3; Invitrogen) using the XCell Surelock system described in 3.2.3.A, until the 
marker dye had migrated 3/4 of the way down the gel. 
 
The gel was removed from the gel plates and transferred to a sheet of 3MM filter 
paper (Whatman) overlaid with a thin plastic wrapping and dried using a Flowgen gel 
drier. Once dry the gel was exposed to Biomax MR-1 X-ray film (Kodac) overnight. 
The X-ray film was then developed using Xograph’s Compact X4 machine according 
to the manufacturer’s instructions using Devalex M and Fixaplus reagents from 
Champion. The developed X-ray film was imaged using an HP Scanjet 4850 Photo 
Scanner (Hewlett Packard). 
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3.3  RESULTS 
 
3.3.1 Producing a TBX22 protein 
 
The optimum growth time for the bacterial cultures following induced expression by 
IPTG was determined by taking samples from induced (I0, I2, I4, I6) and uninduced 
control cultures (U0, U2,U4, U6) following the addition of IPTG to induce the 
expression of the recombinant 6xHis-TBX22 protein. Samples were taken from the 
growing induced and uninduced cultures immediately following the addition of IPTG 
and then after 2, 4 and 6 hours, lysed using a denaturing lysis buffer containing 8M 
urea and analysed by PAGE (Fig. 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 17: Recombinant TBX22 protein expression. IPTG was used to 
induce the expression of recombinant 6xHis-TBX22 protein in E.coli. 
Cultures were lysed using 8M urea and proteins were separated on a 12% 
bis-tris PAGE gel and stained with coomassie blue (see section 3.2.3). 
Samples were removed from bacterial cultures of induced (I0, I2, I4, I6) 
and uninduced cultures (U0, U2, U4, U6) 0, 2, 4 and 6 hours after 
induction. (M, protein mass markers (SM0671, Fermentas) with the 
approximate mass sizes indicated. The arrow indicates the position of the 
6xHis-TBX22 protein on the gel. 
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Figure 18: Purification of the 6xHis-TBX22 protein by Ni-NTA 
affinity column.  Bacterial cultures expressing the recombinant protein 
plasmid were lysed using 8M urea and purified using a Ni-NTA spin 
column. Samples were taken from the initial cell lysate (CL), following 
the first flow-through from the column (FT), after the first wash (W1), 
second wash (W2) and final wash (W3) and from the collected elution 
(E1) and (E2). M is a protein mass marker with approximate sizes 
indicated. The proteins were separated on a 12% bis-tris gel and stained 
with coomassie blue (see 3.2.3). 
 
 A strong band of approximately 70kDa is present on the PAGE gel  in lanes I2, 14 
and I6 but not lanes U0, U2, U4 and U6 (Fig. 17). In order to verify that the protein 
corresponding to this band was indeed the over expressed 6xHis-TBX22 tagged 
protein; a larger 50ml 6xHis-TBX22 plasmid culture was grown, harvested and 
purified using a Ni-NTA column (Fig. 18). The single band (lane E2 in Fig. 18) was 
excised and verified as TBX22 by MALDI-TOF (see 3.2.3.c, Fig. 19 and Appendix 
2). 
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 Using the Mowse scoring algorithm (Pappin et al. 1993), it was confirmed that 
the protein in the sample matches the human TBX22 protein sequence. The scores 
from this test show that the probability of detected peptides matching the human 
TBX22 protein sequence is much higher than would be expected by chance. A Mowse 
score of anything greater than 78 indicates that there is less than a 0.05% likelihood of 
the protein in the sample being the TBX22 protein sequence by chance alone. The 
highest Mowse score from the output of the MALDI-TOF experiment (Fig. 19, full 
report in Appendix 2) is 141 and matches to the protein sequence AAK63189, which 
is human TBX22. All of the other matches lie below the accepted threshold of 
significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: A Probability based Mowse score of the protein samples 
compared to the human TBX22 protein sequence.  The shaded region 
shows those scores where p>0.05. The highest Mowse score is 141 and 
can therefore be considered to be a significant match. For full report see 
Appendix 2. 
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Figure 20: Lysing the bacterial cultures under non-denaturing 
conditions. A coomassie blue stained PAGE gel of bacterial 
expression cultures lysed using the buffers from Table 12. S, Sodium 
dihydrogen Phosphate; S+, Sodium dihydrogen Phosphate, 5mM β-
mercaptoethanol;T, Tris-Cl; T+, Tris-Cl, 5mM β-mercaptoethanol; P, 
PBS, P+, PBS, 5mM β-mercaptoethanol; IP, IP-50. U is 8M urea and 
M is a protein mass marker SM0661 from Fermentas, with the 
approximate mass sizes indicated. Electrophoresis and staining 
conditions are outlined in 3.2.3. 
Having established that a human TBX22 protein could be biosynthesised using E. 
coli, a number of different buffers were used to lyse the cells and solubilise the 
protein under native conditions. Samples were taken from the cell cultures lysed using 
the different native buffers (see 3.2.1.I) and analysed on a denaturing PAGE gel for 
the presence of a 70kDa over-expressed protein (Fig. 20).  
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  No band was detected on the PAGE gel from any of the different native buffer 
lysates employed (lanes S-IP in Fig. 20) corresponding to the over-expressed protein 
observed in the urea buffer lysate (lane U in Fig. 20). The protein had been produced, 
as could be seen from the 70kDa band on the PAGE gel from the urea lysed cells, but 
could not be solubilised using the native buffers and was therefore absent from the 
PAGE gel in these lanes.  
 
As the TBX22 protein could be detected in the urea lysed cells, the denatured TBX22 
protein from this sample was applied to a NI-NTA column; while the protein was 
attached to the column, urea was gradually removed from the buffer (see 3.2.1.A). 
However, when the urea concentration in the wash buffer became less than ~3.5M the 
protein come out of solution and blocked the pores in the spin column. Thus, this 
approach would not be suitable for the re-folding of the TBX22 recombinant protein. 
  
 The 6xHis-TBX22 pET100/D-TOPO plasmid was expressed in a Rabbit 
Reticulocyte Transcription/Translation System (see 3.2.2). The presence of the 6xHis-
TBX22 protein in the cell lysate could be detected on a Western blot using an anti-
6xHis tag antibody (see 3.3.3.B). Samples were taken from the rabbit reticulate lysate 
following the transcription/translation reaction and analysed against a control rabbit 
reticulate cell lysate that had not been incubated with the 6xHis-TBX22 expression 
vector (Fig. 21). Using an anti-6xHis antibody, the recombinant protein was detected 
in the cell lysate that had been incubated with the TBX22 expression plasmid (lane T 
in Fig. 21) but was absent from the cell lysate only (lane RL in Fig. 21). 
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Figure 21: Detection of the 6xHis-TBX22 protein from a rabbit 
reticulocyte lysate.  An  ~ 70kDa protein was detected by an anti-6xHis 
antibody by Western blot. Lane T is the lysate incubated with the 6xHis-
TBX22 plasmid, RL is the lysate only, M is a pre-stained Protein marker 
with approximate sizes indicated. Visualisation of the antibody was 
achieved using HRP and DAB staining (see 3.2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2 Determining a TBX22 preferential DNA binding sequence 
 
Utilising the 6xHis-TBX22 protein produced by the transcription/translation system, 
an in vitro oligonucleotide selection assay using the double stranded random 
oligonucleotides was performed as described in section 3.2.4. Following five rounds 
of selection and amplification using the binding site selection assay, the resulting 
clones containing the oligonucleotide DNA to which TBX22 bound were sequenced. 
These sequences or their complement were aligned and a consensus sequence 
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Table 14: Determining the TBX22 binding site. The aligned sequences of the 
cloned DNA isolated from the DNA binding site selection assay following five 
rounds of selection are shown, with red nucleotides highlighting a direct match with 
the Barchyury DNA T1/2-site. The frequency of each nucleotide at that position in 
the binding sequence is shown in the lower half of the table.  The TBX22 binding 
site was determined from the consensus sequence of the aligned clones. W = A or T 
as per the standard IUPAC codes (IUPAC-IUB 1971). The position of each 
nucleotide within the aligned sequence is shown in the first row of the table. 
identified (see Table 14). An example chromotagram and complete alignment of the 
full 26 base random oligonucleotides are presented in Appendix 4.  
Clone ID  Sequence 
Base Position  1 2 3 4 5 6 7 8 9 10 
515-1  C G G T G C G A C C 
515-2  C G G T G A T A T G 
515-3  A C G T G T C T T A 
515-4  T G G T G T T A A C 
515-6  A C G T G T C T T A 
515-8  G C G T G T C C A A 
515-12  A G G T G C T G T C 
515-14  A G G T G T C C G A 
515-15  A C G T G T C T T A 
515-17  T G G T G T G G A A 
515-19  A G G T G T C T T A 
515-20  A G G T G T G A T C 
515-21  A G G T G T C T T A 
515-23  A G G T G T C T T A 
515-24  A G G T G T C T T A 
515-25  A C G T G T C T T A 
515-27  A C G T G C A A C A 
515-28  A G G T G A C G C A 
515-29  C G G T G T G A C G 
515-30  A G G T G T G C G T 
            
Base  Nucleotide Frequency  
A  14 0 0 0 0 2 1 6 3 13 
C  3 6 0 0 0 3 11 3 4 4 
G  1 14 20 0 20 0 5 3 2 2 
T  2 0 0 20 0 15 3 8 11 1 
            
TBX22 Consensus A G G T G T C W T A 
Brachyury ½ site A G G T G T G A A A 
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Figure 22: An electromobility shift assay of the TBX22 protein. TBX22 
protein is able to bind to and cause a band shift in the lane containing DNA 
probes of  the determined TBX22 consensus sequence – W=T_oligo and a 
previously reported  TBX22 DNA binding sequence (Andreou et al. 2007) 
– Cont_oligo. 1 – W=T_oligo only, 2 – W=T_oligo and rabbit reticulocyte 
lysate control, 3 – W=T_oligo and TBX22 lysate, 4 –  W=T_oligo and 
TBX22 lysate with anti-TBX22 antibody, 5 - Cont_oligo and rabbit 
reticulocyte lysate control, 6 – Cont_oligo and TBX22 lysate, 7 – 
Cont_oligo and TBX22 lysate with anti-TBX22 antibody. 
RRL – rabbit reticulocyte lysate; TBX22 – rabbit reticulocyte lysate 
containing TBX22 protein; W=T – W=T_oligo; Cont – Cont_oligo; α-
TBX22 = anti-TBX22 antibody. The black and clear arrows indicate 
possible shifted bands. 
The consensus TBX22 binding site – AGGTGTCWTA - was identified by aligning 
the DNA sequences of the 20 clones (Table 14). An electromobility shift assay 
(EMSA) was used to verify that TBX22 did indeed bind to this consensus DNA 
binding site (see 3.2.5), using the rabbit reticulocyte cell lysate and the pTNT-TBX22 
protein. The resulting EMSA can be seen in Figure 22.  
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 The derived TBX22 DNA binding sequence oligo (W=T_oligo, lane 3 in Fig. 
22) is shown to bind to a protein within the lysate containing the TBX22 protein 
which results in a shifted band on the gel (position indicated by the black arrow in 
Fig. 22). A similar shift can be seen in lane 6 of Fig. 22 (Cont_oligo), which shows 
the shift by an oligonucleotide that has already been shown to bind TBX22 (Andreou 
et al. 2007) and serves as a positive control for this experiment. The cell lysate that 
did not contain the over expressed TBX22 protein (lane 2 in Fig. 22) did not display 
this shifted band illustrating the specificity of the W=T_oligo for a target site that is 
present within the cell lysate containing the 6xHis-TBX22 protein and which is not 
present in the rabbit reticulocyte lysate alone. In addition to this shifted band, both the 
W=T_oligo and the Cont_oligo show a more intense higher molecular weight band on 
the EMSA (position indicated by clear arrow in Fig. 22) in the presence of the lysate 
containing the TBX22 protein (lanes 3 and 6 in Fig. 22) when compared to the cell 
lysate only lane (lanes 2 and 5 in Fig. 22). It is possible that this more intense band is 
actually caused by binding of the W=T_oligo and Cont_oligo to a full length TBX22 
protein and that the lower shifted band is due to binding of the oligos to a smaller, 
incompletely transcribed or translatedTBX22 polypeptide. An alternative explanation 
for the presence of the high molecular weight band is that the W=T_oligo and 
Cont_oligo are binding with additional proteins within the lysate containing the 
TBX22 protein. Further work would be required to discriminate between these two 
possibilities. 
 
Further support of the specificity of the W=T_oligo for a target site within the lysate 
containing the TBX22 protein is demonstrated by the ability of an unlabelled 
oligonucleotide, with the same sequence as that of the consensus TBX22 binding site, 
to completely compete out the shift of the labelled oligo (lane 4 in Fig. 23). The cold 
W=T_oligo was also able to remove the higher molecular weight band (position 
indicated by a clear arrow) seen in lanes 2, 3 and 5.   
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a        b  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Specificity is further confirmed by the failure to compete out this shift (lane 5 in Fig. 
23a) by an unlabelled mutant oligonucleotide that has an identical sequence to the 
Figure 23: TBX22 DNA binding consensus sequence binds specifically to 
lysate containing TBX22 protein a. The shifted band (black arrow) seen with 
the W=T_oligo (lane 2) is not seen with the Mut_oligo which contains 2 changes 
for the DNA consensus sequence in positions essential for binding with TBX22 
(lane 3). A cold W=T_oligo (lane 4) is able to compete out the band shift seen 
with the labelled W=T_oligo. Specificity of the W=T_oligo to shift TBX22 is 
retained in the presence of an unlabelled non-specific competitor Mut_oligo (lane 
5). Lane 1 is the W=T_oligo only, lane 6 is the Mut_oligo only.  
b. Lanes with both the W=T oligo (lane 8) and the 515-20 oligo (lane 10) show 
shifts with the lysate with TBX22 protein in comparison to the lysate alone (lanes 
7 and 11). Lane 9 is W=T oligo only. 
a. and b. were electrophoresed on separate gels but the lanes are labelled in 
consecutive order to assist identification within the text. 
RRL – rabbit reticulocyte lysate; TBX22 – rabbit reticulocyte lysate containing 
TBX22 protein; W=T – W=T oligo; Cold W=T – unlabelled W=T oligo; Mut – 
Mut_oligo; Cold Mut = unlabelled Mut_oligo; 515-20 – 515-20 oligo. The black 
and clear arrows indicate the position of possible shifts on the gel. 
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consensus TBX22 binding site, except at bases 2 and 3 in which the guanine bases 
have been replaced with adenine bases. The Mut_oligo also differs from the 
W=T_oligo, but not the actual TBX22 consensus sequence, which can be either an 
adenine or thymine at the 8th base position, as this base is an adenine base as opposed 
to the thymine residue of the W=T oligo (see Table 13). Unfortunately the absence of 
the rabbit reticulocyte lysate only control lane in the first gel of Fig. 23 somewhat 
hinders direct comparison with the effects of the Mut_oligo on the lysate containing 
TBX22 protein (lane 3). However, taken all together, this experiment suggests that a 
protein within the lysate containing TBX22 can bind to the derived consensus 
sequence (W=T oligo). As the only known difference between the rabbit reticulocyte 
lysate and the lysate containing TBX22 protein is the TBX22 protein, this supports 
the argument that the TBX22 protein can bind to the W=T oligo. 
 
 In order to confirm this, a super-shift experiment using an anti-TBX22 antibody was 
required. However, the anti-TBX22 antibody was unable to super-shift the 
“TBX22”/W=T_oligo complex (lane 4 in Fig. 22) or the “TBX22”/Cont_oligo (lane 7 
in Fig. 22). Similarly the anti-His antibody also did not super-shift the complex under 
the same conditions (data not shown). Whilst the ability of the anti-TBX22 antibody 
to bind to 6xHis-TBX22 protein has not been tested, the anti-His antibody has been 
demonstrated to bind to this protein (Fig. 21). If the anti-His antibody had been 
employed using different experimental conditions, perhaps a super-shift confirming 
the specificity of the TBX22 DNA binding site to the TBX22 protein would have 
been achieved. However, in the absence of this data, it cannot be excluded that both 
the W=T_oligo and Cont_oligo are actually binding, and hence shifting, a protein 
other than the 6xHis-TBX22 protein. 
 
The fact that shifts with the TBX22 DNA binding consensus sequence (W=T oligo) 
were seen in these experiments partially authenticates the co-immunoprecipitation 
experiments (3.2.4). As the consensus DNA binding sequence was also the most 
represented sequence in the list of clones sequenced from the in vitro oligonucleotide 
selection assay: six of the twenty clones sequenced contain a sequence that is identical 
to the TBX22 consensus binding site, whereas five of the clones had thymine at the 
eighth position (oligos 515-15, 515-19, 515-21, 515-23 and 515-14 (see Table 14).  
Further justification of the results of the in vitro oligonucleotide selection assay can be 
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seen in Fig. 23. The 515-20_oligo, which contained a sequence identified in the in 
vitro oligonucleotide selection assay, but which differed from the TBX22 consensus 
sequence at two bases, was also capable of causing a shift with the TBXB2 protein 
(lane 10 in Fig. 23). It appears that the higher molecular weight band (clear arrow) 
seen with the W=T_oligo (lane 8 in Fig 23) is not present in the lane containing the 
515-20_oligo (lane 10 in Fig. 23). The absence of this band may reflect a genuine 
difference in the binding capability of the 515-20_oligo compared to the W=T_oligo 
or Cont_oligo, or may be due to an artefact of the experiment, perhaps due to 
radioactive incorporation variances between the different oligonucleotides. If the 
result reflects a genuine deficiency in the binding of the 515-20_oligo to a protein 
within the lysate containing TBX22 then four possible explanations are put forward 
below: 
 
 The 515-20_oligo binds more specifically to the 6xHis-TBX22 protein then either the 
W=T_oligo or Cont_oligo. If this is the case, then the higher molecular weight band 
that appears in the lanes with the lysate containing TBX22 protein and the W=T_oligo 
and Cont_oligo (indicated by the clear arrows in Fig. 22 and Fig. 23), could be due to 
the oligos binding to other proteins in the lysate. This is less likely because the higher 
bands are not seen with the rabbit reticulocyte lysate alone (compare lanes 2 & 3 and 
lanes 5 & 6, Fig. 22). However, there is perhaps partial support for this explanation in 
the fact that the 515-20_oligo contains a single DNA sequence that bound to the 
6xHis-TBX22 protein, as opposed to a consensus sequence composed of several 
combined sequences for the other two oligos which could account for the non-
specificity of these oligos to the 6xHis-TBX22 protein. A second hypothesis is that 
the W=T_oligo and Cont_oligo are binding to the 6xHis-TBX22 protein which is 
complexed to other biomolecules, thus increasing the molecular weight and showing 
as a higher band on the EMSA. If this complex is changing the conformation of the 
6xHis-TBX22 in such a way that the 515-20_oligo can no longer bind, no 
corresponding band would be seen on an EMSA and only the lower shifted band 
(indicated by the black arrow) would be visible due to the binding to the “free” 6xHis-
TBX22 protein. If either of these two possible explanations are correct, then this 
would give further credence that the shift in Figs. 22 and 23 indicted by the black 
arrow is due to binding of the TBX22 protein to the different oligonucleotides (W=T; 
Cont_Oligo; 515-20). 
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A third possible reason to explain an absence of a higher band in the 515-20_oligo 
lane may be due to the fact that both the W=T_oligo and Cont_oligo are able to 
concatamerize and then bind multiple copies of TBX22 – which appears as a higher 
band on a gel - which the 515-20_oligo is not capable of doing. A fourth explanation 
for this missing band may be that, as has been previously stated, it cannot be 
definitely concluded that the oligonucleotides are actually binding to the TBX22 
protein as a super-shift was not detected with the antibodies and conditions tested. It 
could be argued then, that the different bands detected in the EMSA experiments 
when using the various oligonucleotides are not in fact due to binding with 6xHis-
TBX22 protein, but result from DNA binding to very different proteins within the 
rabbit reticulocyte cell lysate. 
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3.4  DISCUSSION 
 
X-ray crystallography has shown how T-box proteins bind to their DNA recognition 
sites (Muller and Herrmann 1997; Coll et al. 2002). Contact is made at specific sites 
between the T-box protein and the DNA molecule (Fig. 24), although X-ray 
crystallography studies have yet to detail the exact mechanism for the TBX22 protein 
and the DNA molecule. 
  
The T-box protein binds to the DNA as either a dimer, with specific interaction 
between each dimer, as is the case with the Brachyury protein (Fig. 24a) or as a single 
monomer, as is the case with TBX3 (Fig. 24b). In either case, if the protein was 
folded such that these recognition sites were either not accessible to the DNA or the 
structure of the protein was physically altered, protein binding to the DNA would not 
be possible. Therefore it is essential that any production of recombinant protein that 
will be used for functional studies preserves the native protein structure. 
 
One of the greatest challenges in isolating a relatively pure synthetic protein is 
maintaining the native protein conformation or where this can not be achieved easily, 
the re-folding of a denatured protein back to its native state.  
 
 
a       b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24:  T-box proteins contact DNA at specific recognition 
sites. X-ray crystallographic images of a) the Xenopus T protein  
(Muller and Herrmann 1997) and b) human TBX3  (Coll et al. 2002) 
bound to DNA. 
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Expression in E.coli has been successfully employed as a strategy for the production 
of other functionally active T-box proteins (Sinha et al. 2000; Ghosh et al. 2001) and 
was an obvious approach to produce TBX22. The addition of a fusion tag to the 
protein not only aids the purification (especially in the absence of a specific antibody 
to the protein of interest), but also can help to stabilise the expression of recombinant 
proteins and may also assist in re-folding the protein if required. The two most 
common fusion tags are glutathione S-transferase (GST) and 6 histidine residues 
(6xHis). 6xHis was chosen as the preferred tag as it has the advantage of being a small 
tag and therefore being less likely to interfere with the structure and function of the 
TBX22 protein and can be purified in a one-step recovery process (Hochuli 1988).  
 
Induction of the 6xHis-TBX22 expression vector by IPTG drove the production of an 
over-expressed additional protein, absent in the uninduced cultures, which could 
clearly be seen in the cell lysates on a coomassie stained denaturing PAGE gel (Fig. 
17).  This band migrates to just below 70kDa on the PAGE gel when compared with 
the marker protein ladder.  However, the predicted molecular weight of the 6xHis-
TBX22 fusion protein using the online protein molecular weight prediction tool 
hosted by the bioinformatics organisation (http://www.bioinformatics .org/sms/prot 
_mw.html) is 62.05 kDa (theTBX22 protein and DNA sequences can be seen in 
Appendix 3). This molecular weight prediction does not account for any post-
translational modification of the protein that may occur and therefore taking this into 
account the over-expressed band in the induced cultures is migrating to approximately 
the expected position on the PAGE gel. 
 
Following Ni-NTA spin column purification, the over-expressed band seen in the 
induced cell lysate (Fig. 17) was isolated and appeared as a single band on a 
denaturing PAGE gel (Fig. 18), thus verifying that the over-expressed protein 
contained a 6xHis tag that was accessible by the Ni-NTA column and was therefore 
likely to be accessible to an anti-6xHis antibody in future experiments. MALDI-TOF 
mass fingerprinting analysis of the excised band after Ni-NTA purification revealed 
that the protein was unquestionably that of human TBX22 (Fig. 19 and Appendix 2).  
All of the other matches in the sample fell below the threshold level of significance 
showing that the 6xHis-TBX22 protein had been synthesised and successfully 
purified. 
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Although a 6xHis-TBX22 protein had been successfully produced and recovered by 
over-expression in bacterial cells and purification on a Ni-NTA column, doing so 
under non-denaturing conditions could not be achieved easily (Fig. 20). The 6xHis-
TBX22 protein could not be solubilised using many different lysis buffers (Table 12). 
This is a common problem when producing recombinant proteins in this manner 
(Casey et al. 1998) as the over-expressed protein is often accumulated as insoluble 
protein aggregates known as inclusion bodies within the host bacterial cells 
(Villaverde and Carrio 2003; Ventura and Villaverde 2006). Whilst it is theoretically 
possible to re-fold the denatured protein once it is purified, it is not always achievable. 
Attempts to re-fold the 6xHis-TBX22 protein whilst bound to the NI-NTA column, a 
method used to re-fold a 6xHis-TBX5 protein (Ghosh et al. 2001), proved 
unsuccessful. Once the urea in the buffer solution fell below ~ 3.5M the protein was 
no-longer soluble and came out of solution, blocking the column. Another approach 
was investigated, party due to the difficulties in re-folding the denatured protein and 
partly because re-folding a denatured protein does not always return the protein to its 
true native state (Shortle 1996).  
 
An in vitro transcription/translation (TNT) system (see 3.2.2) was able to express the 
same plasmid used in the bacterial cell expression studies. This method uses pre-lysed 
cell extracts, meaning the recovery of the protein is not needed in applications where 
the whole cell lysate can be used.  This is an appealing approach to use as it 
eliminates the need to solubilise or re-fold the protein. However, due to the limitations 
of the TNT technology, a much reduced protein yield is obtained. This has the 
consequence that there is insufficient sample to either see a band on a coomassie 
stained gel or, more importantly to use in a MALDI-TOF mass fingerprint 
experiment. Nevertheless, by using an anti-6xHis antibody, a protein can be detected 
by Western blot (lane T in Fig. 21). This protein is not present in the cell lysate that 
does not contain the 6xHis-TBX22 pET100/D-TOPO expression vector (lane RL in 
Fig. 21), showing that this protein is being expressed by the plasmid in the TNT cell 
lysate system. This protein shows a similar migration when compared to a protein 
marker by Western blot following denaturing PAGE (Fig. 21) to the migration seen 
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by the 6xHis-TBX22 protein expressed by the bacterial cells when run on a 
denaturing PAGE gel (figs. 17 and 18).  
 
Is the protein detected by Western blot (Fig. 21) the 6xHis-TBX22 protein, and is the 
protein in its native state? The evidence would suggest that both are likely to be the 
case. Although this protein cannot be verified by MALDI-TOF analysis due to the 
low sample yield, it is being expressed from the same plasmid that was used in the 
bacterial expression system and that protein was verified by MALDI-TOF analysis to 
be 6xHis-TBX22. As the protein synthesised by the TNT method was detected using 
an anti-6xHis antibody, one can be assured that the N-terminal 6xHis tag is present. 
Furthermore, the over-expressed proteins generated in both bacterial and mammalian 
cells have similar sizes as shown by their migrating to the same extent on a PAGE gel. 
As the proteins expressed by the TNT system are produced in a pre cell lysed 
environment and if the whole cell lysate can be used, no additional recovery process 
will be required which will make it more likely that the protein will retain its native 
conformation. Taken together there is satisfactory support that the protein produced 
by the TNT system is 6xHis-TBX22 protein and will be suitable for use in further 
functional studies, provided that using the whole cell lysate -which will include the 
6xHis-TBX22 protein – will not compromise such studies. 
 
There are additional benefits to using the TNT system over the bacterial expression 
method. As the TNT system employs mammalian cells, the post-translation protein 
modifications produced by this approach will be closer to the in vivo TBX22 protein 
than could be achieved by the prokaryote bacterial system, which has different post-
translation mechanisms.  
 
Using the protein expressed by the TNT system; an in vitro oligonucleotide selection 
assay yielded a TBX22 preferential DNA binding sequence: AGGTGTCWTA, where 
W is either an adenine or thymine (Table 14). The binding specificity of TBX22 to 
this sequence was confirmed when cold specific competitor reduced the binding of 
TBX22 to the DNA consensus oligonucleotide (lane 4 in Fig. 23a) and TBX22 was 
shown not to bind to an oligonucleotide with a similar sequence that differed at 2 key 
bases (Mut_oligo, lane 3 in Fig. 23a). Although it was not possible to show a super-
shift using a TBX22 antibody (lane 4 Fig. 22), this may be because the antibody used 
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was not actually binding to the protein at all. Antibodies are notoriously fragile in 
their ability to bind to their ligand when used under different environmental 
conditions. Although the antibody used in this study had been specifically designed 
for use in gel-shift experiments, the manufacturer could not guarantee that it would 
successfully bind to a TBX22 protein produced using a Rabbit Reticulocyte 
Transcription/Translation System or in cell lysate conditions. If an antibody that could 
bind TBX22 under the conditions used in this study were available, then a super-shift 
of consensus DNA binding sequence may well be observed. As no super-shift could 
be demonstrated in an EMSA experiment, the band shifts witnessed in the EMSA 
experiments could possibly be caused by binding of the oligos to proteins other than 
the TBX22 protein. Although an anti-His antibody demonstrated that a protein 
containing a 6xHis tag was being synthesised by the TNT system (Fig. 21), due to the 
lack of a super-shift even using this same antibody in an EMSA (results not shown), it 
is possible that the shifted bands may be due an experimental artefact. 
 
The derived TBX22 DNA binding sequence is similar to the Brachyury T1/2-site, 
expect for slight deviations at the 3  end of the sequence (Table 14). In comparative 
binding studies three Xenopus proteins Xbra, VegT and Eomesodermin whilst all 
showing binding to the same core Brachyury T1/2-site, all showed binding to various 
deviations from this sequence, most frequently at the flanking ends of this motif 
(Conlon et al., 2001). A study by another group reported that TBX22 preferentially 
binds to the sequence AGGTGTGAAATTGTCACCT (Andreou et al., 2007), which 
is orientated such that the second T1/2-site is inverted compared to the Brachyury T-
site. However, the authors found that binding to one T1/2-site was possible, albeit in 
the presence of an antibody to help stabilise the protein/DNA complex. It has been 
previously noted that variations in binding assay conditions can influence T-box 
binding to DNA: one study reports that Xbra cannot bind to a T1/2-site (Casey et al., 
1998), whereas two separate studies reported that indeed it can (Carreira et al., 1998; 
Sinha et al., 2000). Sinah and colleagues, point to salt and non-specific competitor 
concentrations as being a likely explanation for the differences between the reported 
findings of the three binding studies. These experimental differences could also be an 
explanation as to why the preferential TBX22 DNA binding site of this study and that 
of Andreou and colleagues do not exactly match. In addition, the authors of the latter 
study report that the full length inverted palindromic DNA binding sequence they 
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have derived for TBX22 is a sequence that is not naturally present in the human 
genome and propose it is more likely that the in vivo DNA binding site is a half site 
(Andreou et al., 2007). Therefore, both that study and the data presented here suggest 
that the DNA binding element of potential target genes for TBX22 is likely to contain 
a sequence similar to a Brachyury T1/2-site. 
 
The identified TBX22 binding sequence is similar to one half of the Brachyury DNA 
binding sequence, except that the seventh position, which is a guanine residue in the 
Brachyury target sequence,  is replaced by a cytosine base in the TBX22 binding 
sequence. Also at the eighth and ninth positions, where the Brachyury protein 
preferentially binds to an adenine base, TBX22 seems capable of binding to either an 
adenine or a thymine residue at the eighth position and has a preference for a thymine 
residue at the ninth position (see Table 14). 
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CHAPTER 4  
 
 
TBX22 DOWNSTREAM TARGETS 
 
 
4.1  INTRODUCTION 
 
 The in vitro techniques described in Chapter 3 identified a TBX22 binding sequence 
which can be used to search sequences of potential downstream target genes. The 
results of these searches can then be experimentally verified to reveal genuine T-box 
target genes. Such an approach has uncovered several Brachyury targets (Casey et al. 
1998; Casey et al. 1999) as well as for other T-box proteins (Ghosh et al. 2001; 
Garnett et al. 2009). 
 
Even after the identification of potential downstream target genes, validating them can 
still be an arduous task. Brachyury was the first T-box protein for which a preferential 
DNA binding sequence was identified (Kispert and Herrmann 1993) but it took a 
further five years before a downstream target gene was reported (Casey et al. 1998). 
Therefore, if TBX22 target genes were to be identified, careful consideration would 
have to be given to how the search was performed and also to exactly which genes 
would be included in the screen. 
 
Although a DNA binding consensus sequence that was similar to the Brachyury T1/2-
site had been determined for TBX22 (Chapter 3), it did not necessarily mean that this 
sequence would be the exact in vitro target for TBX22. For example, it had been 
shown that although the original T protein, Brachyury, would preferentially bind to 
the sequence – TTTCACACCTAGGTGTGAA, the DNA binding site in an in vivo 
target for the Xenopus Brachyury homologue Xbra, was – ATTCACACGT (Tada et 
al., 1998). This sequence, whist being very similar to the Brachyury T1/2-site, was not 
identical, showing that the actual in vivo T-box targets may show some degree of 
divergence from the preferential DNA binding site determined by an in vitro 
oligonucleotide selection assay.  
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A search strategy is needed that balances using a search sequence that is flexible 
enough not to miss potential targets, and using a sequence that is too encompassing 
which would lead to excessive numbers of matches to target sequences, potentially 
generating many false positives.  
 
With this in mind, a more generic binding site than the consensus TBX22 DNA 
binding site was constructed by compiling the binding sequences of other known T-
box target sequences and incorporating the preferential TBX22 binding site 
determined in Chapter 3. This sequence is referred to as the “generic T-box binding 
site”.  The promiscuity of different T-box proteins to their DNA target sequences has 
been demonstrated several times (for review see Tada and Smith 2001). Indeed all T-
box proteins tested have been reported to bind to the Brachyury target sequence, even 
if the experimentally derived DNA binding sequence and the preferred Brachyury 
DNA binding site were not exactly alike (Sinha et al. 2000; Conlon et al. 2001). 
 
As TBX22 is disrupted in CPX (Braybrook et al. 2001; Marcano et al. 2004; 
Chaabouni et al. 2005; Suphapeetiporn et al. 2007; Pauws et al. 2009b), one could 
reasonably assume that when TBX22 downstream target genes are disrupted, they too 
may give rise to a similar cleft palate phenotype. Therefore, all genes shown to 
underlie a cleft palate disorder would be candidates in which to screen for the 
presence of the identified preferential TBX22 binding site and the generic T-box 
binding site. Following the identification of a potential TBX22 target by such a 
screen, further evidence would be needed to determine whether the gene could be a 
TBX22 target in vivo: information gained from gene expression studies, animal 
models, gene function and involvement in human disease will be invaluable in 
supporting, or indeed dismissing, any of the genes identified from the screening 
procedure as having the potential to be an actual TBX22 downstream target. 
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4.2  MATERIALS AND METHODS 
 
4.2.1 Electrophoretic Mobility Shift Assay of an MSX1 oligonucleotide 
 
 An EMSA was performed in the same way as detailed in 3.2.5, with an 
additional double-stranded oligonucleotide containing the exact sequence found in the 
MSX1 promoter (MSX1_oligo). This was prepared by annealing the oligonucleotides 
5΄-CGAGAGGTGTTGAGCGAG-3΄and 5΄-CTCGCTCAACACCT CTCG-3΄, which 
was 5΄end labelled using [γ_32P]ATP as in 3.2.5.A. For competition studies, a cold 
MSX1_oligo was also prepared by annealing the same oligonucleotides, but was not 
5΄end labelled. The cold MSX1_oligo was used in an excess ratio of 100:1 with the 
labelled MSX1_oligo added to the binding reaction (see 3.2.5). The sequences of the 
MSX1_oligo and the W=T_oligo also used are given along with all the other double-
stranded oligonucleotide and PCR primers are given in Appendix 1. 
 
 
4.2.2 Non-radioactive in situ Hybridisation 
   
Paraffin sections of human embryonic tissue were used to determine the expression 
pattern of MSX1. The material was prepared in the same manner as outlined in 2.2.1. 
 
A.  DNA TEMPLATE PREPARATION AND RNA TRANSCRIPTION 
Forward and reverse primers for MSX1 containing a T7 RNA polymerase sequence 
and an SP6 RNA polymerase sequence respectively (see Appendix 1 for primer 
sequence) were used to generate a DNA template by PCR (see 3.2.1.B) using 25 
cycles and an annealing temperature of 62oC. The resulting amplicon was extracted 
from a 1% agarose gel and purified by elution through a gel extraction column 
(Qiagen) following the manufacturer’s instructions. 
 
Using a DIG-labelling kit (Roche Applied-Science) sense and antisense riboprobes 
were synthesised using T7 and SP6 RNA polymerases respectively from the purified 
DNA template following the manufacturer’s directions, except 75ng of PCR 
fragment, rather than 1µg of plasmid DNA was used in the reaction. 
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B.  PROBE VERIFICATION AND QUANTIFICATION 
 
 All probe concentrations were confirmed using a nanodrop instrument 
(Thermo) and the probe length was verified by electrophoresis on an agarose- 
formamide gel. Here, the agarose gel is prepared by adding 1g agarose to 41ml of 
DEPC treated H20 and dissolved by heating in a microwave and re-adjusted to 41ml. 
9ml 37% formamide (Merk) is then added to the cooled mixture and the gel is poured 
into a casting mould containing a comb. RNA samples and an RNA ladder are heated 
to 70oC cooled on ice and RNA loading buffer (Fermentas) is added to the samples to 
a final concentration of 1X. 6µl of ladder and sample are electrophoresed on the gel in 
1X MOPS–EDTA (Sigma) running buffer for 2 hours at 50V. The gel is then removed 
from the tank and cassette and transferred to SYBR Green (Molecular Probes) for 15 
minutes with agitation, rinsed in H2O and the migration of the samples compared to 
the RNA ladder under UV illumination. 
 
C.  PROBE HYBRIDISATION 
   
 All solutions used were made using DEPC treated H2O or PBS and all 
glassware used to contain these solutions was baked at 180ºC for 4 hours before use to 
denature RNAses. To remove the paraffin wax the slides containing the sectioned 
material were transferred to metal racks and taken through three 5 minute changes of 
xylene. The xylene was then removed from the sections by 3 minute washes in 1:1 
xylene/ethanol, two changes in 100% and then 90%, 70% and 50% ethanol washes. 
The ethanol was removed from the sections by two separate 2 minute washes in PBS 
and then the sections were subjected to proteolytic digestion by 20µg/ml Proteinase K 
(Sigma) in PBS at 37°C. The sections were then rinsed for 30 seconds in PBS and 
then fixed in 4% PFA for 20 minutes at room temperature. Following fixation, the 
sections were rinsed in 2 changes of PBS and then were placed in a 0.1M 
triethanolamine pH 8.0, 0.25% acetic anhydride/PBS solution for 10 minutes. The 
sections were then given two more rinses in PBS before being dehydrated in 50%, 
70%, 90% and finally two 100% ethanol washes for 2 mins each. The sections were 
then air dried under a filtered air stream. 
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 A hybridisation mix is prepared by first heating the labelled probe (4.2.2.A) to 
70oC for five minutes and then cooling on ice. For each slide, 100µl Dig Easy Hyb 
Mix (Roche Applied Sciences) containing 300ng of the prepared RNA probe is used 
to cover the slide and a glass cover-slip is placed carefully on top. The slides are then 
placed inside plastic trays and the plastic trays placed inside a hybridisation chamber 
with a paper towel soaked in 2X SSC. The hybridisation is performed overnight at 
68ºC. 
 
D.  POST HYBRIDISATION WASHES 
 
  Following hybridisation, the slides were taken out of the hybridisation oven 
and removed from the trays. The cover-slips were removed by rinsing the slides in 5X 
SSC, pre warmed to 60ºC, and the slides placed in plastic slide racks. The slides were 
then washed in two 10 minute washes of 5X SSC at 60ºC, followed two 10 minute 
washes in 2X SSC first at 60oC and then at room temperature.  
 
E.  ANTIBODY DETECTION 
 
 The slides were removed from the hybridisation wash and given three 10 
minute washes in wash buffer (0.1M Tris (pH 7.6), 0.15M NaCl). The slides were 
then covered in a blocking solution of 10% fetal calf serum (Sigma; previously heat 
inactivated at 58ºC for 30mins) diluted in the antibody detection buffer (0.1M Tris 
(pH 7.6), 0.15M NaCl, 2% fetal calf serum) and left for 1 hour at room temperature. 
Next, the blocking solution was poured from the slides and 150µl anti-DIG antibody 
(Roche Applied-Science) diluted 1:1000 in 2% fetal calf serum/antibody detection 
buffer was placed directly onto the slide and covered with pieces of laboratory 
parafilm (Pechiney Plastic Packaging Company). The slides were then incubated 
overnight at 4ºC. 
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F.  Signal Detection 
 
 The parafilm covers were removed from the slides by rinsing in the antibody 
detection buffer and performing three 10 minute washes in this buffer. The slides 
were then transferred to a signal detection buffer (0.1M Tris (pH 9.5), 0.1M NaCl) 
and three further 5 minute washes were performed in this buffer. NBT/BCIP (Roche 
Applied Science) was diluted to 20µl/ml in the signal detection buffer and the reaction 
left to develop in the dark overnight. The following day the slides were rinsed in 
several changes of H2O and mounted using Aquamount (VWR) and cover slips added. 
Images were taken as described in 2.2.2.G 
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4.3  RESULTS  
 
4.3.1 Computational Search for Potential TBX22 Target Genes 
 
A. GENERATING A GENERIC T-BOX BINDING SITE   
 
In an attempt not to excluded possible bona fide TBX22 downstream target genes that 
did not exactly match the derived TBX22 DNA binding site, a generic T-box binding 
site was compiled by combining the TBX22 DNA binding consensus sequence 
(Chapter 3) with the sequences, or reverse complement of T-box half sites with which 
it showed similarity (see Table 15 below and Table 10, Chapter 3). All of the 
nucleotides that occurred more than once in the same position when these sequences 
were aligned were included in the generic T-box DNA binding sequence. However, in 
the binding sequences identified for human TBX5 (Ghosh et al. 2001) and mouse 
Tbx6 (White and Chapman 2005) any nucleotide may be positioned at the final two 
nucleotide positions (RGGTGTBRNN and AGGTGTBRNN respectively). 
Incorporating N at positions 9 and 10 in the generic T-box binding site would 
effectively have given a search sequence of just eight nucleotides. Therefore, the 
information from human TBX5 and mouse Tbx6 at positions 9 and 10 was not 
included when compiling the sequences used to determine the generic T-box binding 
site. 
 
This gave a final generic T-box binding sequence of AGGTGTBDWR, which 
provided a more flexible binding site target sequence than the identified TBX22 
binding site alone (Chapter 3), but one that should still be  specific enough not to 
generate large numbers of false positive results. 
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Table 15: Sequences of T-box protein DNA binding sites included when 
determining the generic T-box binding site.  The DNA binding sequences of the 
different T-box proteins shown in this table include both the preferred in vitro DNA 
binding sites and known in vivo target sequences. Standard IUPAC abbreviations 
have been used to represent ambiguous bases (see Table 11, Chapter 3). One of the 
half-sites of the TBX22 binding site identified by Andreou et al. 2007 is shown. The 
other has a similar sequence but is in the opposite orientation.  
 
Species Protein 
 
DNA Binding Site 
 
References 
Human Brachyury  A G G T G T G A A A  (Papapetrou et al. 1997) 
Human TBX1  A G G T G T G A A A  (Sinha et al. 2000) 
Human TBX2  A G G T G T G A A A  
(Sinha et al. 2000; Lingbeek et al. 
2002) 
Human TBX3  T G G T G C C A A A  (Lingbeek et al. 2002) 
Human TBX5  R G G T G T B R    (Ghosh et al. 2001) 
Human TBX22  A G G T G T G A A A  (Andreou et al. 2007) 
Mouse Brachyury  A G G T G T G A A A  (Kispert et al. 1995) 
Mouse Tbx6  A G G T G T B R    (White and Chapman 2005) 
Xenopus VegT  A G G T G T C T T G  (Casey et al. 1999) 
Xenopus VegT  A G G T G T G A A G  (Hyde and Old 2000) 
Xenopus Xbra  A G G T G T G A A A  (Casey et al. 1998) 
Xenopus Xbra  A G G T G T C T T G  (Casey et al. 1999) 
Ciona Ci-Bra  A G G A G G T G C C  (Di Gregorio and Levine 1999) 
Human TBX22  A G G T G T C W T A  See Chapter 3 
Generic T-box 
Binding Site  A G G T G T B D W R   
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B.  SEARCHING HUMAN CLEFT PALATE GENES FOR A GENERIC T-BOX BINDING SITE 
 
Single genes that had been shown to underlie a disease phenotype that included a cleft 
palate were identified from OMIM (Online Mendelian Inheritance in Man; 
http://www.ncbi.nlm.nih.gov/omim/). Genes shown to be implicated in a cleft palate 
phenotype by linkage analysis, but were not specifically shown to be disrupted in an 
individual with a cleft palate, were not included. Similarly, instances where large 
DNA regions or chromosome abnormalities were implicated in cleft palate disorders 
were also not included. Appendix 5 gives the full list of genes screened. As of the 
tenth of February 2010, data mining the OMIM database revealed 132 genes that had 
been shown to cause a human genetic abnormality that included a cleft palate (first 
column of Appendix 5).  
 
Having compiled a list of known human cleft palate causing genes, the 2kb sequence 
upstream from the start of transcription of each of the genes identified was used to 
search for the presence of the TBX22 consensus sequence and the generic T-box 
binding sequence. 2kb were selected as the size of the sequence to screen,  following 
the protocol of a previous T-box gene study (Ghosh et al. 2001). The DNA sequence 
used for the search and also the position of the start of transcription was based upon 
that given by the gene reference sequence archived in the RefSeq depository at the 
NCBI (http://www.ncbi.nlm.nih.gov/RefSeq/). The current RefSeq sequence (Pruitt et 
al. 2007) of these genes and the position of the gene within the GenBank accession 
numbers (Benson et al. 2008) used are highlighted in the second column of Appendix 
5. Entries with a suffix “complement” denote that the gene is transcribed from the 
other strand to that given by the GenBank accession number stated. The third column 
of Appendix 5 shows the 2kb sequence which was searched for the presence of the 
derived TBX22 DNA binding consensus sequence (AGGTGTCWTA) and the generic 
T-box binding site (AGGTGTBDWR).  
 
 A web based version of Fuzznuc, housed by Anabench online molecular 
biology tools (http://anabench.bcm.umontreal.ca/anabench/index.jsp), was used to 
perform the search for the presence of potential in vitro binding sites in the isolated 
2kb region upstream of the cleft palate causing genes. Fuzznuc was developed as part 
of the EMBOSS package (Rice et al. 2000) and is a bioinformatics tool which allows 
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the user to search longer sequences for the presence of short sequences containing 
ambiguous nucleotides at the same position in the search sequence. 
 A screen of the 2kb promoter regions of these 132 identified genes for the presence 
of the derived TBX22 DNA binding consensus sequence did not uncover any 
matches. The list included the TBX22 gene itself, to which TBX22 is known to bind 
(Andreou et al. 2007). A search for the generic T-box binding site - AGGTGTBDWR 
- was performed both with a limit of no mis-matches and also allowing for 1 mis-
match to the search sequence.  
 
Twelve genes were identified as having the generic T-box binding sequence (allowing 
no mis-matches) present in the 2kb search region (column 4 in Appendix 5 and 
summarised in Table 16).  
Gene 
Position from start of 
transcription 
Sequence of match to the 
generic T-box site and 
nucleotide position within 
binding site 
    1 2 3 4 5 6 7 8 9 10 
ESCO2 1501-1510 A G G T G T T A A G 
FOXC2 124-133 A G G T G T G G A A 
FTO 1677-1687 A G G T G T C T T G 
GPC3 473-482 A G G T G T T A A G 
KIAA1279 196-205 A G G T G T G G T G 
MSX1 1166-1175 A G G T G T T G T G 
POMT2 1648-1657 A G G T G T C T A A 
PTCH2 383-392 A G G T G T G G T G 
RAPSN 53-62 A G G T G T G G T G 
RPS19 731-720 A G G T G T G G T G 
SPINT2 870-879 A G G T G T G G T G 
SUMO1 71-80 A G G T G T G A A G 
Sequence of generic T-box binding site A G G T G T B D W R 
 
 
 
Table 16: A list of the human cleft palate genes containing a hit to the generic T-box 
binding site. The numbers show the nucleotide position upstream from the start of 
transcription and the specific sequence at that site is shown. B = C or G or T; D = A or G 
 or T; R = A or G; W = T or A (see Table 11). 
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However, none of these identified genes had a sequence that matched directly with 
any of the clones sequenced from the oligonucleotide selection assay (see Table 14). 
This is perhaps due to the differences between the “perfect” target site identified from 
every single possible DNA sequence using such an assay under experimental 
conditions and the true gene target sites that exist in vivo. Similarly, none of these 
sequences were an exact match to the TBX22 DNA binding consensus sequence 
identified in Chapter 3. ESCO2 and POMT2 had the closest matches to this sequence, 
differing by only one base in each case; the remaining ten genes all differed from the 
derived TBX22 DNA binding sequence at three bases. However, all of these base 
differences were outside of the core sequence that is common amongst all of the 
known T-box DNA binding sequences (see Table 15). 
 
The results when this search was performed allowing one mis-match can be seen in 
column 5 of Appendix 5. This less stringent search, as may have been expected, 
produced many hits. Indeed, all but 30 of the 132 genes showed a hit to the search 
sequence. Several genes showed more than one potential generic T-box binding site 
and sixteen had three or more sites detected using the 1 mis-match search criterion. 
These genes are shown in Table 17 and include TBX22 for which four binding sites 
were identified.  
 
Further evidence that a gene identified from the in silico search might be a TBX22 
downstream target was sought from mouse models. The human cleft palate genes 
identified in 4.3.1.B were used to search the Mouse Genome Database (MGD) 
database (http://www.informatics.jax.org) for the presence of a cleft palate phenotype 
in the mutant mouse with a disruption in those genes. The MGD (Bult et al. 2008; 
Blake et al. 2009) is an electronic depository for the genomic, phenotypic and gene 
expression information gathered from mutant mouse models for the purpose of 
investigation of human genetic disease. Of the 132 human cleft palate genes, a mouse 
model for that gene had been reported in the literature for 108 and of these 108 
mutants, 39 were reported to have a cleft palate phenotype (final column, Appendix 
5). 
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Gene 
Position 
from start of 
transcription 
Sequence of 1 mis-match to 
the generic T-box site 
    1 2 3 4 5 6 7 8 9 10 
617-626 A G G T G T A T A A 
705-714 A A G T G T C A T G 
1390-1399 A G G T G T T C T A 
BMP4 
1583-1592 A G G T G T T T C A 
260-269 A T G T G T G G A A 
586-595 A A G T G T C A A A 
927-936 A G G T G A G G T G 
1383-1392 A G G G G T G G A G 
COL2A1 
1820-1829 A G G G G T G G A G 
178-187 A G G A G T C A A A 
914-923 A G G T C T T G T G EFNB1 
1239-1248 A G G T G T C T T T 
355-364 A G G T G T C G A T 
926-935 G G G T G T G G T G GDF1 
1599-1608 G G G T G T G A A A 
674-683 A G G T G T T A C G 
1196-1205 A G C T G T C A T G GLI2 
1472-1481 A T G T G T G A T G 
61-70 A G C T G T C A A G 
550-559 A G G T G T T A T C 
740-749 A G G T G T G G G A 
1597-1606 G G G T G T C A A A 
HOXA2 
1657-1666 A G G T G C T T A A 
27-36 A G G T A T C T A A 
441-450 A G C T G T T G T G 
930-939 A G G T G G T T A G 
MKS1 
525-534 A G G T C T G T A G 
26-35 A G G T G G G A T G 
569-578 A G G T G T G A A C PEX7 
1804-1813 A G C T G T C G T A 
continued overleaf … 
135 
 
Gene 
Position 
from start of 
transcription 
Sequence of 1 mis-match to 
the generic T-box site 
  
  1 2 3 4 5 6 7 8 9 10 
249-258 A G C T G T G T A A 
615- 624 A C G T G T G A A A 
626-635 A G G T T T T T A A 
PROK2 
669-678 A G C T G T T T A A 
834-843 A G G T G T G C T G 
895-904 A G G T G T T G G G PROKR2 
1406-1415 A G G A G T G G T G 
355-364 A G G C G T G G T G 
977-986 A G G T G G G G A A 
1242-1251 T G G T G T T A A A 
1678-1687 G G G T G T C T T G 
1862-1871 A G G T G C C T A A 
RAPSN 
1893-1902 A G G T G G C A A G 
170-179 A G G T G T G A A C 
1124-1133 A G G T T T T T A A RPL5 
1220-1229 A A G T G T T T T A 
534-543 A G C T G T T G T G 
1015-1024 A G G T G A G G A A SLC26A2 
1157-1166 T G G T G T T T T G 
991-1000 A G G G G T T T T A 
1044-1053 C G G T G T G G T A 
1094-1103 A G G T A T G G T G 
TBX22 
1461-1470 A G G T G T A A A G 
631-640 A G G C G T G G A A 
853-852 A G G G G T G G A A TNNT3 
1519-1528 C G G T G T C T A G 
284-293 A G G T G A G T A A 
1057-1066 A G A T G T G G A A ZEB2 
1410-1419 A G G T G T A G A G 
 
Table 17: Human cleft palate genes showing three or more generic T-box 
binding sites with a one base mis-match. The position upstream from the start 
of transcription and the specific sequence at that site is shown along with the 
nucleotide position of each base.  
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 Combining the information from the genes that contained a hit to the generic 
T-box sequence or to a minimum of three hits to the 1 mis-match sequence within 
their promoter sequence with the information from the mouse mutants increased the 
likelihood of identifying biologically relevant candidates for downstream targets of 
TBX22. Of the 132 identified human cleft palate causing genes, 10 fell into this 
category and are summarised in Table 18. 
 
  
 
 
 
 
 
 
 
 
 
One of the genes from Table 18 - MSX1 - was then examined further as a candidate 
TBX22 downstream target. The reasoning behind the decision to examine MSX1 as a 
potential candidate and the exclusion of the other genes is expanded upon in the 
Discussion at the end of this chapter. Briefly, when information from known gene 
expression patterns, function and available evidence from mouse mutants was 
examined two genes remained as strong candidates- MSX1 and SUMO1. TBX22 had 
already been shown to undergo sumoylation (Andreou et al. 2007) and so it was 
decided to pursue MSX1. To verify whether the generic T-box binding sequence 
identified within the MSX1 promoter (see Table 16) could bind the TBX22 protein, an 
EMSA (section 3.2.5) was performed using an oligonucleotide containing this 
sequence – MSX1_oligo (section 4.2.1). A band shift in an EMSA was seen with the 
MSX1_oligo (lane 2) similar to that seen with the W=T_oligo (lane 5). Furthermore, 
specificity of the binding of the MSX1_oligo to a protein within the lysate containing 
the TBX22 protein is confirmed by a cold MSX1_oligo competing out the shifted 
band (lane 4). This cold competitor can also remove the higher band (indicated by the 
clear arrow) seen in lanes 2, 3 and 4 as did the W=T competitor oligo (see lane 4 Fig. 
23a in Chapter 3).
GENE 
FOXC2 
MSX1 
SUMO1 
COL2A1 
EFNB1 
GLI2 
HOXA2 
MKS1 
TBX22 
ZEB2 
Table 18: The known human cleft palate causing genes 
that contain either an exact match to the generic T-box 
binding site, or at least 3 copies of a 1 base mis-match to 
it, in a 2kb region from the start of transcription and 
also give rise to a cleft palate phenotype when disrupted 
in mouse. 
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Figure 25: The cell lysate containing TBX22 protein causes a band shift with 
an oligo to the TBX22 binding site identified by the in silico screen of 2kb of 
the MSX1 promoter (MSX1_oligo). The MSX1_oligo (lane 2) and W=T_oligo 
(lane 5) bind to a protein in the lysate containing the TBX22 protein and cause a 
shift on the gel when compared to the rabbit reticulocyte lysate control (lane 3). A 
cold MSX1_oligo is able to compete with the labelled MSX1_oligo and eliminate 
the shift (lane 4). Lane 1 is the labelled MSX1_oligo only and lane 6 is the 
W=T_oligo only. 
RRL – rabbit reticulocyte lysate; TBX22 – lysate containing the TBX22 protein; 
W=T – W=T_oligo; MSX1 – MSX1_oligo; Cold MSX1 – unlabelled MSX1_ 
oligo. The black and clear arrows indicate the position of potential shifts. 
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In common with the EMSA studies in Chapter 3, experiments using ant-TBX22 
antibodies did not produce a super-shift (data not shown) and so it could not be 
confirmed directly that the MSX1_oligo was indeed binding to the TBX22 protein. 
However, the results from this EMSA experiment are consistent with the possibility of 
MSX1 being a candidate as a downstream TBX22 target gene. The expression of 
MSX1 was compared to that of TBX22 during human palatogenesis. 
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Figure 26: mRNA expression of MSX1 and TBX22 in the developing 
palate.  The expression of MSX1 is revealed by non-radioactive in situ 
hybridisation (a, c and d) and is shown in relation to the expression of 
TBX22 by radioactive in situ hybridisation (b, d and f). The images show 
the expression detected by the antisense probe; the sense probe gave no 
detectable signal for either gene (data not shown).  Hybridisation of the 
antisense probe is to a CS18 (a, c and d) and CS19 (b, d and f) human 
embryo sectioned in the sagittal plane through comparable regions in both 
embryos. The rectangles shown on images a, b, c and d depict the 
approximate area highlighted in the image directly below it.  
t – tongue, mand – mandible, n – nasal pit, mnp – medial nasal process, 
ps – palatal shelf. 
Bar =1000µm in that and the image adjacent to it. 
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From the low power magnification images of the expression of MSX1 and TBX22 (a 
and b in Fig. 26) it can be seen that both genes have discrete regions of expression in 
the developing embryonic face. In the higher magnification images (d and f in Fig. 
26) TBX22, as was seen in the transverse sections at CS19 (Fig. 11, Chapter 2), is 
weakly expressed at the base of the tongue.  In contrast to this, MSX1 is expressed 
more strongly in the mesenchyme of the mandible (c and e in Fig. 26), as can be seen 
from the position of the signal in relation to that of TBX22.  
 
Stronger TBX22 expression is seen within the mesenchyme surrounding the nasal pit 
with the most intense signal being restricted to mesenchyme immediately adjacent to 
the epithelial cell layer posterior to the nasal pit. The expression of MSX1 is restricted 
to the mesenchyme within the most anterior region of the palate. Close comparison of 
this same region hybridised with the TBX22 antisense probe in the CS19 embryo 
shows that TBX22 is not being expressed (f in Fig. 26). Similarly, in the mesenchyme 
in the region below the forebrain and above the nasal pit, where lower levels of 
TBX22 are expressed, no MSX1 expression is detected. These data indicate that MSX1 
and TBX22 may be expressed in a complementary pattern within the developing 
palate and other facial structures; where TBX22 is detected MSX1 is absent and vice 
versa.  
 
The experiments for the two genes have been conducted in different human embryos 
which are of slightly different ages (CS18- MSX1and CS19- TBX22) and which have 
been sectioned at slightly different angles. As both the morphology of the facial 
structures (see 1.2) and the expression pattern of TBX22 (see Chapter 2) are changing 
rapidly during this stage of development, the definitive conclusion that TBX22 and 
MSX1 are indeed expressed in a complementary pattern cannot not be made. 
Additionally, the two experiments have been conducted using different techniques – 
TBX22 by radioactive in situ and MSX1 using a non-radioactive labelling method. To 
increase confidence when drawing such a conclusion, the same in situ method 
performed on consecutive sections should be employed. However, to definitively 
show that TBX22 protein is present in the same cells, or those adjacent to those that 
are transcribing MSX1, an immunohistochemistry methodology using an anti-TBX22 
antibody in the same embryo section as and in situ probe for MSX1 would be required. 
However, this is difficult due to the previously discussed problems with antibodies for 
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TBX22 (section 3.3.2 and 3.4).
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4.4  DISCUSSION 
 
Searching promoter regions of 132 known human cleft palate causing genes for the 
presence of the TBX22 DNA consensus sequence did not yield any hits. However 
screening the same set of genes with a generic T-box binding sequence produced 
several potential matches. This is perhaps not surprising given that a search for targets 
of the T-box gene, T-bet, by chromatin immunoprecipitation, identified 832 protein 
coding target genes in human Th1 cells (Jenner et al. 2009). However, only the first 
2kb region upstream relative to the start of transcription was examined for the 
presence of potential TBX22 binding sites. It is therefore possible that potential 
TBX22 binding sites present in areas that extend beyond this region have been 
missed, as the promoter can extend for several kilobases upstream of the start of 
transcription (for review see Levine and Tjian 2003). Similarly, any intronic 
regulatory regions within the gene which act as binding sites would also not be 
detected.  
 
Whilst ten genes were found to contain a direct match to the generic T-box binding 
sequence within the 2kb region examined (Table 16), relaxing the conditions to allow 
a 1 base mis-match to the generic binding sequence produced more gene hits. 
Relaxing the stringency of the binding site search sequence in this manner produced a 
hit in 102 of the 132 genes investigated. While it is possible that all of these genes are 
downstream targets of TBX22, for this study two further criteria were used to refine 
the search. Firstly, as it has been shown that functional T-box binding sites are often 
found together in clusters (Barron et al. 2005; Garnett et al. 2009), genes that 
contained 3 or more of these hits (Table 17) were also considered with those genes 
that contained a direct match.  
 
Secondly, further evidence of possible TBX22 target genes was sought from mouse 
mutants. Of the 132 genes examined only 39 had been reported to display a cleft plate 
when disrupted in the mouse mutant. It has been shown several times that oral clefts 
are not always present when a single gene is disrupted, but when a compound mutant 
is generated with another developmental craniofacial gene a cleft palate phenotype 
arises (Beverdam et al. 2001; Ding et al. 2004; Alkuraya et al. 2006). In cases where 
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a single gene disruption does cause a cleft palate mutant phenotype, generating 
compound mutants with other clefting genes often increases the frequency and/or the 
severity of the cleft (Alkuraya et al. 2006; Nakatomi et al. 2010). 
 
Possible TBX22 downstream targets, therefore, were identified if they met the 
following criteria: 
a) the promoter region screened contained either the generic T-box binding sequence 
or at least three copies of the “1 mis-match” sequence and b) a mouse mutant for that 
gene displayed a cleft palate phenotype. This generated 10 candidate genes for 
consideration, one of which was already known to be a TBX22 target – TBX22 
(Andreou et al. 2007). From the remaining nine genes (Table 18), MSX1 was chosen 
for further study as being the most likely to be a TBX22 target gene for the following 
reasons:  
 
Mutations in the ZEB2 gene give rise to Mowat-Wilson syndrome (Cacheux et al. 
2001). This is a complex syndrome where mental retardation and impaired motor 
development are prominent features (Mowat et al. 2003). Whilst there has been little 
to suggest that ZEB2 has a significant role in craniofacial development, interactions 
with TGFβ1 have been demonstrated (Gregory et al. 2008) and associations to CL/P 
and TGFβ1 have been made (Stoll et al. 2004). The  Zeb1+/-; Zeb2-/- compound mutant 
was reported as having a cleft of the maxilla (Miyoshi et al. 2006). However, as the 
cleft seen in CPX is of the secondary palate, ZEB2 was not considered as being a 
good candidate as a TBX22 target gene. MKS1 is the gene disrupted in Meckel 
syndrome (Kyttala et al. 2006). The protein encoded by MKS1 has been shown to be 
associated with cilia formation in most tissues (Weatherbee et al. 2009) and as such 
was not considered to have a specific role in palatogenesis and therefore interaction 
with TBX22 was considered unlikely. Whist a Hoxa2 mutant has a cleft plate 
phenotype (Barrow and Capecchi 1999) the expression of Hoxa2 in developing 
pharyngeal arches (Barrow et al. 2000; Trainor and Krumlauf 2001; Creuzet et al. 
2005) precedes that of TBX22 and is therefore unlikely to be downstream of TBX22.  
 
Three of the ten genes identified as potential TBX22 candidate targets (see Table 18) 
have been shown to have a role in cartilage or bone differentiation - FOXC2, COL2A1 
and EFNB1 (Vandenberg et al. 1991; Mo et al. 1997; Barbieri et al. 2003; Compagni 
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et al. 2003; Kim et al. 2009a). This is interesting given that the major role of TBX22 
based on phenotypic observation of the TBX22 null mutant mouse was adjudged to be 
in osteoblast formation (Pauws et al. 2009a). EFNB1 is the gene mutated in 
craniofrontonasal syndrome (Twigg et al. 2004; Wieland et al. 2005; Torii et al. 
2007).  EphB2/EphB3 receptor mutants have a cleft palate phenotype and other 
abnormal ossification patterns (Compagni et al. 2003). Mouse Efnb1 is expressed in 
neural crest cells that have migrated to the frontonasal process (Twigg et al. 2004). As 
this expression would precede that of TBX22, EFNB1 was not considered further as a 
target gene. 
 
A FOXC2 mutation was reported in a patient with Lymphedema-distichiasis 
syndrome (Tanpaiboon et al. 2010), one of the characteristics of which being a cleft 
palate. Moreover, the palatal shelves of the FOXC2 null mutants failed to fuse (De 
Felice et al. 1998). However as FOXC2 has been shown to be involved in 
mesenchymal-epithelial transformation (Hader et al. 2010) it could be postulated that 
the failure of the palatal shelves to fuse was due to incorrect mesenchymal-epithelial 
transformation of the MEE (see 1.2.5). However, the expression pattern of TBX22 
seen in Chapter 2, suggests that TBX22 has a role in the proliferation of the 
mesenchyme within the palatal shelves and on this basis FOXC2 was not taken 
forward for further investigation as a TBX22 target.  
 
Although mutations in COL2A1 cause Stickler syndrome (Vintiner et al. 1991), an 
association between COL2A1 and non-syndromic cleft palate has also been 
established (Melkoniemi et al. 2003). The finding that COL2A1 has a role in 
chondrocyte differentiation (Vandenberg et al. 1991; Barbieri et al. 2003) made this 
genes less likely to be a TBX22 target for the same reasons as for FOXC2, namely 
that the TBX22 expression patterns suggests that it is likely to have a role in 
mesenchyme proliferation. 
 
Point mutations in GLI2 have been suggested to cause non-syndromic CL/P (Vieira et 
al. 2005). Additionally, Gli2 has been shown to be expressed in mouse palatal shelves 
and Gli2 mutant mice have a severe cleft secondary palate (Mo et al. 1997). In these 
mice, the palatal shelves are sometimes completely missing or else palatal shelf 
elevation was delayed. As mesenchyme-epithelial transition was unaffected (Mo et al. 
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1997) this points towards a role in proliferation – similar to the expected role of 
TBX22 based upon the gene expression results (Chapter 2). However the Gli2 mutant 
has other skeletal abnormalities indicating that Gli2 has a more general role in skeletal 
development, rather than in palatogenesis specifically, so Gli2 was not chosen for 
further investigation. 
 
Of the ten genes identified from the in silico screen (Table 18) two were known to 
cause non-syndromic CL/P causing (see Table 4, Chapter 1), namely SUMO1 and 
MSX1. These genes therefore were the strongest candidates for being authentic 
TBX22 targets. While it can be hypothesised that TBX22 may target SUMO1 in auto-
regulatory manner, an interaction between TBX22 and SUMO1 had already been 
demonstrated: TBX22 undergoes sumoylation; (Andreou et al. 2007).  The remaining 
gene, MSX1, was therefore chosen for further investigation. 
 
The heterozygous Msx1-/- knockout mouse has a cleft of the secondary palate 
(Satokata and Maas 1994). The palatal shelves of this mutant are correctly elevated, 
but have not fused with each other or with the nasal septum, correlating with the sites 
of TBX22 expression (see Chapter 2). The authors postulate that the failure of the 
palatal shelves to fuse in the Msx1-/Msx1- mutant is a consequence of insufficient 
accumulation of mesenchymal tissue within the palatal shelves.  
 
Msx1 has been shown to be expressed in the mandibular arch of the developing mouse 
embryo by in situ hybridisation (Robert et al. 1989) and was shown by northern blot 
to be expressed in the developing palate and in primary cultures of murine embryonic 
palate mesenchymal cells (Nugent and Greene 1998). Later it was reported that Msx1 
in the developing mouse face was exclusively expressed in the mesenchyme of the 
medial nasal, lateral nasal, maxillary and mandibular processes (Mackenzie et al. 
1991; Jowett et al. 1993). The evidence from tissue in situ hybridisation to human 
sections is consistent with this (Fig. 26), and moreover the expression would appear to 
be complementary to that of TBX22 (see Chapter 2 and Fig. 26). The expression 
profile of the TBX22 and MSX1 genes was examined in separate embryos and at 
slightly different developmental stages which obviously hinders the extent to which 
conclusions concerning the relative localisation of these genes can be made. These 
problems are always more difficult to overcome when working directly in human 
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rather than animal models due to the restricted availability of the material to perform 
such experiments. As a consequence of the limited tissue availability, repeating the 
same gene expression patterns in similar stage embryos is not always possible. 
International coordination in creating and populating human gene expression 
databases has long since been identified as one important way to try and address 
theses issues (Strachan et al. 1997). The aim would be to provide the comparison of 
gene expression patterns from as large a data set as possible, whilst making the most 
effective use of this limited and valuable material. 
 
Despite the limitations of working with human material and the differences in embryo 
sections and stages used in the experiments here, the gene expression patterns of 
human TBX22 and MSX1 would appear to correlate with what has been shown in 
mouse. In the mouse, Msx1 is restricted to the anterior region of the palatal shelves 
(Welsh and O'Brien 2009) and Tbx22 is restricted to the posterior region of the palatal 
shelves (Pantalacci et al. 2008; Welsh and O'Brien 2009). An equivalent expression 
pattern of these genes is also seen in human palate development (Fig. 26 and, for 
TBX22 only,  Baybrook et al 2001) and it could be possible that MSX1 expression was 
being restricted to the anterior palate by TBX22 regulation.  
 
Interaction of MSX1 and T-box proteins at a protein-protein level has already been 
demonstrated (Boogerd et al. 2008). In addition, although TBX22 itself is not the 
causative gene in a Brazilian family displaying ankyloglossia and tooth anomalies 
(Acevedo et al. 2010), the authors do suggest that a downstream gene of TBX22 
could be responsible. Mutations in MSX1 have been shown to cause tooth 
abnormalities (van den Boogaard et al. 2000) and tooth deformities are also seen, in 
addition to a cleft palate, in the Pax9+/-; Msx1+/- compound mutant mouse (Nakatomi 
et al. 2010), perhaps suggesting a combined role for these genes in tooth formation as 
well as palatogenesis. 
 
To verify that the MSX1 gene had the potential to be regulated by TBX22, an EMSA 
was performed using an oligonucleotide containing the generic T-box binding 
sequence as found in the MSX1 promoter (Table 16). The results of this EMSA 
showed that, in vitro, this sequence could bind to the lysate containing TBX22 protein 
(Fig. 25) and therefore supported the idea that the MSX1 gene could be a TBX22 
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target. The promoter region of the MSX1 gene in which the T-box binding site was 
found is known to contain several transcription factor binding elements and to show 
extensive conservation with the mouse Msx1 promoter, including many of the 
consensus binding sites (Shen et al. 1994; Gonzalez et al. 1998). The identified 
generic T-box binding site in the MSX1 promoter (AGGTGTTGTG) is positioned 834 
bases upstream from start of transcription. A similar sequence (AGGTCTTCTG) was 
found 1103 bases upstream from the start of transcription of the mouse Msx1 gene. In 
the 5th and 8th positions in the site there is a change from G>C. None of the binding 
sites shown in Table 15 have a C in either the 5th or 8th position of the binding sites (in 
vitro established or in vivo where known) for a number of T-box genes. In vivo 
binding sites have been shown to be different to those established in vitro in several 
cases (Casey et al. 1998; Casey et al. 1999) so the significance of the G>C change at 
two positions is not clear. There are differences in expression and regulation of 
orthologues in mouse and human (for example see Fougerousse et al. 2000) and 
presumably such differences, in at least some cases, explain why no cleft palate is 
seen in 69 of the 108 mouse mutants for genes underlying human cleft palate 
disorders (Appendix 5). The presence of a similar site to the generic T-box binding 
site within the Msx1 promoter, however, supports the possibility that MSX1 is a 
downstream target gene.  
 
 The results from the EMSA studies using the MSX1_oligo, together with the 
expression data and the malformations seen in the Msx1 mutant mouse (Satokata and 
Maas 1994) go some way in providing evidence for the possibility that MSX1 is 
regulated by TBX22. Therefore, further in vitro experiments were carried out to see if 
MSX1 were indeed a true TBX22 downstream target (Chapter 5). 
 
The generic T-box binding sequence was generated by aligning all of the known T-
box DNA binding sites. The TBX22 preferential DNA binding sequence, identified in 
Chapter 3, was also included when compiling the generic T-box binding sequence. 
However, even if this sequence was not known the same generic T-box binding site 
would have been compiled (see Table 15). On the basis of this and the fact that all T-
box proteins are known to bind to a similar DNA sequence (Sinha et al. 2000; Tada 
and Smith 2001), the identification of the in vitro preferential DNA binding site may 
well be redundant. Indeed, a previous study identified a preferential 20 base DNA 
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binding sequence for TBX22 (Andreou et al. 2007). This sequence consisted of 2 half 
binding sites in opposite orientations separated by 3 nucleotides (Table 15), although 
this sequence as a whole is not actually present within the genome. Including the half-
site does not change the generic T-box binding site generated (Table 15). In fact, with 
advances in chromatin immunoprecipitation techniques – ChIP, reviewed in (Horak 
and Snyder 2002; Wong and Wei 2009), the DNA binding sequence has, to some 
extent, become incidental as protein-DNA interactions can be investigated directly 
within the cell. Using this approach would identify actual transcription factor target 
genes directly, although confirmation of these interactions is still needed by other in 
vitro methods (Garnett et al. 2009). 
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CHAPTER 5  
 
 
MSX1: A POTENTIAL TBX22 TARGET GENE 
 
 
5.1  INTRODUCTION 
 
As has previously been described, the possibility of an interaction between TBX22 
and MSX1 is supported by their abutting expression patterns in the palatal shelves in 
human (Chapter 4); a similar restricted expression to either the anterior or posterior 
poles of the palatal shelves in mouse (Li and Ding 2007; Pantalacci et al. 2008); both 
Tbx22 (Satokata and Maas 1994; Pauws et al. 2009a) Msx1 mutant mice displaying a 
cleft palate, and the fact that mutations in both of these genes result in non-syndromic 
cleft palate in human (van den Boogaard et al. 2000; Braybrook et al. 2001) . Also of 
note, is the fact that both MSX1 and TBX22 proteins have been shown to undergo 
post-translational modification by SUMO1 (Gupta and Bei 2006; Andreou et al. 
2007), which is interesting as haploinsufficiency of the SUMO1 gene causes non-
syndromic CL/P (Alkuraya et al. 2006). Direct protein-protein interaction of MSX1 
and T-box proteins has also been reported to exist via their respective homeobox and 
T-box domains, (Boogerd et al. 2008).  
 
With the results form the EMSA study in Chapter 4 give encouragement that TBX22 
may binding to an oligonucleotide with a sequence found in the MSX1 promoter,, this 
increased support for MSX1 being a possible downstream target gene of TBX22. 
However, further investigation as to whether MSX1 was indeed an in vivo TBX22 
target was still needed. Therefore, the effect of over-expressed TBX22 on a reporter 
gene, fused downstream of the MSX1 promoter region (containing the potential 
TBX22 binding site), was explored in human cell lines. 
 
Initially, it had been planned to perform the transfection studies using the human 
embryonic palatal mesenchyme (HEPM) cell line (ECACC No. 90120505). The 
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rationale behind this being that if TBX22 were indeed capable of trans regulation of 
the MSX1 gene during palatogenesis, then the best model to explore this would be to 
utilise those cells where this would take place in vivo - the embryonic palate 
mesenchyme. However, following several unsuccessful attempts using several 
different transfection reagents, the decision was made to change to another cell line 
that was known to transfect easily. 
 
Previous studies had shown that TBX22 was endogenously expressed in several cell 
lines that could easily be transfected (Andreou et al. 2007) meaning that these cells 
should be capable of transcribing and translating a transfected TBX22 plasmid. 
However, in the same study, it was reported that TBX22 repressed the transcription of 
TBX22 in an autoregulatory manner. This posed a potential problem: if one was to 
over-express a TBX22 protein in a cell that had endogenous TBX22 expression, due 
to transcriptional repression of the endogenous TBX22 by the transfected TBX22, the 
net effect could in fact be a reduction in the total TBX22 protein in the cell. To 
account for this, experiments were performed in two cell lines – one which had been 
shown to endogenously express TBX22 – HeLa, and one which did not – 293T.  
 
The HeLa cell line is derived from cervical carcinoma epithelial cells (Gey et al. 
1952) from a woman named Henrietta Lacks, from whom the cell line name is taken 
(Jones et al. 1971). They are an immortal aneuploid cell line and are widely used in 
functional studies, including the study of the trans regulation of reporter genes by the 
Brachyury protein (Kispert et al. 1995). HEK 293T cells are a highly transfectable 
derivative of 293 cells, a hypo-triploid human embryonic kidney cell line, into which 
the gene for SV40 T-antigen has been inserted. 
 
A Dual Reporter system was used to visualize the effect of TBX22 on an MSX1 
promoter. This system employs two separate luciferase reporter genes: one as an 
experimental reporter, the other being used as an internal control. The benefit of 
having an internal control reporter means that experimental variance, arising from 
differences in cell density, cell viability and transfection efficiency can be eliminated. 
The experimental reporter is a firefly (Photinus pyralis) luciferase which is cloned 
downstream of the MSX1 promoter sequence. The internal control is a Renilla 
reniformis luciferase under the control of a Herpes Simplex Virus thymidine kinase 
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(HSV-TK) promoter. Both luciferase gene constructs are co-transfected and the 
resultant protein for which they code can be assayed sequentially. This is possible as 
each luciferase enzyme can be activated by separate substrates to emit a 
bioluminescent signal. The amount of luminescence generated is proportional to the 
amount of luciferase enzyme present. To account for inter-experimental differences, 
the assay is normalised using the ratio of the luminescence generated by the firefly to 
that of the Renilla luciferases.  
 
The effect of TBX22 on the MSX1 reporter plasmid was assessed by comparing the 
normalised result of the luciferase assay for cells co-transfected with either 26.7ng or 
53.4ng of the TBX22 expression plasmid, or the same plasmid lacking the TBX22 
coding sequence. This plasmid was co-transfected with a firefly luciferase gene under 
the control of an MSX1 promoter fragment and the Renilla reporter control. The MSX1 
reporter contained the TBX22 binding site and also covered the region of the MSX1 
promoter which had previously been shown to contain the minimal elements required 
to drive expression of the MSX1 gene (Gonzalez et al. 1998). An overview of the 
experiment and the different plasmids used in each transfection is shown in Table 19, 
section 5.2.2.B.
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5.2  MATERIALS AND METHODS 
 
5.2.1  Preparation of the Expression and Reporter constructs 
 
A.  PREPARATION OF THE PCR3.1_TBX22 EXPRESSION PLASMID 
 
A 1566bp fragment (bases 132-1697 of GenBank accession No. NM_001109878) 
which included the entire TBX22 coding sequence and Kozac initiation sequence was 
PCR amplified (see 3.2.1.B), using the Pfu DNA polymerase and forward primer 5 -
GGGATGGCTCTGAGCTCTC-3  and reverse primer 5 -
CATAAGGTAATGGTTAATTGCTGAA-3  with 50ng of I.M.A.G.E. clone 
BC014194 (Geneservice) as a starting template for 25 cycles with an annealing 
temperature 55oC. After the PCR reaction, the tubes were placed on ice and 1 unit of 
Taq polymerase was added to the reaction and placed in hot block at 72oC for 10 
minutes. This was necessary in order to produce a 3  adenosine residue to the 
fragment to assist with the ligation of the insert into the plasmid vector. The DNA was 
then phenol-chloroform extracted/ethanol precipitated (see 2.2.2.A) and re-suspended 
in 30µl TE buffer.  An approximate 2 molar excess ratio of insert:vector was used for 
the ligation (see 3.2.1.C). A 10µl ligation reaction containing 1µl 10X ligation buffer 
(60mM Tris-Cl, pH 7.5, 500mM KCl, 25 mM MgCl2, 0.01% gelatin), 60ng pCR3.1 
cloning vector (Invitrogen),  40ng DNA fragment and 4 units of T4 DNA ligase 
(Invitrogen) was incubated overnight at 15oC. 2µl of the ligation reaction was 
transformed into One Shot TOP10F’ competent cells (Invitrogen) as per the heat 
shock method described in 3.2.1.D.  
 
The pCR3.1 cloning vector is an eukaryotic expression vector that drives expression 
of a cloned gene product using the promoter/enhancer region from the human 
cytomegalovirus, CMV (Thomsen et al. 1984). In addition, the cloning vector confers 
a polyadenylation signal to produce a 3  poly-A tail to the transcribed gene insert to 
reduce degradation of the recombinant protein mRNA and facilitates translation 
(Mangus et al. 2003). 
 
For use as a control plasmid, the cloning site of the pCR3.1 vector was removed by 
enzymatic digestion using EcoRI (Promega) following the manufacturer’s guidelines. 
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The DNA was then gel purified using a Qiagen Gel Extraction Kit following the 
manufacturer’s directions and the plasmid was self-ligated using 4 units of T4 DNA 
ligase and 1µl 10X ligation buffer (see above) with 20ng of the digested vector in a 
10µl reaction at 15oC overnight. The ligation reaction was then transformed as per the 
TBX22 expression plasmid above. 
 
 
B.  PREPARATION OF THE MSX1 REPORTER PLASMID (M-PROM) 
 
983 bp of the MSX1 promoter (947860-948820 of GenBank accession No. 
NT_006051.17) was cloned commercially by the GeneScript Corporation into a 
pUC57 vector between the SacI and HindIII restriction enzyme sites of the multiple 
cloning site (see Fig. 27). The fragment was excised from the plasmid by double 
digestion with these enzymes in the Multi Core buffer from Promega according to the 
manufacturer’s recommended guidelines. The pGL4.17[luc2/Neo] vector (Promega) 
was similarly double digested with both of these enzymes and products of both 
reactions were electrophoresed on a 1% agarose gel. The resulting lower molecular 
weight band from the pUC57 vector and the ~ 5.5 kb band from the 
pGL4.17[luc2/Neo] vector were excised from the gel and purified using a Qiagen gel 
extraction kit following the manufacturer’s instructions. A ligation reaction and 
subsequent transformation into TOP10F’ competent cells was then performed using 
the digested MSX1 promoter fragment and pGL4.17[luc2/Neo] vector, as described 
for the TBX22 expression construct  above (5.2.1.A), to generate the MSX1 promoter  
reporter plasmid M_prom: the pGL4.17[luc2/Neo] vector carrying the firefly 
luciferase gene luc2 cloned downstream of the MSX1 promoter fragment. 
 
 
C.  PREPARATION OF THE RENILLA INTERNAL CONTROL REPORTER PLASMID 
(PGL4.74[HRLUC/TK). 
 
An internal control reporter plasmid pGL4.74[hRluc/TK] was supplied by the 
manufacturer (Promega) as pure plasmid DNA and could be used directly in the 
transfection studies. The pGL4.74[hRluc/TK] plasmid carries the Renilla hRluc 
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luciferase gene, which is driven by the Herpes Simplex Virus thymidine kinase (HSV-
TK) promoter (Wigler et al. 1979). 
 
 
  
  
 
 
Figure 27: A schematic diagram showing the position of the 983bp 
fragment from the MSX1 promoter within the pUC57 cloning vector.  
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5.2.2  Co-transfection of the Expression and Reporter constructs 
 
A.  CELL CULTURE PROPAGATION 
 
HeLa cells ECACC No. 93021013 and 239T cells ATCC No. CRL-11268 were 
propagated in culture medium containing minimum essential medium (MEM) with 
non-essential amino acids (NEAA) and Earle’s Salts (Gibco) with 2mM L-glutamine 
(Gibco) and 10% fetal bovine serum (FBS, Sigma) in a 5% CO2 incubator at 37oC. 
The cultures were subcultured by splitting them 1:3 when they reached 70-80% 
confluence by removing the culture media and washing the cells in PBS (Gibco) and 
then adding 0.5g/L of trypsin and 0.2g/L of EDTA (Gibco) and allowing the cells to 
detach from the culture vessel. Fresh culture medium was then added and the cultures 
were aspirated into new culture flasks at the appropriate dilution. 
 
For transfection, the HeLa cells were seeded at a density of 1 X 104 cells per well and 
the 293T cells at 2 X 104 cells per well, as per the directions given in the Promega 
transfection database for each cell line (http://www.promega.com/techserv/ 
tools/fugenehdtool/), in a clear bottom 96-well BD Optilux plates (BD Falcon) in a 
100µl volume. The resultant cultures obtained 50-70% confluence in 24 hours.  
 
 
B. TRANSFECTION PROCEDURE 
 
Transfection grade DNA was obtained by culturing the transformed TOP10F’ 
competent cells containing each of the 4 separate plasmids (pCR3.1_TBX22; 
pCR3.1_Null; M_prom or pGL4.74[hRluc/TK]) using the method described in 5.2.1, 
and preparing plasmid DNA using a plasmid mini kit (Qiagen), following the 
manufacturer’s instructions and eluting in 20µl volume of Milli-Q H2O. The 
concentration and purity were verified by a Nanodrop spectrophotometer. The insert 
sequence and orientation of the TBX22 expression plasmid was verified by 
sequencing analysis using 5 -TAATACGACTCACTATAGGG- 3  and 5 -
TAGAAGGCACAGTCGAGG-3 . The sequence of the MSX1 reporter insert was 
verified using sequencing primers 5  -CTAGCAAAATAGGCTGTCCC-3  and 5  -
TCGATATGTGCGTCGGTAAA-3 . (see 3.2.1.F).  
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A third internal reporter was transfected into the cells alongside the TBX22 
expression and MSX1 promoter reporter plasmids. This control plasmid contained the 
Renilla hRluc gene which is driven by the HSV-TK promoter. 
 
The FuGENE HD transfection reagent (Promega) was used to co-transfect the cells 
with either: a no TBX22 control (53.4ng pCR3.1_Null), 26.7ng pCR3.1_TBX22, or 
53.4ng pCR3.1_TBX22 expression plasmid, together with 26.7ng of the M_prom and 
26.7ng of the pGL4.74[hRluc/TK] reporter plasmids per well. In each case the 
required amount of each plasmid DNA was added to diluted FuGENE HD as per the 
manufacturer’s directions, the tubes were tapped gently to mix the contents and 
incubated at room temperature for 20 minutes before 5µl of the transfection reagent 
and DNA were pipetted directly into the wells of the HeLa or 293T cells. Each of the 
transfections is detailed below and an overview is given in Table 19:- 
 
No TBX22 Control 
1100ng pCR3.1_Null, 550ng M_prom and 550ng pGL4.2[hRluc/TK] was 
added to 103µl H2O and 6.6µl of FuGENE HD reagent. 
5µl of the transfection mix was added to each well. 
 
26.7ng TBX22 
550ng pCR3.1_TBX22, 550ng M_prom and 550ng pGL4.2[hRluc/TK] was 
added to 103µl H2O and 6.6µl of FuGENE HD reagent. 
4.95µl of the transfection mix was added to each well. 
 
53.4ng TBX22 
1100ng pCR3.1_TBX22, 550ng M_prom and 550ng pGL4.2[hRluc/TK] was 
added to 103µl H2O and 6.6µl of FuGENE HD reagent. 
5µl of the transfection mix was added to each well. 
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Experiment Plasmids transfected Luciferase Expected Result 
Experimental 
Transfection 
(26.7ng TBX22 
or 53.4ng 
TBX22) 
pCR3.1_TBX22 
 
M_prom 
(pGL4.17[luc2/Neo] 
vector with MSX1 
promoter) 
 
pGL4.2[hRluc/TK] 
None 
 
 
Firefly 
luciferase 
 
Renilla 
luciferase 
Over-expression of 
TBX22 
 
Expression of firefly 
reporter gene 
 
Expression of 
Renilla control 
reporter gene 
Control 
Transfection 
pCR3.1_Null 
 
M_prom 
(pGL4.17[luc2/Neo] 
vector with MSX1 
promoter) 
 
pGL4.2[hRluc/TK] 
None 
 
 
Firefly 
luciferase 
 
Renilla 
luciferase 
No recombinant 
expression of TBX22 
 
Expression of firefly 
reporter gene 
 
Expression of 
Renilla control 
reporter gene 
Blank 
Transfection 
No Plasmids None 
No luciferase 
expression. Value to 
which lumenesence  
assays can be 
blanked 
 
 
 
 
The cells had been seeded the previous day at the appropriate cell density described 
above, so that they were 50-70% confluent. 5µl of each of the transfection 
reagent:DNA complexes was added to separate wells of a 96-well plate. For both cell 
lines, three independent experiments were performed using different 96-well plates 
with four-to-six replicates in each of the transfection conditions (ie control 
Table 19: A summary of the plasmids used in the transfection 
experiments.  
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transfection with pCR3.1_Null; transfection with 26.7ng pCR3.1_TBX22 or 
transfection with 53.4ng pCR3.1_TBX22 together with co-transfection with 26.7ng 
M_prom and 26.7ng pGL4.2[hRluc/TK]). Once the transfection reagents had been 
added to the wells containing the cells, the culture plates were returned to the 
incubator and incubated for a further 24 hours before being lysed and luciferase levels 
determined.  
 
The six 96-well plates used for these experiments were arranged as described in Fig. 
28. Cells were not grown in the outside wells (columns 1 and 12 and rows A and H) 
so as to reduce the light interference from within the luminometer. The cells were also 
spaced so that a row of blank wells was positioned between each of the 3 transfection 
conditions so as to reduce the effects of cross-talk (Irawan et al. 2005) between wells. 
The cultures in one of the wells of each 96-well plate was left free from transfection 
reagents and served as a blank in the luciferase assay (5.2.2.D.)  Following luciferase 
detection using a luminometer (see 5.2.2.C), if an experimental Renilla luciferase 
value was not statistically different from the Renilla luciferase of this blank assay, 
then it was considered that the transfection had failed and hence that whole column 
(including results for the other experimental conditions) were excluded. This was 
done in order to retain the same number of samples for each condition.  
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B   ● ● ● ● ● ●     
C             
D   ● ● ● ● ● ●   ●  
E             
F             
G   ● ● ● ● ● ●     
H             
Figure 28: A representation of the layout of the 96-well plate used for each 
transfection experiment. For both the HeLa and 293T cells, 3 separate experiments 
were performed, each using a different 96-well plate, setup similar to that above. For 
every experiment, three rows of cells containing 4-6 wells of growing cells were 
transfected with one of the transfection conditions: 26.7ng pCR3.1_Null (black dots); 
26.7ng pCR3.1_TBX22 (red dots) or 53.4ng pCR3.1_TBX22 (blue dots). All three 
transfections were co-transfected with 26.7ng M_prom and 26.7ng pGL4.2[hRluc/TK]. 
A blank transfection was also prepared for each experiment (yellow dot). 
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C.  LUCIFERASE ASSAY  
  
The culture medium was aspirated from the wells and the cells rinsed with PBS to 
remove detached cells and residual growth media. The PBS was then completely 
removed and 20µl of 1X Passive Lysis buffer (PLB, Promega) was added to each well 
and the plate agitated on a gentle rocker at room temperature for 15 minutes.  
 
The injector tips of a Fluoroskan Ascent FL luminometer (Thermo) were cleaned by 
rinsing in Milli-Q H2O and then soaked in 70% ethanol overnight, before being 
thoroughly rinsed with Milli-Q H2O. Luciferase assay reagent II (LARII, Promega) 
and the Stop & Glo reagent (Promega) were prepared following the manufacturer’s 
instructions and placed in separate injectors, which were primed before use. For each 
well that was to be measured, the luminometer was programmed to perform a 2 
second premeasurement delay; inject 100µl LARII and take a 10 second measurement 
of the luminescence, wait 2 seconds, inject 100µl of the Stop & Glo reagent and then 
take a 10 second reading of the luminescence, before repeating this cycle at the next 
marked well. Statistical analysis of the results was performed using Minitab 15.1.0.0 
(Microsoft). 
 
 Pilot data generated from previous experiments using HeLa cells only is 
shown in Appendix 7.  
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5.2.3  Detection of TBX22 and MSX1 expression in HeLa and 293T cells 
 
A.  RNA ISOLATION 
 
HeLa and 293T cells growing in a T75 culture flask were lysed directly in the culture 
vessel by the addition of 7.5ml TRIzol reagent (Invitrogen) and passing the cell lysate 
through the pipette tip several times to homogenise the cells. The cells were incubated 
in this reagent for 5 minutes and then transferred to a 15ml Falcon tube. 1.5ml of 
chloroform was added to the solution and mixed thoroughly by shaking the tube and 
left to incubate at room temperature for 3 minutes. A Micro Centaur (Sanyo) bench 
top centrifuge was used throughout this procedure and the sample was phase 
separated by centrifugation at 12,000g for 15 minutes at 4oC in this instrument. 
Following centrifugation, the RNA was collected from the upper aqueous phase and 
transferred to a separate tube. 3.75ml isopropanol was added to the aqueous phase and 
incubated at room temperature for 10 minutes to precipitate the RNA. The samples 
were then centrifuged at 12,000g for 15 minutes at 4oC and the supernatant removed. 
8ml 75% ethanol was added to the RNA pellet, mixed with a vortex and centrifuged 
once more at 7,500g for 5 minutes at 4oC. The supernatant was again removed from 
the sample and the pellet was left to air dry for 5 minutes. The RNA was redissolved 
using 100µl of RNase free Milli-Q H2O. 
 
 
B.  FIRST STRAND CDNA SYNTHESIS 
 
First strand cDNA was synthesised by adding 1µg RNA from the lysed cells (5.2.3.A) 
to 2.5µM anchored oligo(dT)18 primer (Roche), 60µM random hexamer primer 
(Roche) and brought to a total of 13µl with RNase free Milli-Q H2O. The reaction was 
heated in a hot-block for 10 minutes at 65oC and then immediately placed on ice. 4µl 
5X Transcriptor Reverse Transcriptase reaction buffer (5X buffer: 250mM Tris-Cl, 
150mM KCl, 40 mM MgCl2, pH 8.5; Roche), 0.5µl Protector RNase Inhibitor 
(40U/µl; Roche), 2µl dNTP’s mix (10mM ATP, CTP, GCP, TCP; Roche) and 0.5µl 
Transcriptor Reverse Transcriptase (20U/µl; Roche) were then added to the vial and 
the contents mixed gently. The tubes were then transferred to a Dyad MJ Research 
thermocycler and incubated for 10 minutes at 25oC followed by incubation at 50oC for 
1 hour. The Reverse Transcriptase enzyme was inactivated by a final incubation at 
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85oC for 5 minutes. The tubes were then cooled on ice and stored at -25oC. A control 
reaction using no Transcriptor Reverse Transcriptase enzyme was also performed. 
 
 
C.  DETECTION BY RT-PCR 
 
The presence of a TBX22 and MSX1 cDNA fragment was determined using a PCR 
reaction (3.2.1.B), with 2µl of the first strand synthesis and reverse transcriptase 
negative reactions (5.2.3.B) as template DNA. 5 - AAGCGGGCAGGCGGATGTTC -
3  and 5 - AGGTCTCTCCCGAGCAGGGT -3  primers were used to detect TBX22 
with an annealing temperature of 61oC; primers 5 - AGAAGATGCGCTCGTCAAAG 
-3  and 5 - CCATATCTTCACCTGCGTCTC -3  were used for MSX1 with an 
annealing temperature of 54oC and primers 5 - TGCACCACCAACTGCTTAGC -3  
and 5 - GGCATGGACTGTGGTCATGAG -3  were used for GAPDH with an 
annealing temperature of 53oC. Details of these primers are given in Appendix 1. 
Electrophoresis was then performed using 5µl of the RT-PCR reaction on a 1.2% 
agarose gel and visualised under UV light. The resulting image was captured using a 
Gene Genius (Syngen) system. 
 
 
5.2.4  Detection of luciferase by Western blot 
 
In order to determine that the MSX1 promoter was capable of driving the expression 
of the luciferase gene, the cells transfected under the no TBX22 conditions (i.e. with 
pCR3.1_Null , M_prom andpGL4.2[hRluc/TK]) were lysed as in 5.2.2.C and then 
assayed for the presence of the luciferase protein by Western blot (see 3.2.3.B) using 
an anti-luciferase antibody (Promega), at a concentration of 1µg/ml, followed by a 
secondary anti-goat HRP antibody (Vector Laboratories) used at a dilution of 1:200.  
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5.3  RESULTS 
 
All the sets of primer pairs used amplify regions in their respective genes that bridge 
exon/intron boundaries, ensuring that the amplification of MSX1 and TBX22 cannot be 
from genomic DNA contamination. Fragments amplified from genomic DNA using 
these primers would be unlikely to result in the generation of amplicons, due to the 
significant distance between the two primer annealing sites (2479 bp for TBX22 pair 
and 2608bp for MSX1 pair). Lanes 2, 7 and 12 in Fig. 29 are a PCR reaction using 
cDNA samples prepared from the RNA of HeLa cells and lanes 3, 8 and 13 from 
RNA samples from HeLa cells without the addition of the Reverse Transcriptase 
enzyme which serve as a negative control for the experiment. Similarly, lanes 4, 9 and 
14 shown the result of a PCR reaction using cDNA samples prepared from the RNA 
of 293T cells and lanes 5, 10 and 15 from RNA samples from 293T cells without the 
addition of the Reverse Transcriptase enzyme. 
 
As MSX1 and TBX22 are both expressed around CS18 (see Fig. 26, Chapter 4 and 
Chapter 2 Fig 13 and 14 for TBX22) , whole embryonic RNA prepared from a CS18 
embryo (supplied by the HDBR, see 1.2) was used as a positive control for both 
primer pairs (Fig. 29 lanes 1 and 6). Additionally, GAPDH primers were also used 
(see Appendix 1 for sequence) as a positive control for the RNA from each of the 
samples (Fig. 29 lane 11 - CS18 cDNA; lane 12 – HeLa cDNA; lane 14 – 293T 
cDNA) which generates an amplicon of 86bp. 
 
 The RT-PCR using primers to TBX22 gave a positive band for the HeLa cell line 
(lane 2 in Fig. 29), but did not produce a product from the 293T cells (lane 4 in Fig. 
29). The migration of the fragment on the agarose gel corresponds to that expected by 
amplification of the cDNA of 219bp, showing that, as has been previously reported 
(Andreou et al. 2007), HeLa cells endogenously express TBX22 and 293T cells do 
not.  
 
RT-PCR using primers to MSX1 gave a positive band for both HeLa and 293T cell 
lines (lanes 7 and 9 respectively in Fig. 29), amplifying a product of the expected 
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Figure 29: HeLa cells express endogenous TBX22 and MSX1, 239T cells express 
MSX1 only. The TBX22 primers amplified a 219 bp product in the control CS18 
cDNA (lane 1) and HeLa cDNA (lane 2), but no amplicon is detected in cDNA from 
293T cells (lane 4). No product is detected in the Reverse Transcriptase negative 
samples from either HeLa (lane 3) or 239T cells (lane 5).  
A 271 bp product is amplified by the MSX1 primers from the cDNA of the control 
CS18 (lane 6), HeLa cells (lane 7) and the 293T cells (lane 9). No amplification was 
seen in the Reverse Transcriptase negative samples from HeLa (lane 8) or 239T cells 
(lane 10). 
A positive control GAPDH primer pair amplified a product of the expected size of 
86bp in the cDNA of the CS18 (lane 11), HeLa (lane 12) and 293T cells (lane 14). No 
product was detected in the Reverse Transcriptase negative samples from HeLa (lane 
13) or 239T cells (lane 15).  
TBX22 – amplified using TBX22 primers (lanes 1-5); MSX1 – amplified using MSX1 
primers (lanes 6-10); GAPDH – amplified using GAPDH primers (lanes 11-15).  
CS18 – cDNA from whole CS18 embryo; HeLa – cDNA from HeLa cells; HeLa RT- –
Reverse Transcriptase negative samples prepared from HeLa RNA; 293T – cDNA 
from 239T cells; 293T RT- –Reverse Transcriptase negative samples prepared from 
293T cell RNA. L is a 100bp DNA mass marker (Promega) with approximate sizes 
indicated. 
271bp. Thus, it may be concluded that both the HeLa and 293T cell lines used in these 
experiments express MSX1 mRNA transcripts. 
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   If a luciferase assay was going to provide meaningful data to compare the 
effects of over-expressing TBX22, it was important to determine that the MSX1 
promoter reporter plasmid (M_prom) was capable of driving expression of the 
luciferase protein. Figure 30 shows the presence, albeit very weakly, of luciferase 
protein in transfected HeLa (lane 5 in Fig. 30a) and transfected 293T cells (lane 6 in 
Fig. 30a) compared to the untransfected cells (lanes 3 and 4 in Fig. 30a).  The 
predicted protein of 550 amino acid residues has a molecular weight of 60.64 kDa 
(sequence information from Promega website - http://www.promega.com/vectors/ 
pgl4.17.txt; luc2 gene nucleotides 100-1752 were translated using the ExPASy online 
translation tool hosted by the Swiss Institute of Bioinformatics - 
http://www.expasy.ch/tools/dna.html).  
 
Although the luciferase protein seen in the transfected HeLa cells (lane 5 Fig. 30) 
appears weaker than that seen in the 293T cells (lane 6 Fig. 30), this may be due to the 
difference in seeding densities: HeLa cells seeded at 1 X 104 cells per well and the 
293T cells at 2 X 104 cells per well (see 5.2.2). 
  
As the M_prom plasmid was expressing the luciferase protein in both cell types, the 
effect of over-expressing TBX22 protein in these cells on the amount of luciferase 
produced would be predicted to indicate any regulatory effect of TBX22 on the MSX1 
promoter fragment. This experiment was done by using a luminometer to measure the 
amount of luminescence emitted by the transfected cells after the addition of a 
suitable substrate for the luciferase protein. The report from the Fluoroskan 
luminometer showing the absolute values for all of the replicates from each of the 3 
independent experiments at each transfection condition (no TBX22, 26.7ng TBX22 or 
53.4ng of TBX22 plasmid) is shown in Appendix 6 and the successful transfections 
are summarised in Tables 20 and 21.  
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Figure 30: Luciferase expression driven by the MSX1 promoter in 
HeLa and 293T cells.  a. Luciferase protein is detected in HeLa cells 
(lane 5) and 239T cells (lane 6) transfected with the 1100ng 
pCR3.1_Null, 550ng M_prom and 550ng pGL4.2[hRluc/TK] using an 
anti-luciferase antibody (see 5.2.4). The dotted-box shows the region 
shown in b, which shows lanes 3 - 6 at higher magnification and 
increased contrast to aid identification. The ladder (lane 7) is a PageRule 
Prestained Protein Ladder (SM0671; Fermentas) with the approximate 
migration of protein molecular weights indicated (kDa). Lane 3 is from 
untransfected HeLa cells and lane 4 is untransfected 293T cells. The 
luciferase protein is detected using an anti-luciferase antibody (see 5.2.4), 
which is then visualised using HRP/DAB (see 3.2.3).
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 M_prom + No TBX22 M_prom + 26.7ng TBX22 M_prom + 53.4ng TBX22 Cells alone 
Experiment Firefly  Luciferase 
Renilla 
Luciferase Ratio 
Firefly 
Luciferase 
Renilla  
Luciferase Ratio 
Firefly 
Luciferase 
Renilla  
Luciferase Ratio 
Renilla  
Luciferase 
5.945508 1.276604 4.657284 3.431129 2.157015 1.590684 7.038646 2.153371 3.268664 
5.766866 0.760457 7.583426 2.500051 1.420697 1.759736 5.615232 1.727434 3.250620 1 
3.494552 0.773907 4.515471 1.771932 0.908001 1.951466 10.131340 2.766837 3.661705 
0.294113 
 
10.354900 1.319740 7.846167 3.784751 2.534476 1.493307 3.903111 1.189683 3.280799 
14.131780 1.022790 13.816893 5.896039 1.648178 3.577307 3.326693 1.238724 2.685580 2 
12.511860 2.583470 4.843044 5.253373 1.932231 2.718812 3.420082 1.610355 2.123806 
0.345382 
 
14.678420 1.317048 11.144939 5.040354 1.188119 4.242297 2.773540 1.432939 1.935560 
7.049310 1.650263 4.271628 6.646171 2.227520 2.983664 5.246964 1.698936 3.088382 3 
5.330808 1.173110 4.544167 3.344198 0.753062 4.440801 7.771098 1.403407 5.537309 
0.108811 
 
 
 
Table 20: Expression of Luciferase from the M_prom promoter in HeLa cells. The relative light units from the firefly 
luciferase, are normalised to the Renilla luciferase transfection control values (Ratio) following transfection with either 
26.7ng pCR3.1_Null plasmid (No TBX22), 26.7ng of pCR3.1_TBX22 or 53.4ng pCR3.1_TBX22, together with the 26.7ng 
M_prom and 26.7ng pGL4.2[hRluc/TK] control plasmid. The values for the non transfected cell (Control Renilla) for each 
experiment are also shown. 
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 M_prom + No TBX22 M_prom + 26.7ng TBX22 M_prom + 53.4ng TBX22 Cells alone 
 
Firefly 
Luciferase 
Renilla  
Luciferase Ratio 
Firefly 
Luciferase 
Renilla  
Luciferase Ratio 
Firefly 
Luciferase 
Renilla  
Luciferase Ratio 
Renilla  
Luciferase 
2.401089 2.922685 0.821535 1.01768 0.476687 2.1349 2.207481 1.834464 1.203338 
2.721097 1.302751 2.088731 0.756599 1.392531 0.543326 0.875337 1.267416 0.690647 1 
1.165447 1.693124 0.688341 0.127379 1.340891 0.094995 1.368239 1.181022 1.158521 
0.408504 
1.45233 1.45233 1.03901 2.505352 2.384261 1.050788 2.343781 1.584134 1.479535 
0.658094 0.658094 2.745829 2.052036 0.344296 5.960101 3.325981 1.246932 2.667331 
2.29725 2.29725 2.116814 0.294337 2.399177 0.122682 2.070588 2.344638 0.883116 
2 
1.12741 1.12741 0.679699 1.42744 0.870507 1.639781 1.351431 2.06572 0.654218 
0.370679 
1.4602 1.026468 1.422548 1.462127 0.629199 2.323792 1.317282 2.435744 0.540813 
2.296965 1.202742 1.909774 2.79639 2.114703 1.322356 1.817282 0.536731 3.385835 
0.560777 0.213527 2.626264 1.443196 0.800868 1.802039 3.217748 0.827336 3.889287 
2.655885 1.371096 1.937053 2.067135 1.280424 1.614414 1.946758 2.025865 0.960951 
3 
1.558073 1.77942 0.875607 1.385782 1.087407 1.274391 1.93726 1.66293 1.164968 
0.346546 
Table 21: Expression of Luciferase from the M_prom promoter in 239T cells. The relative light units from the firefly 
luciferase, are normalised to the Renilla luciferase transfection control values (Ratio) following transfection with either 
26.7ng pCR3.1_Null plasmid (No TBX22), 26.7ng of pCR3.1_TBX22 or 53.4ng pCR3.1_TBX22, together with the 26.7ng 
M_prom and 26.7ng pGL4.2[hRluc/TK] control plasmid. The values for the non transfected cell (Control Renilla) for each 
experiment are also shown. 
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To verify that the transfections used in the experiments were reliable, a student’s t-test 
was employed to confirm that there was no statistical significance in the luminescence 
emitted from the control reporter plasmid (pGL4.2[hRluc/TK]) and each of the three 
different transfection conditions. 
 
For the 239T cells at a 95% confidence interval, no statistical significance was found 
between the pCR3.1_Null plasmid and 26.7ng of pCR3.1_TBX22 plasmid (p-value = 
0.430); between pCR3.1_Null plasmid and 53.4ng of pCR3.1_TBX22 plasmid (p-
value = 0.959); or between the 26.7ng of pCR3.1_TBX22 plasmid and 53.4ng of 
pCR3.1_TBX22 plasmid (p-value = 0.387). The distribution about the mean of these 
values is represented in Fig. 31a. 
 
For the HeLa cells at a 95% confidence interval, no statistical significance was found 
between the pCR3.1_Null plasmid and 26.7ng of pCR3.1_TBX22 plasmid (p-value = 
0.262); between pCR3.1_Null plasmid and 53.4ng of pCR3.1_TBX22 plasmid (p-
value = 0.153); or between the 26.7ng of pCR3.1_TBX22 plasmid and 53.4ng of 
pCR3.1_TBX22 plasmid (p-value = 0.852). The distribution about the mean of these 
values is represented in Fig. 31b. 
 
As no statistical difference was found between any transfection conditions and the 
luminescence emitted from the pGL4.2[hRluc/TK] plasmid, the experiments analysed 
were considered successful. Therefore the ratios for the firefly/Renilla luciferase 
assays were examined for statistical differences between the no TBX22, 26.7ng 
TBX22 and 53.4ng TBX22 conditions. As the comparison was between ratios, a 
Mann-Whitney U test (Wilcoxon 1945), which is a test of medians is preferable to a 
student’s t-test, which is a test of means, but should only be used be used when 
comparing parametric data.
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Figure 31: An interval plot showing there was no significant 
difference between absolute relative light units emitted from 
the control Renilla luciferase. The results of the 293T (a) and 
HeLa (b) cell transfections showing the distribution about the mean 
for each of the Renilla luciferase values for the three different 
transfection conditions: No TBX22 (pCR3.1_Null plasmid), 26.7ng 
TBX22 or 53.4ng TBX22. 
a 
b 
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 When the results in the HeLa cells are plotted (Fig. 32) it appears that there is 
a difference between the no TBX22 and both the 26.7ng or 53.4ng TBX22 conditions.  
The median result for the no TBX22 condition is 4.843, 26.7ng TBX22 - 2.719 and 
53.4ng TBX22 - 3.251 (Fig. 32). The comparison of ratios of firefly to Renilla 
luciferase, between the no TBX22 and 26.7ng TBX22 experimental conditions is 
statistically significant using a Mann-Whitney U test at a 95% confidence interval 
with a p-value = 0.0006 and the comparison between no TBX22 and 53.4ng TBX22 
conditions is significant with a p-value = 0.002. There was no statistical significance 
between the 26.7ng TBX22 and the 53.4ng TBX22 conditions (p-value = 0.3772). 
Figure 32: A box-plot of the normalised ratios of firefly/Renilla 
luciferase for no TBX22, 26.7ng TBX22 and 53.4ng TBX22 in 
HeLa cells. The horizontal line in each box represents the median 
result for each condition, the shaded box represent values between the 
25th and 75th percentile and the vertical line extends to the range of 
values. An * denotes a statistical outlier.  
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 The same Mann-Whitney U test was employed to test whether there was a 
statistically significant difference between the medians of the no TBX22, 26.7ng 
TBX22 and 53.4ng TBX22 transfection conditions in the 293T cells. Using a 95% 
confidence interval the difference between the no TBX22 and 26.7ng TBX22 
conditions has a p-value =  0.7075 and between no TBX22 and 53.4ng TBX22 the p-
value = 0.7508. Therefore, one must conclude that there is not a statistically 
significant difference between the no TBX22 and either the 53.4ng or 26.7ng TBX22 
conditions. As above, the data have been represented in a box plot, the median values 
are no TBX22 – 1.666; 26.7ng TBX22 – 1.468 and 53.4ng TBX22 – 1.162; (Fig. 33). 
Figure 33 indicates visually that there are no differences between these three 
experimental conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: A box-plot of the normalised ratios of firefly/Renilla luciferase 
for no TBX22, 26.7ng TBX22 and 53.4ng TBX22 in 293T cells. A graphical 
representation of the ratios of firefly/Renilla luciferase values transfected 
under no TBX22, 26.7ng TBX22 and 53.4ng TBX22 conditions. Visual 
inspection suggests that there are that no significant differences between the 
medians and this is confirmed using a Mann-Whitney U test (see text). The 
horizontal line in each box represents the median result for each condition, the 
shaded box represent values between the 25th and 75th percentile and the 
vertical line extends to the range of values. An * denotes a statistical outlier.  
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5.4  DISCUSSION 
 
Initially it had been intended to study the effect of TBX22 on the MSX1 promoter in a 
cell line derived from human embryonic palatal mesenchyme cells (HEPM – 
[ECACC# 90120505] (Yoneda and Pratt 1981)). This cell line would have been 
preferable to the HeLa cell line used, as they would have been a closer model to the 
environment of potential TBX22/MSX1 interactions in the developing palate in vivo. 
However, these cells proved difficult to transfect using several transfection reagents 
(FuGENE6 (Roche), FuGENE HD (Promega), TransPass D1 (New England Biolabs) 
- data not shown. Although mammalian non-dividing cells are notoriously difficult 
cell lines to transfect (Subramanian et al. 1999), there are several dividing cell lines 
that are also known to be difficult to transfect using lipid-cation based transfer, for 
example the monocytic cell lines U937 and THP-1 (Martinet et al. 2003). A 
transfection method that was not tested in the present study, however, was 
electroporation; which has been shown to increase the transfection efficiency of cell 
lines that have proven challenging to transfect (Melkonyan et al. 1996). Although the 
technological advancements in chemical transfection are now generally considered to 
yield superior transfection efficiency to that achieved by electroporation, it is a 
method that may be capable of transfecting HEPM cells and could be employed in 
future studies. 
 
The transfection strategy used in this study attempted to co-transfect three separate 
plasmids: the MSX1 reporter plasmid (M_prom; 6530bp), the internal control plasmid 
(pGL4.2[hRluc/Tk]; 4237bp) and either the TBX22 expression plasmid 
(pCR3.1_TBX22; 6623bp) or expression control plasmid (pCR3.1_Null;5045bp). 
Transfection of three plasmids of such size is a technically challenging task. However, 
as the M_prom plasmid was successfully transfected and produced a protein which 
could be detected by Western blot (Fig. 30), then it is likely that the other plasmids 
were also transfected successfully.  
 
Detection of TBX22 in the transfected cells was also attempted by Western blot using 
the same antibody used in Chapter 3 (section 3.2.5.B); however this did not result in 
any detectable signal. As TBX22 was detected by RT-PCR (Fig. 29) in the non-
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transfected HeLa cells, at least some TBX22 protein would be expected to be detected 
in these cells. However, as this was not seen, it was assumed that either the antibody 
did not function in Western blots or there were problems with antibody specificity as 
discussed in Chapter 3. To circumvent the difficulty of using an unreliable anti-
TBX22 antibody, the expression of a tagged TBX22 protein would have perhaps been 
a more suitable approach. There are several antibodies available to reliably detect 
protein tags, for example the 6xHis employed in the earlier bacterial expression 
experiments (see Chapter 3). 
 
 
RT-PCR was considered to at least determine the presence of transfected TBX22 
mRNA, however as the pCR3.1_TBX22 plasmid contains only the TBX22 cDNA, 
then unless the cDNA could be prepared from RNA with absolutely no DNA 
contamination, it would have been impossible to tell whether the primers were 
annealing and amplifying the cDNA from the reverse transcribed RNA, or if in fact 
they would be amplifying contaminating pCR3.1_TBX22 plasmid DNA. As it was 
considered that the preparation of cDNA could not be guaranteed to be completely 
devoid of DNA contamination, unfortunately, the presence of the transfected TBX22 
protein in the 293T cells could not be verified and the possibility exists that no 
TBX22 protein is being produced by the pCR3.1_TBX22 expression vector. 
Obviously if this plasmid is not driving expression of TBX22, then one cannot draw 
any conclusions from the effect TBX22 has upon the transcription levels of MSX1 in 
this system. 
 
 The Dual Reporter system is based upon the assumption that the transfection 
efficiency of the internal control plasmid is proportional to that of the experimental 
reporter.  As the Renilla control plasmid (pGL4.2[hRluc/Tk]) did not show any 
significant variance between the experiments (see Fig. 31), a reliable and reproducible 
transfection between experiments is occurring. Furthermore, by normalising the 
results to this internal control reporter (pGL4.2[hRluc/TK]) differences in transfection 
efficiency between assays should be accounted for.  
 
There are various assumptions that have been made during the interpretation of the 
transfection study results, which have not been accounted for as the appropriate 
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controls were not incorporated into the experimental design. These assumptions and 
those controls that ought to have been employed to test these assumptions are shown 
in Table 22. 
Assumption being 
made 
Control to test for this assumption 
and expected outcome 
Consequence to 
interpretation of results if 
assumption is not accurate 
TBX22 protein is 
being produced by 
the pCR3.1_TBX22 
expression plasmid. 
Western blot using either anti-
TBX22 antibody or an antibody to a 
tagged TBX22 protein construct to 
ensure TBX22 protein is being 
expressed. 
If TBX22 is not being 
produced by the expression 
vector, the effects of TBX22 
on the transcription of MSX1 
cannot be measured using this 
experiment. 
TBX22 is binding to 
the MSX1 promoter 
and not to some 
other region of the 
M_prom vector. 
Replace the MSX1 promoter with a 
promoter that will drive expression 
of the luciferase but does not contain 
a T-box binding site. Over 
expressing TBX22 should have no 
affect upon the luciferase levels of 
such a construct. 
If TBX22 is binding to a 
region on the M_prom vector 
other than the MSX1 promoter, 
then TBX22 does not regulate 
transcription of MSX1. 
TBX22 is binding to 
the MSX1 promoter 
at the identified T-
box DNA binding 
domain and not at 
another region 
outside of this site. 
 
 
Replace the T-box binding site of 
the MSX1 promoter with the 
sequence of the Mut_oligo that did 
not show binding to TBX22 in the 
EMSA studies. Over expression of 
TBX22 should not alter luciferase 
levels of the MSX1 promoter 
containing the Mut_oligo sequence. 
TBX22 does not regulate 
transcription via the identified 
T-box binding domain (i.e. it is 
acting non-directly via some 
intermediary protein(s)), or the 
T-box binding domain is 
positioned at a different 
location on the MSX1 
promoter. 
TBX22 is binding to 
the MSX1 promoter 
and altering the level 
of transcription of a 
reporter vector. 
Replace the TBX22 DNA binding 
domain with a mutated sequence 
that is known not to bind DNA. 
Over expressing this protein would 
not be expected to have an affect on 
the expression of luciferase. 
TBX22 does not regulate 
transcription of MSX1 via the 
identified T-box binding 
domain (i.e. it is acting non-
directly via some intermediary 
protein(s). 
The M_prom 
construct is driving 
the expression of the 
luciferase. 
Measure the amount of luciferase 
produced by a luciferase reporter 
construct containing the reverse 
complement of the MSX1 promoter 
sequence. The level of luciferase 
expressed by such a construct would 
be expected to be significantly less 
than that seen with the M_prom 
vector with the MSX1 promoter in 
the correct orientation. TBX22 
would not be anticipated to bind to 
such a sequence. 
The apparent expression of 
luciferase by the M_prom 
construct is actually due to low 
level expression of luciferase 
produced solely by the 
pGL4.17 vector. In which case 
altering the level of TBX22 
expression will have no 
detectable effect upon 
transcription acting via the 
MSX1 promoter. 
Table 22: A summary of the assumptions made in the interpretation of results 
for the transfection assay and the controls that should be included to verify that 
they hold true. 
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 Clearly there are several further controls needed to in order to ascertain 
whether the assumptions being made in these experiments are valid. The lack of these 
controls means that that definitive conclusions cannot be drawn from these studies. 
However, providing that the assumptions made in Table 22 are correct, the results of 
the transfection studies would suggest that over expression of TBX22 in the HeLa cell 
line reduced the expression from the MSX1 reporter construct. Figure 32 shows an 
overall reduction in M_prom reporter activity when co- transfected with the 
pCR3.1_TBX22 plasmid, compared with co-transfection with the pCR31._Null 
plasmid. However, at the higher levels of TBX22 transfection, the reduction of 
expression appears more variable and with a slightly higher median than is seen in 
26.7ng TBX22 conditions. Whilst the Mann-Whitney U test shows that differences 
seen in the medians between the 26.7ng pCR3.1_TBX22 and 53.4ng pCR3.1_TBX22 
plasmids are not statistically significant, the small increase seen in the median of the 
53.4ng pCR3.1_TBX22 plasmid transfection may be due to an auto-regulatory effect 
of the endogenous TBX22 (Andreou et al. 2007) resulting in an overall net reduction 
in the amount of TBX22 protein in the cell. 
 
The addition of TBX22 had no effect on the MSX1 reporter in the 293T cells. As these 
cells were shown not to express TBX22, one could postulate that other factors required 
for the action of TBX22 may also be absent. SUMO1, for example, as sumoylation of 
TBX22 has been shown to be a necessary requirement for it to function as a repressor 
(Andreou et al. 2007).  
The results of the transfection experiments hold up the possibility that TBX22 can 
regulate the expression of MSX1 in HeLa cells. Evidence that TBX22 may bind to a 
DNA-binding site found in the MSX1 promoter (Chapter 4), together with these 
results suggest that regulation of MSX1 by TBX22 may be due to direct protein-DNA 
interaction. However, the Tbx22 null mutant mouse did not display a significant 
difference in the distribution of expression of Msx1 within the developing palatal 
shelves, although the authors do suggest that an increase in Msx2 was seen in the 
posterior tongue (Pauws et al. 2009a). It is possible that there may be functional 
compensation by other T-box genes in the repression of Msx1 in the palatal shelves in 
vivo in the absence of Tbx22, for example by Tbx1 which has been shown to be 
necessary for secondary palate elongation (Goudy et al. 2010). Investigations in 
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development of the chick frontonasal process identified a role for TBX22 in the 
regulation of proliferation in this region (Higashihori et al. 2010) and it is possible 
that TBX22 exerts its effect over MSX1 in the developing lip where both genes are 
expressed (Figs.13, 14 in Chapter 2 and Fig. 26 in Chapter 4). The authors also 
suggest that as TBX22 has an involvement in proliferation within the frontonasal 
prominence that subtle changes to proliferation within the palatal shelves may also be 
occurring in the Tbx22 null mouse. Therefore, the possibility exists that subtle 
changes in Msx1 expression may also be seen within the palatal shelves of the Tbx22-/- 
mutant. 
 
Evidence already exists for transcriptional repression by T-box genes. It has been 
shown that TBX22 functions to repress expression of itself (Andreou et al. 2007) and 
both TBX2 and TBX3 have been shown to repress expression of target genes 
(Brummelkamp et al. 2002; Paxton et al. 2002; Prince et al. 2004). Interestingly, a 
conserved MSX1 binding site has been identified within the 5 -region of the TBX22 
gene (Herr et al. 2003), raising the possibility of a regulatory feedback loop between 
TBX22 and MSX1. Indeed it has been proposed that a similar regulation both 
upstream and downstream exists between TBX22 and MSX2 (Higashihori et al. 
2010).  
 
The fact that a difference in the effect of TBX22 upon the repression on the MSX1 
reporter construct was seen between the HeLa and 293T cell lines supports the 
sensitivity and effectiveness of the Dual Reporter assay and it has been employed to 
study the effects of over expressing proteins on the transcription of luciferase 
promoter reporters in several studies (Liu et al. 2008; Ma et al. 2008; Zhang and 
Nohturfft 2008; Hou et al. 2009). The repression of MSX1 was only seen in HeLa 
cells and whilst this is derived from a human cell line, it could still be considered that 
this is an artificial environment as they are aneuploid cells and as such are abnormal. 
However, as many functional studies have employed HeLa cells in the analysis of 
protein function, including that of Brachyury (Kispert et al. 1995) and also TBX22 
previously (Andreou et al. 2007), they remain a useful tool for understanding what is 
occurring in vivo under normal conditions.  
178 
CHAPTER 6 
 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
 
6.1  CONCLUSION 
 
This thesis aimed to uncover the developmental expression pattern and protein-DNA 
binding properties of human TBX22, identify potential downstream target genes and 
evaluate one such gene. This has revealed several new insights in this field. 
 
The spatiotemporal expression of human TBX22 during the formation of the lip and 
palate was characterised and was shown to correlate with features disrupted in CPX. 
TBX22, in addition, is strongly expressed in the medial and lateral nasal processes 
during the formation of lip. This expression pattern has now also been demonstrated 
in mouse and chick (Braybrook et al. 2002; Bush et al. 2002; Haenig et al. 2002; Herr 
et al. 2003) and gene expression similarities within the formation of the oral cavity in 
zebrafish have also been uncovered (Jezewski et al. 2009). As a result of the common 
gene expression pattern seen in human and these animal models, the results of 
function studies of TBX22 undertaken in these animal models (Pauws et al. 2009a; 
Higashihori et al. 2010) can be reliably extrapolated to man. 
 
Several genes expressed in the palate during extension of the palatal shelves in mouse 
have expression domains restricted to either the anterior or posterior palatal shelves. 
Tbx22 being one such gene with restricted expression to the posterior palate. This has 
exposed distinct regulatory pathways for the anterior and posterior palate formation 
(Li and Ding 2007; Pantalacci et al. 2008; Welsh and O'Brien 2009). In human the 
anterior palate is proportionately smaller in comparison to the posterior palate than in 
mouse. This makes it more difficult to distinguish between expression in the primary 
palate and expression in the anterior secondary palate in human. TBX22 is clearly 
expressed in posterior secondary palate in human, similar to that reported for mouse 
and chick (Bush et al. 2002; Haenig et al. 2002; Herr et al. 2003) 
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A mouse lacking Tbx22 has now been created (Pauws et al. 2009a) and this mutant 
displays many of the phenotypic features seen in CPX. The attachment of the tongue 
to the mandible at a more anterior position than in the wild type mouse was seen in all 
mutants, representing a mild form of ankyloglossia; a disruption to the formation of 
the palatal rugae was evident; in some mutants there was incomplete disruption to the 
oro-nasal membrane leading to choanal atresia ultimately resulting in post natal 
lethality; in surviving mutants a notch was seen in the posterior hard palate akin to 
submucous cleft palate and a few of the mutants analysed were born with an overt 
cleft palate. Further investigation of the secondary palate revealed a lack of 
mineralisation of the palatal bone and under development of the vomer, leading the 
authors to conclude that the major role of Tbx22 is in the regulation of palatal 
osteoblast formation (Paws et al, 2009).  However, as TBX22 was seen to be 
expressed at the sites of the vertically elongating palatal shelves (Chapter 2), a further 
role for TBX22 in the regulation the proliferation of the mesenchyme within the 
palatal shelves seems probable. 
 
Experiments in chick have begun to uncover a function for TBX22 during formation 
of the lip (Higashihori et al. 2010), where over-expression of TBX22 in the chick 
frontonasal mass leads to a cleft lip. Although cleft lip is not a feature seen in the 
classic CPX phenotype, where mutations both to the coding and promoter regions in 
the affected individuals lead to an overall reduction of functional TBX22 (Braybrook 
et al. 2001; Braybrook et al. 2002; Marcano et al. 2004; Andreou et al. 2007; 
Suphapeetiporn et al. 2007; Pauws et al. 2009b), Higashihori and colleagues postulate 
that genetic or environmental influences affecting the regulation of TBX22, resulting 
in a gain of functional TBX22, may indeed give rise to a cleft lip in humans. The 
expression data from human would support this, given the strong expression seen in 
the nasal processes during formation of the lip (Chapter 2). 
 
The third Chapter of this thesis identified a TBX22 DNA binding sequence that is 
similar to the Brachyury half site (Kispert and Herrmann 1993) and to half of the 
DNA sequence previously shown to bind to TBX22 (Andreou et al. 2007). Different 
T-box proteins have been shown to bind to the same DNA sequence: Xbra, TBX1 and 
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TBX2 were all shown to bind to the same DNA sequence - AGGTGTGAAAT (Sinha 
et al. 2000), although the mechanism by which this was achieved was different. 
 
 Whilst TBX1 bound to the DNA as a dimer in a similar manner to that reported for 
Xbra, TBX2 bound as a monomer. As the TBX22 DNA binding site reported in 
Chapter 3 resembles a Brachyury half site, it is likely that TBX22 binds to the DNA 
as a monomer, although confirmation of this would need to be provided using X-ray 
crystallography techniques, as has been shown for the human Brachyury protein 
(Papapetrou et al. 1997). The targeting of the same DNA binding site by different T-
box proteins is postulated as one mechanism by which they regulate gene expression. 
During cardiac development, for example, it has been proposed that Tbx18 competes 
with Tbx5 for the same binding site on the Nppa promoter (Farin et al. 2007). Once 
bound Tbx18 acts as a repressor, whereas Tbx5 functions as a transcriptional 
activator. It would be enlightening to investigate whether other T-box genes, 
particularly the other TBX1 family genes which share over-lapping gene expression 
patterns during craniofacial development – TBX1/10/15 and 18 (Chapman et al. 1996; 
Agulnik et al. 1998; Kraus et al. 2001a; Bush et al. 2003), have a similar antagonistic 
regulatory mechanism in some or all cases.  
 
Incorporating the TBX22 DNA binding site identified above with all of the previously 
determined T-box binding sites, a generic T-box binding site was devised. An in silico 
screen for the presence of this site within the promoter regions of 132 potential 
TBX22 target gene candidates is described in Chapter 4. This resulted in the 
identification of 102 genes, with at least one copy of a sequence that exactly matched, 
or had only one mis-match to the generic T-box binding site in the 2kb promoter 
region screened. Although only one gene was selected for further analysis, it is 
conceivable that all of these genes could be TBX22 targets. The actual number of 
TBX22 gene targets may well turn out to be much higher: a chromatin 
immunoprecipitation (ChIP) study aiming to identify T-bet targets, uncovered 832 
protein coding target genes in human Th1 cells (Jenner et al. 2009) and a similar 
whole genome approach at identifying TBX22 targets may well uncover a large 
number of potential target genes. However, the in silico approach employed in this 
study focused upon a sub-set of candidate genes – those genes which when disrupted 
had been shown to cause a human cleft palate phenotype. This approach whilst 
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identifying a number of likely TBX22 target gene candidates, at the same time also 
excluded some genes that one could consider as potential TBX22 targets based upon 
known gene expression patterns, their presence in regions linked to cleft palate 
disorders or that give rise to cleft palate in mouse but have not yet been shown to have 
a role in human cleft palate disorders (Gritli-Linde 2007; Gritli-Linde 2008; Jugessur 
et al. 2009). Similarly, only the first 2kb of the promoter upstream for the 
transcription start site was screened for the presence of the binding site and regions 
outside of this region either further upstream or indeed within intronic gene regions 
would have been missed.  Although it is not impossible that all of the human cleft 
palate causing genes may contain a TBX22 binding site, it would seem rather unlikely 
that all of these are indeed true in vivo TBX22 target genes. The in silico search 
employed in this study was probably always going to produce many false positive 
target genes. If one assumes that each of the 4 bases is equally represented throughout 
the genome then the generic T-box binding sequence used to search the promoter 
regions – AGGTGTBDWR - has an approximate 1:30,000 chance of appearing by 
chance alone. If the human genome has approximately 3 billion bases, then this would 
mean that there would be around 100,000 copies of this sequence occurring by chance 
in the genome. It is fanciful to imagine that TBX22 actually has anywhere near this 
number of target genes and therefore applying a similar search strategy to the entire 
genome would be unproductive and a more direct targeting approach, such as ChIP 
(Horak and Snyder 2002; Weinmann 2004; Wong and Wei 2009), is required to 
extend the search genome wide for TBX22 targets. 
 
Although many genes were identified as potential TBX22 target gene candidates 
using the in silico screen, only 10 of these also display a cleft palate in the known 
mouse mutants for these genes (Table 18 Chapter 4 and Appendix 5). From this sub-
set only two were known to be involved in non-syndromic cleft palate and as protein-
protein interaction had already been demonstrated between one of these and TBX22 
(Andreou et al. 2007), the other - MSX1, was selected for further investigation. 
 
There was evidence that  the level of transcription from an MSX1 gene reporter 
(M_prom, Chapter 5) was repressed in HeLa cells in which a TBX22  expression 
construct (pCR3.1_TBX22, Chapter 5) had also been transfected. However, as several 
controls were absent from the transfection study experiments (see Table 22), the 
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mechanism responsible for the repression could not be identified with certainty. This 
repression was seen when both 26.7ng and 53.4ng of the TBX22 expression construct 
(pCR3.1_TBX22) were transfected into the HeLa cells, although no dosage effect 
with the different amounts used was observed. Indeed, the repression was statistically 
equal in both cases. Repression was only observed in HeLa cells - a cell line known to 
endogenously express TBX22 (Andreou et al. 2007) and Fig. 29, Chapter 5). There 
was no difference in expression of the MSX1 reporter in the presence or absence of 
TBX22 in the 293T cells, a cell-line that did not show endogenous TBX22 expression 
(Fig. 29 in Chapter5). Although it was not experimentally confirmed, the cells lacking 
endogenous TBX22 expression were postulated to also lack the necessary co-factors 
needed for TBX22 to repress expression from the MSX1 reporter. The essential 
requirement for co-factors, such as YAP and TAZ, as well as other interacting T-box 
proteins for correct T-box protein trans regulation of target genes has previously 
reported (Murakami et al. 2005; Boogerd et al. 2008; Boogerd et al. 2009). TBX22 
specifically has been shown to need modification by SUMO1 in order to be able to 
repress activity of downstream target genes (Andreou et al. 2007). 
 
When taken together, the data presented within this thesis (the characterisation of the 
expression pattern of TBX22 and of MSX1 in the palate, the in vitro studies showing 
TBX22 probably binding to a DNA sequence found within the MSX1 promoter and 
then the subsequent repression of an MSX1 gene reporter in HeLa cells) suggest that 
TBX22 may have a role in the regulation of MSX1 transcription. However, the lack of 
a suitable antibody has somewhat hampered the degree to which this conclusion can 
be made: a super-shift was not detected which meant that the EMSA studies could not 
convincingly show that the identified T-box binding site within the MSX1 promoter 
was definitely binding to TBX22. Also, as the expression of TBX22 protein from the 
pCR3.1 expression vector employed in the transfection studies (Chapter 5) could not 
be verified, a completely conclusive statement that TBX22 does indeed negatively 
regulate transcription of MSX1 cannot be made.   
 
The work of others suggest that TBX22 regulates mesenchyme cell proliferation in 
the palatal shelves (see section 1.2.3) and studies in the chick frontonasal mass, 
suggest that TBX22 acts to negatively regulate proliferation in these cells 
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(Higashihori et al. 2010). The in vitro binding studies presented in this study point 
towards a possible repression of MSX1 by TBX22. 
 
A model of how this interaction could be acting during palatogenesis is now 
discussed. However, as the DNA binding site located within the MSX1 promoter was 
identified from a generic T-box binding site, rather by than matching the specific 
TBX22 DNA binding site consensus site, it is possible that any T-box gene maybe 
influencing MSX1 transcription. This would be perhaps even more plausible if the 
expression of any or all of the human T-box gene family proteins are shown to 
overlap with that of TBX22. However, in the model discussed below it is assumed 
that the T-box gene in question is indeed TBX22. 
 
 MSX1 and TBX22 display complementary expression patterns in the palatal shelves: 
MSX1 is restricted to the anterior palate, TBX22 to the posterior (Fig. 26, Chapter 4). 
These restricted anterior/posterior expression patterns have been suggested to underlie 
the future hard and soft palate respectively (Welsh and O'Brien 2009). It is possible 
that TBX22, by down regulating MSX1, assists in maintaining the distinction between 
these two regions. During palatogenesis in the mouse, the anterior palate is extended 
(see 1.2.4) by proliferation of the mesenchyme regulated by Bmp4 (Zhang et al. 
2002). Bmp signalling, through ligand binding with various Bmp-receptors, has been 
shown to induce the activation of Smad8; which in turn promotes mitogenesis (Kawai 
et al. 2000). The mouse null mutant Msx1-/- has a cleft palate (Satokata and Maas 
1994) that was shown to arise due to insufficient cell proliferation in the palate 
mesenchyme (Zhang et al. 2002). By ectopically expressing Bmp4 in the palatal 
mesenchyme of the Msx1-/- mouse, the cleft palate phenotype was rescued. This 
demonstrated Bmp4 to be downstream of Msx1 (Zhang et al. 2002). Furthermore, the 
same authors showed that Msx1 was required for the expression of Bmp4. Thus, by 
repressing MSX1 expression in the posterior palate, TBX22 restricts MSX1 
expression, and therefore BMP4 mediated proliferation to the anterior palate. A 
diagrammatic representation of this is shown in Figure 34 below.  
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Figure 34: A proposed model for repression of MSX1 by 
TBX22 in the formation of the palatal shelves. TBX22 
represses MSX1 in the posterior palatal shelves, thus limiting 
MSX1 to the anterior palate only. MSX1 is able to induce 
proliferation via BMP4, leading to extension of the anterior 
palate. 
 MSX1 
TBX22 
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Identifying human transcription factor target genes is a valuable, but challenging task 
given the obvious limitations that exist compared to the gene targeted mouse models 
that can be created or transplantation experiments that can be performed in chick. This 
means that there may always be a reliance upon such animal models. However the in 
vitro binding studies in the cell culture based experiments used in this thesis are 
necessary to confirm that functional effects witnessed in animal models are applicable 
in human and to verify in vitro findings. Indeed the T-box targets identified by a 
chromatin immunoprecipitation study in developing zebrafish mesoderm (Garnett et 
al. 2009), were still verified using in vitro DNA binding assays similar to that 
employed in this study. 
 
This present study took a candidate TBX22 target gene, based on gene expression and 
other reported evidence, and tested it for possible interaction with TBX22. However, 
an alternative, and perhaps more direct strategy may have been to first uncover 
possible target genes through wider reaching whole transcriptome or proteome 
studies. This could have been achieved by employing a ChIP (Jenner et al. 2009) or 
by a microarray approach (Bhattacherjee et al. 2007) – for example comparing the 
gene expression profile of palate cells in which TBX22 was over expressed to the 
gene expression profile of an unmodified cell, or conversely silenced using an RNAi,- 
using a technique similar to that employed to silence the T-box domain containing 
genes Doc1, 2, and 3 genes in drosophila  (Hamaguchi et al. 2004). One or all of these 
approaches would have been employed had the studies described in this thesis 
commenced now.  
 
Clearly the regulatory pathways involved in craniofacial development are only just 
beginning to emerge, as is the role of TBX22.  However, since the identification of 
the TBX22 gene in 2000 (Laugier-Anfossi and Villard 2000), there has been 
considerable progress as to the function of TBX22. It is now known that  mutations to 
the coding region of TBX22 gave rise to CPX (Braybrook et al. 2001) and that alleles 
containing risk SNP’s within the promoter region of TBX22 are associated with cleft 
palate and ankyloglossia (Pauws et al. 2009b). The spatiotemporal expression pattern 
of TBX22 during craniofacial development in human and model animals has also been 
uncovered (Braybrook et al. 2002; Bush et al. 2002; Haenig et al. 2002; Herr et al. 
2003). Mn1 has been shown to be a transcriptional activator of Tbx22 (Liu et al. 2008) 
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and it can be induced by Fgf8, Fgf2 and Noggin, whilst it is repressed by Bmp4 and 
Bmp7 (Higashihori et al. 2010). Human TBX22 has been demonstrated to be targeted 
for sumoylation and that this is necessary in order for it to exert repression on target 
genes (Andreou et al. 2007). To date the only downstream targets known are TBX22 
itself (Andreou et al. 2007) and possibly MSX1 as identified from the outcome of this 
study. 
 
Elucidating how TBX22, its target genes and the many other genes involved in the 
complex process of craniofacial development, fit together in the signalling and 
regulatory networks that are required for normal development is an admirable goal. 
Not only will these interacting pathways reveal how normal palatogenesis proceeds, 
but also how the effects of disruptions to this process can begin to be understood. 
With this understanding, the ultimate aim of prevention, treatment and counselling of 
patients with craniofacial disorders can be more fully realised. TBX22 clearly has an 
important role in craniofacial development, the findings that many T-box genes, 
including TBX22 are expressed in both overlapping and complementary patterns in the 
very early developing somites (Wardle and Papaioannou 2008) and the identification 
that TBX22 was often deleted in a genome-wide screen of colorectal cancer biopsy 
samples (Ashktorab et al. 2010) points to other as yet unknown roles for TBX22 
outside of craniofacial development. 
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6.2  FUTURE DIRECTIONS 
 
During the formation of the palate it is becoming apparent that the palatal rugae play 
an important role in both defining the anterior/posterior boundary and that they act as 
signalling centres regulating the extension of the anterior palate (Pantalacci et al. 
2008; Welsh and O'Brien 2009). As with many of the models of human development 
our interpretation of this formation is based upon information gained from model 
organisms. It would be crucial to confirm or otherwise, whether the formation of the 
human palatal rugae are formed in a similar orchestrated manner to that observed in 
mice and that the timing of palatal rugae formation is comparable to mouse.  
 
As the search for potential TBX22 target genes continues, a microarray based study 
would certainly enhance progress in this field, as would the information gained 
through chromatin immunoprecipitation genome-wide location analysis or ChIP-on-
Chip (Horak and Snyder 2002; Weinmann 2004; Wong and Wei 2009). In this 
technique cells are cross-linked with formaldehyde to cross-link transcription factors 
whilst bound to DNA. An antibody to the transcription factor is then used to 
immunoprecipitate the protein-DNA and then the cross-links are reversed and the 
DNA purified. The purified DNA can then be labelled and used as probes to a 
genomic microarray containing selected enhancers and promoters. This technique has 
two major advantages over traditional microarray studies which rely on either the 
overexpression or silencing of a transcription factor. The first is that, as the technique 
is performed without altering the environment by artificially expressing or silencing a 
gene of interest, stoichometry of potentially biological relevant proteins will remain. 
The second advantage is that ChIP-on-chip can determine direct targets of the 
transcription factor of interest, as opposed to that of the traditional methods which 
cannot discriminate between direct and indirect target genes. As ChIP-on-chip has 
been successfully employed in revealing several targets of the T-box protein T-bet 
(Townsend et al. 2004), ChIP-on-chip would seem ideally suited in identifying 
downstream TBX22 target genes. However, one essential requirement for a ChIP 
method is a specific and reliable TBX22 antibody, which was unfortunately lacking 
during the investigations performed in this thesis. Although efforts such as the Human 
Antibody Initiative (http://www.hupo.org/research/hai/), which aims to produce 
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antibodies against all human proteins and thoroughly test each one for its ability to 
perform immunoprecipitation, immunoblotting and immunohistochemistry, should 
address this difficulty in the future. 
 
As well as uncovering target genes of TBX22, it is important to uncover protein-
protein interactions between TBX22 and other functional protein partners which may 
affect transcription regulation. Recently, Msx1 and Msx2 have both been shown to 
bind through the homeodomain to the T-box of Tbx2 and these proteins function in 
concert to suppress the expression of Cx43 (Boogerd et al. 2008). It would obviously 
be very interesting to investigate whether there is any protein-protein interaction 
between TBX22 and MSX1. Investigation into possible interactions between TBX22 
and other T-box genes in the regulation of the palate are also likely to be revealing as 
has been described during cardiac formation (Boogerd et al. 2009). 
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 APPENDICES 
 
 
 
APPENDIX 1: OLIGONUCLEOTIDES AND ANTIBODIES 
 
Primers used to generate DNA fragments, which were ligated into 
cloning vectors  
 
Primers used to amplify TBX22 coding sequence for ligation in to the pET100/D-
TOPO vector 
5´-(CACCATGGCTCTGAGCTCTCGGG)-3´ 
5´-(CTAAAGGTAATGGTTAATTGCTGG)-3´ 
 
Primers used to generate PCR product for ligation in to pTNT 
XhoI-HisTBX22(F) 
5´-(CAGCACTCGAGTCACAATGGGGGGTTCTCATCATCATC)-3´ 
SalI-HisTBX22(R) 
5´-(CCATGGTCGACTCGCGCTAAAGGTAATGGT TAATTGCTGGATAC)-3´ 
 
Primers used to generate the pCR3.1_TBX22 plasmid 
5´-(GGGATGGCTCTGAGCTCTC)-3´ 
5´-(CATAAGGTAATGGTTAATTGCTGAA)-3´ 
 
 
Primers used for RT-PCR 
 
TBX22  
5´-(AAGCGGGCAGGCGGATGTTC)-3´ (481-500 NM_001109878) 
5´-(AGGTCTCTCCCGAGCAG GGT)-3´ (680-700 NM_001109878) 
 
MSX1  
5´-(CTGGAGCGCAAGTT CCGCCA)-3´ (616-637 NM_002448) 
5´-(AGGCACCGTAGAG CGAGGCA)-3´’ (872-892 NM_002448) 
 
GAPDH  
5´-(TGCACCACCAACTGCTTAGC)-3´ (556-572 NM_002046) 
5´-(GGCATGGACTGTGGTCATGAG)-3´ (NM_622-642 NM_002046) 
 
 
Sequencing primers 
 
T7 Forward 5´ (TAATACGACTCACTATAGGG) 3´ 
T7 Reverse 5´ (TATGCTAGTTATTGCTCAG) 3´ 
 
M13 Forward 5´-(CGCCAGGGTTTTCCCAGTCACGAC)-3´ 
M13R Reverse 5´-(TCACACAGGAAACAGCTATGAC)-3´ 
  
 
TBX22 coding sequence 
SEQ_1 5´-(GGCACGAGGCAAAGAATC)-3´ 
SEQ_2 5´-(CTGAAAGTCTGGAAGAGAAAG)-3´ 
SEQ_3 5´-(CGCTATAGGTACGTCTAT)-3´ 
SEQ_4 5´-(AGGCCTTCTTTCACTCTC)-3´ 
SEQ_5 5´-(CAGTCTTTAGCCCCACTC)-3´ 
SEQ_6 5´-(TAAAGAAACTGAGTTCAC)-3´ 
 
 
pCR3.1_TBX22 Sequencing 
5’-TAATACGACTCACTATAGGG-3’ 
5’-TAGAAGGCACAGTCGAGG-3’ 
 
M_prom sequencing primer 
5’-CTAGCAAAATAGGCTGTCCC-3’ 
5’-TCGATATGTGCGTCGGTAAA-3’ 
 
 
Oligonucleotides used in the in vitro binding selection  
 
Random Oligo 
5´-(GCTGCAGTTGCACTGAATTCGCCTC(NNNNNNNNNNNNNNNNNNNNN 
NNNNN)GACAGGATCCGCTGAACTGACCTG)-3´ 
 
Randon oligo primers 
5´-(GCTGCAGTTGCACTGAATTCGCCT)-3´ 
5´-(CAGGTCAGTTCAGCGGATCCTGTCG)-3´ 
 
 
Oligonucleotides used in the EMSA experiments 
 
W=T_oligo 
5´-(CGAGAGGTGTCTTACGAG)-3´ 
5´-(CTCGTAAGACACCTCTCG)-3´ 
515-20_oligo 
5´-(CGAGAGGTGTCATACGAG)-3´ 
5´-(CTGGTATGACACCTCTCG)-3´ 
Mut_oligo 
5´-(CGAGAAATGTCATACGAG)-3´ 
5´-(CTCGTATGACATTTCTCG)-3´ 
Cont_oligo 
5´-(CTAGCAAGGTGTGAAATTGTCACCTCAA)-3´ 
5´-(GTTCCACACTTTAACAGTGGAGTTTCGA)-3´ 
MSX1_oligo 
5´-(CGAGAGGTGTTGAGCGAG)-3´ 
5´-(CTCGCTCAACACCTCTCG)-3´ 
 Antibodies  
 
Anti-Luciferase pAb - Promega 
Anti-HisG Antibody – Invitrogen 
Anti-HisG-HRP Antibody Invitrogen 
TBX22 (K-20) X sc-17862 X – Santa Cruz Biotechnology 
 
 
 
 APPENDIX 2: MALDI-TOF ANALYSIS OF THE TBX22 RECOMBINANT 
PROTEIN 
 
 
Appendix 2.1: The protein match to TBX22 is statistically significant.  The only matched protein in the 
sample which lies beyond the level of statistical significance using a Mowes probability score is TBX22, 
which has a probability based Mowes core of 140.  
  
 
Appendix 2.2: The peptides detected by MALDI analysis.  The peptides detected by MALDI analysis are 
aligned to the TBX22 protein and provide 40% coverage of the protein. The peptide identification numbers 
correspond to those in appendix 2.3. 
 Appendix 2.3: A Graphical representation of the peptides detected by MALDI analysis.  The molecular 
mass of the peptides detected in the protein sample by MALDI are represented by their identification 
number which can be found in appendix 2.2 
 APPENDIX 3: THE TBX22 DNA CODING AND PROTEIN SEQUENCE 
 
   ---------|---------|---------|---------|---------|---------| 
-3 GGGatggctctgagctctcgggcgcgtgccttctccgtggaagccttggtggggagaccc  
       M  A  L  S  S  R  A  R  A  F  S  V  E  A  L  V  G  R  P    
   ---------|---------|---------|---------|---------|---------| 
61 agcaaaagaaaactccaagacccaatacaggcggagcagcctgagctgcgggagaaaaag  
20  S  K  R  K  L  Q  D  P  I  Q  A  E  Q  P  E  L  R  E  K  K    
   ---------|---------|---------|---------|---------|---------| 
121 ggcggagaggaagaggaggagagaaggagcagcgctgcagggaagagcgagccgcttgaa  
 40  G  G  E  E  E  E  E  R  R  S  S  A  A  G  K  S  E  P  L  E    
   ---------|---------|---------|---------|---------|---------| 
181 aaacaacctaagacagagccctcaacatctgcttcctctggctgcggcagcgacagcggc  
 60  K  Q  P  K  T  E  P  S  T  S  A  S  S  G  C  G  S  D  S  G    
   ---------|---------|---------|---------|---------|---------| 
241 tacggcaacagctctgaaagtctggaagagaaagatattcaaatggagcttcaaggatct  
 80  Y  G  N  S  S  E  S  L  E  E  K  D  I  Q  M  E  L  Q  G  S    
   ---------|---------|---------|---------|---------|---------| 
301 gaactgtggaaaagattccatgacatcgggactgagatgatcattactaaagcgggcagg  
100  E  L  W  K  R  F  H  D  I  G  T  E  M  I  I  T  K  A  G  R    
   ---------|---------|---------|---------|---------|---------| 
361 cggatgttcccctctgttcgggtcaaggtgaaagggttggatccagggaagcagtaccat  
120  R  M  F  P  S  V  R  V  K  V  K  G  L  D  P  G  K  Q  Y  H    
   ---------|---------|---------|---------|---------|---------| 
421 gtggccatcgatgtggtgccggtggattccaaacgctataggtacgtctatcacagctca  
140  V  A  I  D  V  V  P  V  D  S  K  R  Y  R  Y  V  Y  H  S  S    
    ---------|---------|---------|---------|---------|---------| 
481 cagtggatggtagctgggaatacagaccatttgtgcatcattcctagattctatgttcac  
160  Q  W  M  V  A  G  N  T  D  H  L  C  I  I  P  R  F  Y  V  H    
    ---------|---------|---------|---------|---------|---------| 
541 ccggactcaccctgctcgggagagacctggatgcggcagatcatcagctttgatcgcatg  
180  P  D  S  P  C  S  G  E  T  W  M  R  Q  I  I  S  F  D  R  M    
    ---------|---------|---------|---------|---------|---------| 
601 aaactcaccaacaatgagatggatgacaaaggccacatcattctgcaatccatgcataag  
200  K  L  T  N  N  E  M  D  D  K  G  H  I  I  L  Q  S  M  H  K    
    ---------|---------|---------|---------|---------|---------| 
661 tacaaaccccgagtgcacgtgatagagcaaggcagcagtgttgacctgtcccagattcag  
220  Y  K  P  R  V  H  V  I  E  Q  G  S  S  V  D  L  S  Q  I  Q    
     ---------|---------|---------|---------|---------|---------| 
721 tccttgcccactgaaggtgttaaaacattctcctttaaagaaactgagttcaccacagta  
240  S  L  P  T  E  G  V  K  T  F  S  F  K  E  T  E  F  T  T  V    
    ---------|---------|---------|---------|---------|---------| 
781 acggcttaccaaaaccaacagattacgaaactaaaaatagaaagaaatccttttgctaaa  
260  T  A  Y  Q  N  Q  Q  I  T  K  L  K  I  E  R  N  P  F  A  K    
    ---------|---------|---------|---------|---------|---------| 
841 ggatttagagatactggaagaaacaggggtgtattggatgggcttttagagacctaccca  
280  G  F  R  D  T  G  R  N  R  G  V  L  D  G  L  L  E  T  Y  P            
    ---------|---------|---------|---------|---------|---------| 
901 tggaggccttctttcactctcgattttaaaacctttggcgcagacacacaaagtggaagc  
300  W  R  P  S  F  T  L  D  F  K  T  F  G  A  D  T  Q  S  G  S    
    ---------|---------|---------|---------|---------|---------| 
961 agtggctcatctccagtgacctctagtggaggggccccctctcctttgaactccttactt  
320  S  G  S  S  P  V  T  S  S  G  G  A  P  S  P  L  N  S  L  L    
     
          ---------|---------|---------|---------|---------|---------| 
1021 tctccactttgcttttcacctatgtttcatttacctacaagctcccttggaatgccctgt  
 340  S  P  L  C  F  S  P  M  F  H  L  P  T  S  S  L  G  M  P  C    
     ---------|---------|---------|---------|---------|---------| 
1081 ccagaggcatacctgcccaatgtcaacctgcctctatgctacaagatttgtccaactaat  
 360  P  E  A  Y  L  P  N  V  N  L  P  L  C  Y  K  I  C  P  T  N    
     ---------|---------|---------|---------|---------|---------| 
1141 ttttggcaacagcaacctcttgttttaccggctcctgaaagactagcaagcagcaacagt  
 380  F  W  Q  Q  Q  P  L  V  L  P  A  P  E  R  L  A  S  S  N  S    
     ---------|---------|---------|---------|---------|---------| 
1201 tctcagtctttagccccactcatgatggaagtgcctatgttatcttccctgggggtcacc  
 400  S  Q  S  L  A  P  L  M  M  E  V  P  M  L  S  S  L  G  V  T    
     ---------|---------|---------|---------|---------|---------| 
1261 aattcaaaaagcggttcatctgaagactccagtgatcagtatctacaagcacctaattct  
  420  N  S  K  S  G  S  S  E  D  S  S  D  Q  Y  L  Q  A  P  N  S    
     ---------|---------|---------|---------|---------|---------| 
1321 accaatcaaatgttatatggattacagtcacctggaaatatttttctgccaaactccatc  
 440  T  N  Q  M  L  Y  G  L  Q  S  P  G  N  I  F  L  P  N  S  I    
     ---------|---------|---------|---------|---------|---------| 
1381 accccagaagcacttagttgctcctttcatccttcctatgacttttatagatacaatttc  
 460  T  P  E  A  L  S  C  S  F  H  P  S  Y  D  F  Y  R  Y  N  F    
     ---------|---------|---------|---------|---------|---------| 
1441 tctatgccatctagactgataagtggttccaaccatcttaaagtgaatgacgacagtcaa  
 480  S  M  P  S  R  L  I  S  G  S  N  H  L  K  V  N  D  D  S  Q    
     ---------|---------|---------|---------|---------|---------| 
1501 gtttcttttggagaaggcaaatgtaatcatgttcattggtatccagcaattaaccattac  
 500  V  S  F  G  E  G  K  C  N  H  V  H  W  Y  P  A  I  N  H  Y    
     ------ 
1561 ctttag 1566 
  520 L  *   520 
 
 
 
Appendix 3: The TBX22 DNA coding and protein sequence.  The initiation and stop codons are 
highlighted in bold and the three basses upstream of the translation start site which form part of the Kozac 
sequence are shown in capitals. Single letter amino acid abbreviations are shown below their respective 
codons. 
 APPENDIX 4: ALIGNMENT OF THE CLONES FROM THE IN VITRO DNA 
BINDING ASSAY AND AN EXAMPLE CHROMATOGRAM OF CLONED DNA 
FROM IN VITRO OLIGONUCLEOTIDE BINDING STUDY 
 
  
 
Appendix 4.1: An example of a chromotagram of the DNA from the in vitro oligonucleotide binding assay.  
The sequencing of the clone DNA was performed using the M13 forward and reverse sequencing primers. This 
chromatogram is form the clone 515-1. A Genbank formatted sequence of this trace is shown in appendix 3.2 
 515_1                    941 bp                                    
      
  1 ATGTAATACG ACTCCGTATG GGCCCTCTAG ATGCATGCTC GACGNCGGCC GCCNANTGTG 
 61 ATGGATATCT GCAGAATTCG GCTTGCTGCA GTTGCACTGA ATTCGCCTCG ATATTTGAAT 
121 CCGGTGCGAC CCTTCCGACA GGATCCGCTG AACTGACCTG AAGCCGAATT CCAGCACACT 
181 GGCGGCCGTT ACTAGTGGAT CCGAGCTCGG TACCAAGCTT GATGCATAGC TTGAGTATTC 
241 TATAGTGTCA CCTAAATAGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT 
301 GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT AAAGCCTGGG 
361 GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC GCTTTCCAGT 
421 CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG AGAGGCGGTT 
481 TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG GTCGTTCGGC 
541 TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGGTAATTA CGGTTTATCC ACAGAATTCA 
601 GGGGATAACG CAGGAAAGAA CATGTGAGCC AAAGGCCCGC AAAGGGGCCA AGGAACCCGT 
661 AAAAAAGGGG CCGGGTTTGC TGGGCGNTTT TTTCCCATTA AGGCTTCCCG GCCCCCCTGA 
721 ACGAAGCATC ACAAAAAATC CGNACGTCCA AGTCAGAAGN TGGCGAACCN GACAGGNNNA 
781 TTAAAGAAAA CAGGGTCCCC CGAANAAACA CACCGCGCNC TTTTNGACAA CGGAGAAAAA 
841 AAAGGGGACC ACACGAAAGN GAGAGNACAC AAACACCNGA TGATNAAAGA GCGTACACGG 
901 GGTGTGACGC ACCGGGTATA TATTACACAC AACCCGAGGG T 
 
 
Appendix 4.2: The Genbank formatted sequence of clone 515-1.  The known 5΄ and 3΄ flanking regions of the 
random oligonucleotide used in the in vitro oligonucleotide binding assay are highlighted in bold; the sequence 
used in the alignment of the cloned DNA which generated the TBX22 binding sequence is highlighted in red. 
 APPENDIX 5: THE GENES SHOWN TO CAUSE A CLEFT PLATE IN HUMAN (TAKEN FROM OMIM 10 FEBRUARY 2010) 
Human 
Disease Gene OMIM Gene Ref Seq Nucleotides  Region Searched 
Allowing 1 mis-matches 
from generic T-box 
sequence Found & 
Position 
Mouse Mutant has a 
cleft palate 
abnormality 
ACTB #607371  NC_000007.12 5533312..5536747, complement  5536747..5538747 1238-1247 aggtttgtag No Cleft palate 
ALX3 #136760 NG_012039 5000..15325 3000..5000 584-593 tggtgttgaa No Cleft palate 
    1524-1533 aggtgttttt  
ATR #210600  NC_000003 143650767..143780358, complement 143780358..143782358 710-719 gggtgtggtg No Cleft palate 
    840-849 aggcgtggtg  
ATRX #301040 NC_000023.9 76928375..76647012, complement 76928375..76930375 None No Cleft palate 
B3GALTL #261540 NC_000013.9 30672112..30804413 30670112..30672112 1770-1779 aggggtggag Not Reported 
BCOR #300166 NC_000023.9 39846998..39795561, complement 39846998..39848998 1757-1766 aggtatggag Not Reported 
    1961-1970 aggtatttag  
BMP4 #600625 NC_000014.7 53493304..53486204, complement 53493304..53495304 617-626 aggtgtataa No Cleft palate 
    705-714 aagtgtcatg  
    1390-1399 aggtgttcta  
    1583-1592 aggtgtttca  
BRAF #115150  NG_007873.1 5001..195753 3001..5001 53-62 aggtgccatg No Cleft palate 
    1162-1171 agatgtctag  
BUB1B #257300 NC_000015.8 38240530..38300629 38238530..38240530 260-269 aggggtttag No Cleft palate 
    679-688 aggggttaag  
    1121-1130 aggtggctaa  
CD96 #211750 NC_000003.10 112743616..112853896 112741616..112743616 637-646 aggggtgata Not Reported 
CDH1 #137215  NG_008021.1 5000..103249 3000..5000 1152-1161 cggtgtggtg No Cleft palate 
CHD7 #612370 NG_007009.1 5000..193126 3000..5000 1319-1328 aggtgggaaa Cleft palate 
CHRNG #265000 NC_000002.10 233112681..233119282 233110681..233112681 None No Cleft palate 
CHST14 #601776 NC_000015.9 40763212..40765353 40761212..40763212 569-578 agatgtggag Not Reported 
    1303-1302 atgtgtgttg  
COL11A1 #604841 NG_008033.1 5001..237030 3001..5001 None Cleft palate 
 COL11A2 #184840 NC_000006.10 33268223..33238447, complement 33268223..33270223 772-781 aggtggggtg Cleft palate 
COL2A1 #108300 NG_008072.1 5001..36538 3001..5001 260-269 atgtgtggaa Cleft palate 
    586-595 aagtgtcaaa  
    927-936 aggtgaggtg  
    1383-1392 aggggtggag  
    1820-1829 aggggtggag  
DHCR24 #602398 NC_000001.9 55125509..55087888, complement 55125509..55127509 578-587 agctgttgtg No Cleft palate 
DHCR7 #270400 NC_000011.8 70837125..70823105, complement 70837125..70839125 248-257 agatgttaaa Cleft palate 
    1718-1727 aggtgatgag  
EFNB1 #304110 NC_000023.9 67965556..67978728 67963556..67965556 178-187 aggagtcaaa Cleft palate 
    914-923 aggtcttgtg  
    1239-1248 aggtgtcttt  
DOK7 #254300  NG_013072.1 5000..36176 3000..5000 1623-1632 gggtgtctag No Cleft palate 
ERCC5 #278780 NG_007146.1 5001..35172 3001..5001 None No Cleft palate 
ESCO2 #268300 NG_008117.1 5001..35368 3001..5001 609-618 aggtctggag Not Reported 
EVC #225500 NC_000004.10 5763825..5866932 5761825..5763825 1646-1655 aggcgtggag No Cleft palate 
    1870-1879 aggggtggaa  
EXT1 #215300  NG_007455.1 5001..317457 3001..5001 529-538 aggtctgaaa No Cleft palate 
    748-757 aggtgttttc  
EYA1 #166780 NC_000008.9 72437021..72272222, complement 72437021..72439021 968-977 atgtgtttta Cleft palate 
FAM20C #259775 NC_000007.12 288052..304059 286052..288052 155-164 aggggtgaag Not Reported 
FANCB #300514  NG_007310.1 5001..34656 3001..5001 241-250 gggtgtgaag No Cleft palate 
    264-273 aggtatgaaa  
FBN1 #154700 NC_000015.8 46725210..46487797, complement 46725210..46727210 1978-1987 aggtggggaa No Cleft palate 
FGD1 #305400 NG_008054.1 5001..55713 3001..5001 1043-1052 aggtgggaaa No Cleft palate 
    1337-1346 aggtttgaaa  
FGFR1 #147950 NG_007729.1 5001..62697 3001..5001 None Cleft palate 
FGFR2 #101200 
NC_000010.9 123347962..123227845, 
complement 123347962..123349962 None Cleft palate 
FKRP #236670  NC_000019.8 51941143..51953582 51939143..51941143 None Not Reported 
FKTN #613152 NC_000009.10 107360232..107443220 107358232..107360232 None No Cleft palate 
FLNA #304120 NC_000023.9 153252845..153230091, 153252845..153254845 388-397 acgtgtcatg Cleft palate 
 complement 
    1334-1343 aggtgatgag  
FLNB #272460 NC_000003.10 57969167..58133018 57967167..57969167 463-472 aggtgtgggg No Cleft palate 
FOXC2 #153400 NC_000016.8 85158443..85159948 85156443..85158443  Cleft palate 
FOXE1 #241850 NC_000009.10 99655358..99658818 99653358..99655358 18-27 aggtttttag Cleft palate 
    365-374 aggagttttg  
FRAS1 #219000 NC_000004.10 79198120..79684447 79196120..79198120 1432-1441 cggtgtggtg No Cleft palate 
FREM2 #219000 NG_008125.1 5001..205096 3001..5001 519-528 aggtttcatg No Cleft palate 
FTO #612938 NG_012969.1 5000..415504 3000..5000 1165-1174 gggtgtggtg No Cleft palate 
GDF1 #217095 NC_000019.8 18842116..18840354, complement 18842116..18844116 355-364 aggtgtcgat No Cleft palate 
    926-935 gggtgtggtg  
    1599-1608 gggtgtgaaa  
GJA1 #164200 NG_008308.1 5001..19129 3001..5001 756-765 agatgttata No Cleft palate 
    1454-1463 aggggttgaa  
GJB2 #124500 NC_000013.9 19665114..19659605, complement 19659605..19661605 998-1007 aggtgtgcag No Cleft palate 
GLI2 #610829 NC_000002.10 121266327..121466321 121264327..121266327 674-683 aggtgttacg Cleft palate 
    1196-1205 agctgtcatg  
    1472-1481 atgtgtgatg  
GLI3 #146510 NC_000007.12 42243137..41967072, complement 41967072..41969072 805-814 cggtgtggag Cleft palate 
GPC3 #312870 
NC_000023.9 132947332..132497439, 
complement 132947332..132949332 526-535 gggtgtggag No Cleft palate 
HOXA2 #612290 NG_012078 5000..7421 3000..5000 61-70 agctgtcaag Cleft palate 
    550559 aggtgttatc  
    740-749 aggtgtggga  
    1597-1606 gggtgtcaaa  
    1657-1666 aggtgcttaa  
HYAL1 #601492 NC_000003.10 50324816..50312324, complement 50324816..50326816 938-947 aggtatgaaa No Cleft palate 
HYLS1 #236680 NC_000011.8 125258719..125275749 125256719..125258719 1934-1943 aggtgaggta Not Reported 
ICK #612651 NG_012159.1 5000..65502 3000..5000 1057-1066 aagtgtcaaa Not Reported 
    1342-1341 atgtgttata  
IRF6 #608864 NG_007081.1 5001..23218 3001..5001 1129-1138 aggtgggata Cleft palate 
    1309-1318 aggtgttgca  
 KAL1 +308700 NG_007088.1 5001..208313 3001..5001 1341-1350 aggtggttag Not Reported 
KCNJ2 #170390  NC_000017.9 65677271..65687780 65675271..65677271 410-419 agatgttaaa Cleft palate 
KIAA1279 #235730 NC_000010.9 70418499..70446744 70416499..70418499 602-611 aggtgtgatt Not Reported 
    1286-1295 aggtttgtta  
KRAS #115150 NG_007524.1 5001..50675 3001..5001 113-122 aggtgatgag No Cleft palate 
LARGE #119540 NC_000022.9 32646410..31999063, complement 32646410..32648410 None Not Reported 
LMNA #275210 NC_000001.9 154351085..154376502 154349085..154351085 1544-1553 acgtgtggag No Cleft palate 
LMX1B #161200  NC_000009.10 128416619..128498551 128414619..128416619 None No Cleft palate 
MAP2K1 #115150 NG_008305.1 5001..109672 3001..5001 339-348 aggtgttcaa No Cleft palate 
MAP2K2 #115150 NG_007996.1 5001..38808 3001..5001 649-658 aagtgtctag No Cleft palate 
    1315-1324 aggtttcata  
MED12 #305450 NC_000023.9 70255131..70279029 70253131..70255131 None Not Reported 
MID1 *300552 NG_008197.1 5001..393135 3001..5001 1205-1214 agttgtttaa No Cleft palate 
    1932-1941 aggcgtgtaa  
MKS1 #249000 NC_000017.9 53651665..53637797, complement 53651665..53653665 27-36 aggtatctaa Cleft palate 
    441-450 agctgttgtg  
    930-939 aggtggttag  
MKX *601332 NC_000010.10 28034777..27961802, complement 28036777..28034777 525-534 aggtctgtag  
MSX1 #608874 NG_008121.1 5001..9272 3001..5001  Cleft palate 
MSX2 #168500 NG_008124.1 5001..11328 3001..5001 586-595 aggggtcaag Cleft palate 
    989-998 aggtgccatg  
MTR 1195.3 NG_008959.1 5000..113700 3000..5000 540-549 aggagttgag No Cleft palate 
MYH3 #601680 NC_000017.9 10501340..10472568, complement  1665-1674 gggtgtgatg Not Reported 
    1866-1875 acgtgtggaa  
NBN #251260 NC_000008.9 91066075..91014740, complement 91066075..91068075 None No Cleft palate 
NEB #256030 
NC_000002.10 152299235..152050099, 
complement 152299235..152301235 1385-1394 aggtgctaaa No Cleft palate 
NIPBL #122470 NG_006987.1 4877..193937 2877..4877 192-201 tggtgttgtg No Cleft palate 
    254-263 acgtgtttta  
NKX2-6 #217095 NC_000008.9 23621070..23615909, complement 23621070..23623070 None No Cleft palate 
OFD1 #311200 NC_000023.9 13662801..13697393 13660801..13662801 228-237 aggtctttaa Cleft palate 
    1663-1672 aggggtggag  
 PAX3 #193500 
NC_000002.10 222871944..222772851, 
complement 222871944..222873944 None No Cleft palate 
PEX7 #215100 NC_000006.10 137185416..137276752 137183416..137185416 26-35 aggtgggatg No Cleft palate 
    569-578 aggtgtgaac  
    1804-1813 agctgtcgta  
PHF8 #300263 NC_000023.9 54087036..53979838, complement 53979838..53981838 761-770 agttgtggag Not Reported 
POMT1 #236670 NC_000009.10 133368110..133389014 133366110..133368110 None No Cleft palate 
POMT2 #236670 NC_000014.7 76856970..76811052, complement 76811052..76813052  Not Reported 
PORCN #305600 NC_000023.9 48252315..48264146 48250315..48252315 29-38 aggtgctgtg Not Reported 
    765-774 aggagttttg  
PQBP1 #309500 NC_000023.9 48640139..48645364 48638139..48640139 406-415 aggtctggtg Not Reported 
    1264-1273 aggcgtgtta  
PROK2 #610628 NG_008275.1 5001..18552 3001..5001 249-258 agctgtgtaa No Cleft palate 
    615- 624 acgtgtgaaa  
    626-635 aggtttttaa  
    669-678 agctgtttaa  
PROKR2 #244200   NG_008132.1 5001..17330 3001..5001 834-843 aggtgtgctg No Cleft palate 
    895-904 aggtgttggg  
    1406-1415 aggagtggtg  
PTCH1 #109400 NG_007664.1 5001..78984 3001..5001 None No Cleft palate 
PTCH2 #109400 NC_000001.9 45081203..45060674, complement 45081203..45083203 166-175 agttgttatg No Cleft palate 
    226-235 aggtttcaaa  
PTEN #276950 NG_007466.1 5001..110337 3001..5001 None No Cleft palate 
PTPN11 #151100 NG_007459.1 5000..96181 3000..5000 None No Cleft palate 
PVRL1 #225060 
NC_000011.8 119104645..119014018, 
complement 119104645..119106645 None No Cleft palate 
RAI1 #182290 NG_007101.2 5001..134981 3001..5001 None No Cleft palate 
RAPSN #208150 NG_008312.1 5001..16416 3001..5001 355-364 aggcgtggtg No Cleft palate 
    977-986 aggtggggaa  
    1242-1251 tggtgttaaa  
    1678-1687 gggtgtcttg  
    1862-1871 aggtgcctaa  
     1893-1902 aggtggcaag  
RECQL4 #268400 
NC_000008.9 145714008..145707479, 
complement 145714008..145716008 555-564 aggagtcaag Cleft palate 
ROR2 #268310 NG_008089.1 5001..232561 3001..5001 577-586 gggtgtggaa Cleft palate 
RPGRIP1L #611561 NC_000016.8 52295272..52191319, complement 52295272..52297272 277-286 aggtgtattg Cleft palate 
RPL5 #612561 NG_011779.1 5000..14887 3000..5000 170-179 aggtgtgaac Not Reported 
    1124-1133 aggtttttaa  
    1220-1229 aagtgtttta  
RPL11 #612562 NG_011741.1 5000..9621 3000..5000 371-380 gggtgtggtg Not Reported 
RPS17 #612527 NG_009890.1 4780..8484 2780..4780 1029-1038 aggtgcgttg Not Reported 
    1275-1284 aggtgttggg  
RPS7 #612563 NG_011744.1 5000..10656 3000..5000 None Not Reported 
RPS19 #105650 NG_007080.2 5000..16496 3000..5000  No Cleft palate 
RUNX2 #119600 NG_008020.1 5001..227766 3001..5001 1970-1979 aggagtttta Cleft palate 
SATB2 #119540 
NC_000002.10 200033446..199842469, 
complement 200033446-200033446 1617-1626 aggggtttaa Cleft palate 
SC5DL #607330 NC_000011.8 120668598..120689329 120666598..120668598 1031-1040 atgtgttaaa Cleft palate (Scd5) 
SEMA3E #214800 NC_000007.12 83116260..82831158, complement 82831158..82851158 600     609        1 aggtctgtag No Cleft palate 
SEPT9 #162100 NC_000017.9 72827197..73008273 72825197..72827197 641-650 aggtgccaaa Not Reported 
    1435-1444 aagtgttttg  
SHH #162100 NG_007504.1 5001..14410 3001..5001 None Cleft palate 
SHOX #127300 NC_000023.9 505079..540146 503079..505079 None Cleft palate (SHOX2) 
SHOXY #127300 NC_000024.8 505079..540146 503079..505079 None Cleft palate (SHOX2) 
SIX3 #157170 NC_000002.10 45022541..45025894 45020541..45022541 None No Cleft palate 
SIX5 #113650  NC_000019.8 50964152..50959884, complement 50964152..50966152 None No Cleft palate 
SLC26A2 #222600 NC_000005.8 149320493..149347156 149318493..149320493 534-543 agctgttgtg No Cleft palate 
    1015-1024 aggtgaggaa  
    1157-1166 tggtgttttg  
SLC35D1 #269250 NC_000001.9 67292316..67242439, complement 67292316..67294316 839-848 aggtgtgaac No Cleft palate 
SMS #309583 NC_000023.9 21868763..21922876 21866763..21868763 1698-1707 aggtgtgtgg Not Reported 
SNX3 %601349 
NC_000006.10 108689156..108639410, 
complement 108689156..108691156 520-529 gggtgtcatg No Cleft palate 
SOX2 #206900 NC_000003.10 182912416..182914918 182910416..182912416 1350-1359 aggttttgag No Cleft palate 
 SOX9 #114290 NC_000017.9 67628756..67634156 67626756..67628756 121-130 aggtgtctga Cleft palate 
    915-924 aggtgtttcg  
SPINT2 #270420 NG_013372.1 5000..33156 3000..5000 1325-1334 aggtgtcttc No Cleft palate 
STRA6 #601186 NC_000015.8 72282245..72258860, complement 72282245..72284245 1260-1269 agctgttgaa No Cleft palate 
SUMO1 %119530 
NC_000002.10 202811567..202779148, 
complement 202811567..202813567 952-961 aggtttggta Cleft palate 
TBX1 #188400 NC_000022.9 18124226..18151116 18122226..18124226 1375-1384 aggtgctgtg Cleft palate 
    1985-1994 gggtgtggag  
TBX15 #260660 NG_013361.1 5000..111513 3000..5000 556-565 gggtgtggaa No Cleft palate 
    1917-1926 aggtttggag  
TBX22 #303400 NC_000023.9 79156911..79173924 79154911..79156911 991-1000 aggggtttta Cleft palate 
    1044-1053 cggtgtggta  
    1094-1103 aggtatggtg  
    1461-1470 aggtgtaaag  
TCOF1 #154500 NC_000005.9 149737201..149779870 149735201..149737201 None Cleft palate 
TFAP2A #113620 NG_016151.1 5000..27881 3000-5000 456-465 aggagttaaa Cleft palate (Tcfap2a)  
TGFBR1 #609192 NC_000009.11 101867411..101916473 101865411..101867411 935 gggtgtggtg No Cleft palate 
TGFBR2 #610380 NC_000003.11 30647993..30735633 30645993..30647993 96-105 agctgttaaa No Cleft palate 
TGIF1 #142946 NG_007447.1 5000..51337 3000..5000 None No Cleft palate 
TNNI2 #601680  NG_011621.1 5000..7677 3000..5000 1637-1646 aggtgtggat Not Reported 
TNNT3 #601680 NG_013085.1 5000..24137 3000..5000 631 aggcgtggaa No Cleft palate 
    853 aggggtggaa  
    1519 cggtgtctag  
TP63 #129400  NG_007550.1 5000..270852 3000..5000 1614-1628 aagtgttatg Cleft palate (Trp63) 
TRPS1 #190350 NG_012383.1 5000..265504 3000..5000 1433-1442 aggtgtccta No Cleft palate 
TWIST1 #101400 NG_008114 5000..7204 3000..5000 None Cleft palate 
WNT3 #273395 NC_000017.10 44896081..44841685 44896081..44898081 None No Cleft palate 
WNT7A #276820 NC_000003.11 13921617..13860081 13923617..13921617 None No Cleft palate 
ZEB2 #235730 NW_001838859 4419110..4551938 4417110..4419110 284-293 aggtgagtaa 
Cleft palate (with 
zeb1) 
    1057-1066 agatgtggaa  
    1410-1419 aggtgtagag  
 APPENDIX 6: LUCIFERASE ASSAY REPORT FROM FLUOROSKAN ASCENT FL 
LUMINOMETER 
 
 
 
The following reports contain the read-outs from the Fluroskan 
Ascent FL Luminometer for each of the separate transfection 
experiments. The first three reports are from the three independent 
transfection experiments in HeLa cells and the final three reports 
shown the data from the 293T cell transfections.  
 
 
 
 
No T – is from the cells transfected with the pCR3.1_Null plasmid 
26.7 - is from cells transfected with 26.7ng of pCR3.1_TBX22  
53.4 – is from the cells transfected with 53.4ng of pCR31.TBX22 
 
All of these cells were co-transfected with 50ng M_Prom plasmid 
and 50ng of the pGL4.17[luc2/Neo] plasmid. 
 
 
 
 
 Ctrl is a blank, untransfected cell. 
  
 
  
 
  
  
  
 
 Appendix 7: Luciferase Assay Report from Fluoroskan Ascent FL 
luminometer from original pilot data. 
 
  
  
 
 
 
 
 
